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Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic, inflammatory, systemic autoimmune disease of 
unknown etiology. In a general adult population, the prevalence is 0.5-1%, with women being 
affected significantly more often than men (female:male ratio three:one). RA can occur at any 
age, but first symptoms most frequently emerge between the fourthth and sixth decade.1,2 
Classical symptoms include a symmetrical polyarthritis of small synovial joints of hands and 
feet, although larger joints may also be involved. Direct symptoms of arthritis include pain, 
swelling and stiffness. In the long term, ongoing inflammation leads to joint destruction with 
consequent disability and loss of quality of life.3-6 Systemic symptoms can also occur, including 
vasculitis, interstitial lung fibrosis and rheumatoid nodules.1,2 Furthermore, persistent 
systemic inflammation is associated with an increased risk of infection, malignancies and 
cardiovascular disease.1,7-11 Therefore, the aim of treatment is to inhibit the inflammatory 
process, thus treating symptoms and preventing both direct and indirect damage. 
Pharmacological treatment options
Until the last two decades, the therapeutic arsenal for RA was limited to glucocorticoids, non-
steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease modifying 
anti-rheumatic drugs (csDMARDs) (including amongst others azathioprine, methotrexate, 
hydroxychloroquine, sulfasalazine and leflunomide). Due to recent developments in the 
understanding of the pathogenesis of RA, a new class of drugs, biologic DMARDs (bDMARDs), 
has been developed. bDMARDs have specific points of action that include cellular (B- or T-cells) 
as well as cytokine targets. Among some of the first developed bDMARDs in RA are tumor 
necrosis factor inhibitors (TNFi), which are named after their property to block the cytokine 
tumor necrosis factor.12 TNFi are the most widely used bDMARDs and they include adalimumab, 
certolizumab, etanercept, golimumab and infliximab. bDMARDswith other modes of action 
are abatacept (T-cell co-stimulation inhibitor), anakinra (Il-1 inhibitor), rituximab (inhibitor of 
CD-20 expressing B-cells) and tocilizumab (Il-6 inhibitor). All these bDMARDs have proven to 
be effective RA treatment options by improving clinical, functional and radiographic outcome 
measures.13-17 Another recently introduced class of drugs consists of the targeted synthetic 
DMARDs (tsDMARDs) that include tofacitinib and bariticinib (both Janus Kinase Inhibitors). 
Currently, within these two classes, new drugs are still being developed, further expanding 
the treatment options for RA patients.
Treatment strategies
Concurrent with the development of new treatment options, treatment strategies have 
also changed fundamentally the last few years. The current treatment goal is first to 
achieve remission early after onset of RA, and then to maintain the lowest disease activity 
possible. To achieve low disease activity or remission as soon as possible, treatment should 
be initiated early in the course of the disease and it should include combinations of multiple 
anti-rheumatic drugs.18,19 This concept is known as ‘hit hard, hit early’. Several studies have 
shown that the use of this strategy prevents radiographic joint damage.20-24 As soon as low 
disease activity is reached, the aim is to retain it by tight monitoring of disease activity, setting 
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treatment targets such as low disease activity or remission, and making treatment alterations 
accordingly. This is called ‘tight control’ or ‘treat-to-target’ and these concepts have shown to 
improve clinical, functional and radiological outcomes.25, 26 
Although these developments in treatment options and treatment strategies have improved 
RA care, the use of bDMARDs comes with some important drawbacks. These include (sometimes 
dose dependent) adverse events like an increased risk of infections and non-melanotic skin 
cancer, as well as idiosyncratic adverse reactions like the induction of multiple sclerosis, 
systemic lupus erythematodes or heart failure.27-31 Furthermore, bDMARDs need to be either 
administered intravenously at a day care center or self-administered subcutaneously, both 
posing a burden for patients. Lastly, bDMARDs are expensive (for TNFi in Europe: 14,000 euro 
per patient per year).32, 33 However, with the development of biosimilar DMARDs (bsDMARDs) 
prices have become lower. bsDMARDs are similar to bDMARDs with regard to mode of action, 
equally effective and safe, but less costly.34 To optimise treatment and minimise adverse 
events and costs, a more tailored treatment approach is required. This has lead to another 
concept and the focal point of this thesis: disease activity guided dose optimisation. This 
concept includes: 1) starting a bDMARD when it is necessary to achieve or maintain low 
disease activity, 2) disease activity guided tapering of the bDMARD to the lowest effective dose 
when a patient has reached low disease activity, or remission, 3) discontinuing the bDMARD 
when it is no longer required and 4) restarting or re-escalating the bDMARD in case of a flare. 
The DRESS study
In a number of previous studies, tapering of TNFi has shown to be feasible and safe in RA 
patients who are in remission or have achieved low disease activity.35, 36 Strategy studies that 
investigate a specific dose optimisation strategy are, however, more scarce. One such study 
is the DRESS (Dose REduction Strategies of Subcutaneous TNF inhibitors) study.37 This is a 
randomised controlled pragmatic, non-inferiority strategy trial on disease activity guided 
tapering of TNFi in RA patients with stable low disease activity treated with adalimumab 
or etanercept.37,38 Patients were randomised to either tapering or continuation of full dose 
adalimumab or etanercept. Tapering was done in a stepwise manner until discontinuation 
or until a flare. In case of a flare, the TNFi was restarted or stepwise re-escalated again 
until the lowest effective dose. Outpatient visits were scheduled every three months up to 
eightteen months with extra visits in case of flare symptoms. Results showed that disease 
activity guided dose tapering was feasible in patients with low disease activity or remission 
and non-inferior to continuation of full dose TNFi with regard to prolonged flare. However, 
short-lived flares and minimal radiographic progression were more frequently observed 
in the dose optimisation group. Although these results are very promising, some questions 
remain on long-term benefits and risks of this dose optimisation strategy. In chapter 2.1 long-
term effects of disease activity guided dose optimisation of adalimumab and etanercept will 
be presented, by investigating the three-year follow-up data of the DRESS study. Outcomes 
include disease activity, functioning, short-lived and major flare, radiographic progression 
and adverse events. Additionally, in chapter 2.2, the three-yearcost-effectiveness analysis of 
the DRESS study is described. Furthermore, it is unclear what exactly causes the additional 
radiographic progression in patients that had attempted to taper. It can be hypothesised 
that this is either a temporary effect of the trial-and-error type of tapering strategy, which 
causes flares and temporary rises in disease activity. It can also be an ongoing process caused 
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by lower TNFi exposition. Therefore, in chapter 3 possible causes of the minimal increase in 
radiographic progression in the taper group over eightteen months will be evaluated.
Non TNFi bDMARDS
Feasibility and safety of disease activity guided tapering strategies are shown by results of 
the DRESS study as well as the STRASS trial (Spacing of TNF-blocker injections in Rheumatoid 
ArthritiS Study).37,39 It can be expected that the same will hold true for other bDMARDs like 
abatacept or tocilizumab. Abatacept and tocilizumab have been proven to be effective 
treatment options, either as monotherapy or in combination with a csDMARD.40-46 Tapering or 
discontinuation of abatacept or tocilizumab has been less extensively investigated compared 
to tapering or discontinuation of TNFi, but no large differences in the outcomes have been 
observed.36 However, most studies on dose optimisation of abatacept or tocilizumab have 
focussed on early RA patients or are clinical trials with a strict study protocol and a limited 
follow-up time.47-51 Since dose optimisation has recently been integrated in international 
treatment guidelines for RA18, it is interesting to investigate outcomes after dose optimisation 
in a daily clinical practice setting, with longstanding RA patients, outside a study protocol and 
with longer follow-up time. In chapter 4, dose optimisation of abatacept and tocilizumab in 
daily clinical practice will be investigated in SONATA (Study ON Abatacept and Tocilizumab 
Attenuation), a retrospective, explorative cohort study. The chapter will focus on disease 
activity, functioning, adverse events and persistence of successful tapering or discontinuation. 
Predictors of dose optimisation
Current dose optimisation strategies, as described previously, consist of trial-and-error type 
stepwise tapering until a flare occurs or until the patient can discontinue the drug. This 
has two important drawbacks. First, temporary flaring is inevitable in a subset of patients. 
Although temporary flares do not seem to lower levels of functioning or quality of life,37 they 
still cause suffering due to pain and stiffness. Prevention of flares could be possible when we 
would be able to predict which patient can lower the dose or discontinue the drug and which 
patient cannot. Second, stepwise tapering takes time and is costly. If we would be able to 
identify which patients can discontinue their drugs, no tapering phase would be necessary, 
thus saving time and cost. Unfortunately, no such predictors have been identified yet.52 
One promising predictor for tapering or discontinuation of TNFi might be the multi-biomarker 
score, or MBDA score. Biomarkers have the practical advantage that there is no need for face-
to-face patient contact, which may especially be advantageous for those countries where 
travel distances to health care facilities are greater. Furthermore, they have the potential for 
smaller measurement error than clinical disease activity parameters (although this is often 
not the case). Other claimed advantages might include lower costs and less time-consuming 
measurements as compared to full joint counts. The MBDA score combines twelve serum 
biomarkers in an algorithm that provides a score quantifying disease activity in RA patients 
on a scale from one to a hundred.53, 54 It was designed to correlate with the disease activity 
score based on CRP (DAS28-CRP), although the two can be discordant, which could mean 
either the detection of subclinical synovitis by the MBDA score or false positivity.55, 56 In a 
previous study with early RA patients initiating methotrexate treatment, the MBDA score 
predicted radiographic progression independently of the DAS28.57 Therefore, the MBDA score 
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may provide information on disease activity, complementary to DAS28, either DAS28- CRP 
or -ESR. It may thus also be an interesting candidate predictor for successful tapering or 
discontinuation of a bDMARD in RA patients. In chapter 5.1, we will therefore investigate the 
MBDA score as possible predictor for these outcomes.
Other possible predictors are serum TNFi drug level and anti-TNFi antibodies. These are 
proxies for the treatment, not for disease activity. Clinical scenarios have been proposed in 
which measurement of TNFi drug levels and anti-TNFi antibodies are suggested to be valuable 
as possible predictor for successful tapering or discontinuation of TNFi in RA patients with 
low disease activity or remission.58-60 These scenarios are based on classic pharmacokinetic 
rules and the assumption that bDMARDs work when the serum drug level remains above the 
minimal effective drug concentration during the interval between two administrations.61 
This minimal drug concentration varies between patients, which has led to the assumption 
that each patient has his/her own dose-response curve62. Possible dose response curves are 
1) normal dose response curve, 2) dose-response curve shifted to the left, thus a lower dose is 
necessary to obtain good response, 3) dose-response curve shifted to the right, thus a higher 
dose is necessary to obtain good response, 4) partial response dose response curve, thus the 
patient only response partially on the drug, 5) flat dose response curve, thus the patient does 
not respond to the drug at all.63 Based on these curves, two hypotheses can be postulated 
for dose optimisation in the context of tapering: 1) a patient with low disease activity and a 
high serum TNFi level has a higher chance of successful tapering, as the drug level is above the 
higher boundary of the therapeutic window and a clinical effect might be expected also with 
a lower level and 2) a patient with low disease activity and no or low serum TNFi level and/or 
anti TNFi antibodies has a higher chance of successful discontinuation, since the drug level is 
below the lower boundary of the therapeutic window and a clinical effect of the drug might 
not be present. Although these hypotheses seem rational, studies that test these hypotheses, 
using the right design, are scarce.64, 65 Chapter 5.2 will address these hypotheses. 
Finally, in chapter 6, a summary and general discussion of our findings and insights from the 
abovementioned chapters will be provided. I will also propose clinical recommendations and 
suggestions for future research. 
Aim and outline of this thesis
Based on the above-summarised current knowledge on dose optimisation of bDMARDs several 
questions remain. This thesis aims to answer the following questions:
1. Does the occurrence of prolonged flare remain comparable between TNFi tapering and full 
dose continuation strategy groups in the long term?
2. Do dose tapering strategies of TNFi lead to less adverse events and lower costs in the long 
term?
3. What causes a small increase in radiographic progression in TNFi tapering compared to 
full dose continuation and is this cause only a temporary effect or should we expect more 
radiographic progression in the long term in patients in whom tapering was attempted?
4. Is dose optimisation of other bDMARDs, like abatacept or tocilizumab, also feasible, effective 
and safe in RA patients?
5. Can a multi-biomarker score associated with disease activity predict in which RA patients 
TNFi tapering or discontinuation will be successful?
6. Can serum TNFi levels and anti-TNFi antibodies predict in which RA patients TNFi tapering 
or discontinuation will be successful?
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Abstract
Objective
TNF inhibitors (TNFi) are effective in rheumatoid arthritis (RA), but disadvantages include 
adverse events (AEs) and high costs. This can be improved by disease activity guided dose 
reduction (DR). We aimed to assess long-term outcomes of TNFi DR in RA by using 3 year data 
from the DRESS study. 
Methods
In the intervention phase (month 0-18) of the DRESS study, patients were randomized to DR 
or usual care (UC). In the extension phase (month 18-36), treatment strategies in both groups 
converged to continuation of protocolized tight control and allowed dose optimization. 
Intention-to-treat analyses were done on flare, disease activity (DAS28-CRP), functioning 
(HAQ-DI), quality of life (EQ5D-5L), medication use, radiographic progression (SvdH), and 
adverse events (AE). 
Results
172/180 patients included in the DRESS study were included in the extension phase. Cumulative 
incidences of major flare were 10% and 12% (-2%, 95%CI -8 to 15) in DR and UC group in 
the extension phase, and 17% and 14% (3%, 95%CI -9 to 13) from 0-36 months. Cumulative 
incidences of short-lived flares were 43% (33 to 52%) and 35% (23 to 49%) in DR and UC group in 
the extension phase, and 83% (75 to 90%) and 44% (31 to 58%) from 0-36 months. Mean DAS28-
CRP, HAQ-DI, EQ5D-5L and SvdH remained stable and not significantly different between 
groups. TNFi use remained low in the DR group, and decreased in the UC group. Cumulative 
incidences of AE were not significantly different between groups. 
Conclusions
Safety and efficacy of disease activity guided TNFi DR in RA are maintained up to three years, 
with a large reduction in TNFi use, but no other benefits. Implementation of DR would vastly 
improve the cost-effective use of TNFi.
Introduction
The treatment of rheumatoid arthritis (RA) has improved in the last two decades, due to, 
amongst other things, the introduction of the first widely used class of anticytokine drugs: 
TNF inhibitors (TNFi). These drugs are effective and safe in the treatment of RA, providing 
benefits for symptoms, functioning, quality of life and inhibition of joint damage.1,2
However, TNFi are not without their drawbacks. These include (dose dependent) increased 
risk of infection,3 skin cancer,4 and idiosyncratic adverse reactions like induction of multiple 
sclerosis, lupus or heart failure.5-7 Furthermore, the need for regular self-injection poses a 
burden for patients. Lastly, the costs of these drugs are significant, both per patient per year 
(Europe $17,000, United States $26,000), as well as on a macroeconomic scale.8,9
These disadvantages might be ameliorated by dose reduction or discontinuation of TNFi 
after disease control has been achieved, and this indeed has been shown to be possible in a 
relevant proportion of patients.10-12 A disease activity guided TNFi dose reduction strategy 
has been tested previously in the DRESS study (Dose REduction Strategy of Subcutaneous 
TNF inhibitors), and has been shown to be feasible and non-inferior to usual care with 
regard to prolonged flaring.13 The strategy also did not result in differences in disease activity, 
functioning, quality of life, or relevant radiographic progression after 18 months. However, 
short lived flares and minimal radiographic progression occurred more frequently in the 
dose reduction arm, probably due to the temporary effects of unsuccessful dose reduction 
attempts on disease activity.14 Although no benefits were seen with regard to side effects, the 
cost effectiveness was very high, reaching $440,000 saved per lost Quality Adjusted Life Year 
(QALY).15
Some important questions remain, especially with regard to long-term risks and benefits of this 
strategy. Does the occurrence of major flare remain comparable between groups after longer 
follow-up? Is the small difference in radiographic joint damage between groups only due to 
a temporary difference in disease activity, or should we expect more damage in subsequent 
years? And finally, can a lower risk of adverse events (e.g. infections) be demonstrated? 
In an attempt to answer these questions, we performed an extension study of the original 
DRESS study, exploring long-term effects of this dose reduction strategy on disease activity, 
functioning, quality of life, radiographic progression and (serious) adverse events ((S)AE).
Methods
Study design and participants
This is a long-term extension study of the DRESS study, an 18 month, pragmatic, open label, 
randomized controlled, non-inferiority strategy trial in RA patients, in which a disease activity 
guided dose reduction (DR) strategy of adalimumab or etanercept was compared with usual 
care (UC). For inclusion criteria, we refer to Van Herwaarden et al, BMJ 2015. Disease activity 
was measured using DAS28-CRP (28 joint count based disease activity score with C reactive 
protein (CRP)). 
The DRESS study was registered at the Dutch trial register (www.trialregister.nl, NTR 3216) and 
its design and results have been reported previously.13-17 The extension study was performed 
from May 2014 to January 2016 in the Sint Maartenskliniek Nijmegen and Woerden, The 
Netherlands, and was approved by the local ethics committee (CMO region Arnhem-Nijmegen, 
NL37704.091.11). 
Long-term outcomes of disease activity guided TNFi tapering in RA
2.1
2524
Randomization and masking
In the intervention phase (month 0-18) of the DRESS study, patients were randomized to the 
DR or UC group in a ratio of 2:1, stratified for adalimumab and etanercept. In the extension 
phase (month 18-36) the original group allocation was maintained. Both the intervention and 
extension phase were non-blinded. 
Procedures
In the intervention phase, patients allocated to UC continued a standardized tight control 
treatment protocol (maintaining DAS28-CRP <3.2). 
In the DR group, patients received identical care, with addition of a specific dose 
reduction advice given to the treating rheumatologist for that particular patient. The DR 
strategy consisted of 3-monthly stepwise increase of injection time interval until flare or 
discontinuation. For details we refer to Van Herwaarden et al, BMJ 2015. If the flare persisted 
after 4 weeks despite bridging with intramuscular or intra-articular steroids or NSAIDs, TNFi 
was increased stepwise, if needed, to the shortest registered interval. If a flare persisted 
thereafter, treatment was switched. Only one dose reduction attempt was advised. 
As flare criterion, a DAS28-CRP increase >1.2, or a DAS28-CRP increase >0.6 compared with 
baseline and current DAS28-CRP ≥3.2 was used (short-lived flares).18 Major flare was defined 
as a flare persisting >12 weeks. 
In the extension phase, the treatment strategies in both groups converged to the same 
strategy: treatment choices were left to the discretion of the treating rheumatologist and 
were based on local treatment protocols that included 1) disease activity measurement 
every three to six months and using treat-to-target to achieve at least low disease activity, 
2) a preferential order of biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDS) (see 
Appendix 1), and 3) a bDMARD dose optimization protocol (see Appendix 2). Patients originally 
allocated to UC were therefore also able to initiate TNFi dose reduction (Appendix Figure 1), 
but without specific dose reduction advices. After March 2015, DAS28-CRP cut-off levels for 
low disease activity and remission were slightly lowered to 2.9 and 2.4, as it was shown that 
DAS28-CRP thresholds should be slightly lower in comparison to DAS28-ESR.19
Outcomes 
For the extension phase, the same endpoints were used as in the original DRESS study, although 
in an explorative, non-hypothesis testing manner. The primary endpoint was the difference in 
cumulative incidence of major flare between DR and UC group, during the extension phase 
and during the entire study (0-36 months).
Secondary endpoints were cumulative incidence of patients with short-lived flares, difference 
in Mean Time Weighted (MTW) DAS28-CRP score, MTW functioning, measured with the health 
assessment questionnaire-disability index (HAQ-DI), and quality of life at 36 months measured 
with EuroQol-5D-5L, proportions of patients in whom dose reduction or discontinuation 
was successful, bDMARD use, mean change (Δ) in Sharp-van der Heijde score (SvdH), and 
cumulative incidence and incidence density (ID) of (S)AE. 
Successful dose reduction was defined as being on a lower dose than at baseline with 
concomitant low disease activity, measured both at 18 and 36 months. Successful 
discontinuation was defined as complete withdrawal of adalimumab or etanercept with 
concomitant low disease activity, measured both at 18 and 36 months. 
In the extension phase, DAS28-CRP and HAQ-DI were measured at least every 6 months, and 
an EQ5D-5L was repeated at 36 months. For bDMARD use, the normalized proportion of the 
defined daily dose (DDD) was calculated with interquartile ranges (IQR) with 1.0 being the full 
dose equivalent. 
Radiographs of hands and feet were obtained at 36 months and assessed using the modified 
SvdH score, by the same two blinded, trained readers that assessed the original DRESS 
radiographs. Scoring was done pairwise with radiographs from month 18 and 36 in known 
sequential order, but without rescoring baseline and 18 months, for efficiency reasons, as 
suggested for long-term studies.20 Mean Δ in SvdH, and proportion of patients with ΔSvdH 
exceeding three different cut-off levels were compared between groups: 1) minimal clinical 
important change (MCIC) of eight points in 18 months,21 2) smallest detectable change (SDC)22,23 
and 3) 0.5 SvdH units for minimal radiographic progression. 
Statistical Analysis
Stata IC v 13.1 was used. In the DRESS study, per protocol (PP) analyses were used for the 
primary outcomes because of the non-inferiority nature of the analyses. Because of 1) the 
more exploratory analyses in this extension phase, 2) difficulty defining “per protocol” when 
treatment decisions are left to the treating physician and 3) minor differences in PP and 
intention-to-treat (ITT) analyses in the original study, an ITT approach was chosen. Patients 
who did not give informed consent or were lost to follow-up before 24 months, were excluded. 
All analyses were done for the extension phase, and when appropriate for the entire study. 
Since previously no differences between TNFi (adalimumab or etanercept) were found, 
stratified analyses were deemed unnecessary for the extension phase. 
For the primary analysis, we kept the original non-inferiority margin of 20% difference in 
major flare between DR and UC group, based on the same reasoning as mentioned before.16 
Point estimates with confidence interval (95% CI) of the difference in cumulative incidence of 
major flare between groups were calculated and the upper limits of the confidence interval 
were compared with the non-inferiority margin. A t-test compared mean/median medication 
use (MTW) DAS28-CRP, HAQ-DI and EQ5D-5L. Differences in cumulative incidence of flares, 
and levels of disease activity at 24, 30 and 36 months were compared by Chi-square testing. 
Different time points were tested separately, with no repeated measure analyses performed. 
Role of the funding source
This study was funded by the department of rheumatology at the Sint Maartenskliniek 
Nijmegen, The Netherlands. 
Results
Of 180 patients included in the DRESS study, 172 patients were enrolled in the extension phase: 
115 patients in the DR and 57 in the UC group (Figure 1). Baseline characteristics at start of 
the extension phase were similar between groups, except for higher prevalence of csDMARD 
co-medication in the UC group (Table 1). The percentage of missing data was low: 2% of 
planned visits, and 2% to 8% missing per variable, therefore multiple imputation was deemed 
unnecessary and simple imputation using last observation carried forward in case the last 
observation was missing, or mean of previous and next were calculated for in-between 
missings. 
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Table 1. Patient characteristics at DRESS baseline and at start of DRESS extension phase 
DRESS Baseline DRESS extension
Dose 
reduction 
(n=115)
Usual care 
(n=57)
Dose 
reduction 
(n=115)
Usual care 
(n=57)
General characteristics
Age, years (SD)* 59 (10.0) 58 (9.2) 60.9 (10.0) 59.7 (9.2)
Disease duration (years) † 10 (5-16) 10 (6-16) 11 (7-17) 12 (7-18)
SvdH score‡ 21 (5.5-59) 19 (8.5-46.5)
Female sex 71 (62) 39 (68)
Diagnosis according to 2010 and/or 
1987 ACR criteria, n (%) 109 (95) 57 (100)
Rheumatoid factor positive 90 (78) 47 (82)
Anti-citrullinated peptide antibodies 
positive
82 (71) 44 (77)
Erosive disease 94/112 (84) 52 (91)
Disease activity characteristics
No. of swollen joints† 0 (0-0) 0 (0-1) 0 (0-1) 0 (0-0)
No. of tender joints† 0 (0-1) 0 (0-0) 0 (0-1) 0 (0-1)
Erythrocyte sedimentation rate 
(mm/h)*
17 (14) 16 (10) 20 (15) 16 (10)
C reactive protein (mg/L)* 4 (4) 4 (4) 7 (16) 4 (12)
DAS28-CRP score* 2.2 (0.7) 2.1 (0.8) 2.2 (0.9) 2.0 (0.9)
DAS28-ESR score* 2.5 (0.7) 2.5 (0.8) 2.7 (1.0) 2.5 (1.0)
2011 ACR/EULAR Boolean based 
remission
30 (26) 21 (37) 28 (23) 23 (39)
Treatment characteristics
Etanercept/adalimumab/other 76/39 (66/34) 37/20 (65/35) 73/41/1 (63/36/1) 36/19/2 (63/33/4)
Duration of TNFi use at inclusion 
(years)*
3.5 (2.5) 3.5 (2.2) 5 (2.5) 5 (2.2)
Previous number of csDMARD 
treatments†
2 (1-3) 2 (1-3) 2 (1-3) 2 (1-3)
Previous number of TNFi treatments† 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Concomitant treatment
  csDMARD 68 (59) 45 (79) 69 (60) 40 (70)
  Methotrexate 55 (48) 39 (68) 54 (47) 35 (61)
  Methotrexate dose (mg)* 15.9 (5.7) 16.3 (5.6) 17.0 (6.5) 15.3 (5.0)
  Glucocorticoids 3 (3) 3 (5) 6 (5) 6 (11)
  NSAIDs 63 (55) 34 (60) 70 (61) 35 (61)
Data are number (%) of patients unless stated otherwise. 
*Mean (standard deviation)
†Median (interquartile range)
‡n=101 in the dose reduction group, n=55 in the usual care group.
ACR/EULAR=American College of Rheumatology/European League Against Rheumatism. SvdH=Sharp van der Heijde score. 
DAS28-CRP=28 joint count based disease activity score with C reactive protein. DAS28-ESR=28 joint count based disease 
activity score with erythrocyte sedimentation rate. TNFi=tumor necrosis factor inhibitor. csDMARD=conventional synthetic 
disease modifying antirheumatic drug. MTX= Methotrexate; NSAIDs=non-steroidal anti-inflammatory drugs. 
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Flaring
The cumulative incidences of major flare during the extension phase were 12/115 (10%) in the 
DR and 7/57 (12%) in the UC group (difference -2%, 95% CI -8 to 15%). The upper limit of the 
95% CI around the difference was <20%, compatible with non-inferiority of DR to UC group. 
The cumulative incidence from month 0-36 was 20/115 (17%) in the DR and 8/57 (14%) in the UC 
group (difference 3%, -10 to 15). There was no significant difference in cumulative incidence of 
short-lived flares during the extension phase: 49/115 (43%, 33 to 52%) in the DR and 20/57 (35%, 
23 to 49%) in the UC group. From month 0-36, the cumulative incidence of flare remained 
different between groups: 96/115 (83%, 75 to 90%) in the DR and 25/57 (44%, 31 to 58%) in the 
UC group. Additional analyses within the DR and UC group on the occurrence of major and 
short-lived flares comparing adalimumab with etanercept, showed no significant differences 
in both the extension phase (18-36 months) as well as the whole study duration (0-36 months).
Disease activity, function and quality of life 
In the extension phase, MTW-DAS28-CRP was 2.2 (SD 0.7) in the DR group and 2.1 (SD 0.7) in the 
UC group (difference 0.08, -0.15 to 0.30). MTW-DAS28-CRP from 0-36 months was 2.3 (SD 0.6) in 
the DR group and 2.1 (SD 0.7) in the UC group (difference 0.16, -0.03 to 0.35). DAS28-CRP, HAQ-DI 
and EQ5D-5L remained stable during the extension phase and complete follow-up, and were 
not significantly different between groups at any time point (Figure 2). Disease activity states 
were not significantly different between groups at any time point in the extension phase 
(Appendix Table 1). 
TNFi tapering and medication use
In the intervention phase, 23/115 (20%, 13 to 28%) patients in the DR group had successfully 
discontinued their bDMARD, 52/115 (45%, 36 to 55%) successfully reduced their bDMARD and 
in 40/115 (35%, 26 to 44%) no dose reduction was possible. 19/115 (17%, 10 to 25%) patients in 
the DR group persisted being biologic-free with maintenance of low disease activity from the 
intervention phase until 36 months, and 33/115 (29%, 21 to 38%) of patients in the DR group 
persisted being successfully dose reduced from the intervention phase until 36 months. 
During the intervention phase, 49/57 (86%, 74 to 94%) patients in the UC group did not attempt 
dose reduction (8 patients tapered or discontinued their bDMARD, mostly due to adverse 
events). In the extension phase, in 32/49 (65%, 50 to 78%) patients a dose reduction attempt 
was made. Of these, 19/49 (39%, 25 to 54%) were successfully dose reduced and 7/49 (14%, 1 to 
27%) successfully discontinued at 36 months. In 12/32 (38%, 21 to 56%) patients in the UC group 
in whom a dose reduction attempt was made, a short-lived flare occurred. In patients in the 
UC group in whom a dose reduction attempt was made, 4 experienced a major flare. 2 of these 
patients reached low disease activity at the next visit after re-escalation or reinstallment. The 
remaining 2 patients had a major flare that was due to a high VAS score and high tender joint 
count. Re-escalation was thus deemed unnecessary by both the treating rheumatologist as 
well as the patient. 
At study end, between group differences in numbers of patients successfully tapered or 
stopped were smaller but still existent (Figure 3).
Figure 2. Mean A: Disease activity (measured with DAS28-CRP) B: Functioning (measured with HAQ-DI)  
C: Quality of life (measured with EQ5D-5L) 
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Figure 3. Dose optimization in dose reduction and usual care group (percentages) at 18 and 36 months
During the intervention phase, the proportion of the DDD of TNFi use was 0.50 (IQR 0.48 to 
0.51) in the DR group and 0.92 (0.90 to 0.94) in the UC group (difference -0.42, -0.45 to -0.39). 
During the extension phase, this difference decreased but remained significant: 0.54 (0.51 to 
0.58) in the DR and 0.67 (0.64 to 0.71) in the UC group (difference -0.13, -0.18 to 0.08). From 0-36 
months, DDD was 0.53 (0.51 to 0.54) in the DR and 0.80 (0.78 to 0.82) in the UC group (difference 
-0.27, -0.30 to -0.25). 
In the extension phase, no significant between-group differences in csDMARD use were 
observed. At 36 months, <10% of patients in both groups used oral steroids (difference -1%, -10 
to 8%). During the extension phase, intramuscular or intra-articular glucocorticoid injections 
were given to 48/115 (42%, 33 to 51%) in the DR and 21/57 (37%, 24 to 51%) in the UC group, 
(difference 5%, -11 to 21%).
Radiological outcomes
156 patients (101 DR; 55 UC) had radiographs available at 18 and 36 months. No significant 
difference in mean progression score between groups was observed for the extension phase 
(Table 2). 2/101 (2%) patients in the DR group and no patients in the UC group exceeded the 
MCIC. No significant between-group differences were seen for the SDC (calculated as 5.1 
points) or minimal radiographic progression as cut-off values. 
Table 2. Radiographic outcomes 
Baseline to 18 months 18 to 36 months
Dose 
reduction 
(n=101)
Usual 
care 
(n=55)
Difference 
(95% CI)
Dose 
reduction 
(n=101)
Usual 
care 
(n=55)
Difference 
(95% CI)
Progression total 
SvdH
0.68 (1.5) 0.17 (1.1) 0.51 (0.06 
to 0.97)
1.29 (2.4) 1.45 (2.2) -0.16 (-0.93 
to 0.62)
Progression erosion 0.26 (0.8) 0.13 (0.7) 0.13 (-0.13 
to 0.39)
0.56 (1.3) 0.81 (1.6) -0.25 (-0.71 
to 0.21)
Progression JSN 0.43 (1.2) 0.05 (0.9) 0.38 (0.15 
to 0.75)
0.73 (1.5) 0.64 (1.9) 0.09 (-0.46 
to 0.64)
Progression > MCIC 0 (0%) 0 (0%) 0% (-8 
to 4)
2 (2%) 0 (0%) 2% (-2 to 6)
Progression > SDC 5 (4%) 0 (0%) 4% (-4 to 
10)
3 (3%) 3 (5%) -2% (-9 
to 4)
Progression > 0.5 37 (32%) 9 (15%) 17% (2 to 
29)
50 (50%) 29 (53%) 3% (-20 to 
13)
Progression = in units per 18 months. Data are mean (SD) or n (%). SvdH: modified Sharp-van der Heijde score; JSN: joint space 
narrowing; MCIC: Minimal Clinical Important Change (8 units); SDC: Smallest Detectable Change (5.1 units)
Safety
The cumulative incidence of AEs during the extension phase was equal in both groups: 39/115 
(34%, 25 to 43%) in the DR and 22/57 (39%, 26 to 52%) in the UC group (difference 
-5%, -11 to 21) and the number of patients with SAEs was also not different between groups 
(difference 3%, -11 to 15). From month 0-36, 103/115 (90%, 82 to 94%) patients had an AE in the 
DR group and 54/57 (95%, 85 to 99%) in the UC group (difference -5%, -14 to 4%) and the number 
of patients with SAEs was different (difference 17%, 8 to 31%), caused by a higher incidence 
of elective surgery in the DR group. Overall, low IDs per 100 patient-years were observed for 
other SAE categories with no significant between-group differences (Appendix Table 2).  
Discussion
To our knowledge, this is the first study investigating long-term effects of disease activity 
guided dose reduction of adalimumab and etanercept in RA patients. Results show that 
the initial efficacy and safety of this strategy are maintained. No relevant difference in the 
number of major flares could be demonstrated between DR and UC group, and disease activity, 
functioning and quality of life were also very similar. Furthermore, no significant difference in 
radiographic progression was found, although this might be caused by less contrast between 
groups, due to the converging treatment strategies. However, other benefits of tapering, 
including less adverse events (e.g. infections), were not observed.  
There are some factors to take into account when interpreting our data. The design choices 
that were made for the extension study have advantages but also some drawbacks. 
Considering the latter, the convergence of strategies between groups and subsequent loss of 
Long-term outcomes of disease activity guided TNFi tapering in RALong-term outcomes of disease activity guided TNFi tapering in RA
2.12.1
3332 Long-term outcomes of disease activity guided TNFi tapering in RA
2.1
contrast, should lead to caution when interpreting the lack of differences between groups. 
The similarity in outcomes may be caused by the former dose reduction group doing well, 
but also in part by the original usual care group doing worse than before. However, the latter 
seems less likely, considering the very stable three year course in disease activity, functioning 
and quality of life. The outcomes are also highly comparable between the DR group from 18 
to 36 months and the UC group from 0 to 18 months. Furthermore, in the extension phase of 
this study, flare criteria were altered since it was shown that cut-off values of DAS28-CRP for 
low disease activity and remission should be slightly lower than the validated flare criterion 
cut-offs using DAS28-ESR19. It is unclear, however, how this would have altered our results. 
Tight control would have become even more tight, but this would have occurred in both dose 
reduction and usual care group. Future studies should investigate how using different flare 
criteria influences treatment strategy outcomes.
On the other hand, the design of the study did allow to assess – in the former UC group - what 
level of TNFi dose reduction can be achieved when no specific dose reduction advice is given. 
Interestingly, in the majority of those patients an attempt to dose reduce was observed, 
and subsequent results were also comparable to those in the original DR group. This further 
supports generalizability of the results to clinical practice. 
Although there was some drop-out during the extension phase, for the primary outcome, our 
study seems well powered. For analyses we did not power this study for, a type II error might 
be present. In the design of the original DRESS study, a sample size calculation showed that to 
be able to reject the null hypothesis in this study (i.e. the intervention is inferior compared to 
the control arm by more than the non-inferiority margin) with a power of 80%, and cccounting 
for a 10% drop-out, 180 patients in total were included. At the end of the long-term extension 
phase (month 36), 113 and 57 patients were still included. Thus this is only slightly below the 
numbers as calculated above and total drop-out is still below 10%. 
Comparison of our findings to other long-term studies on disease activity guided dose 
reduction or discontinuation is difficult, due to paucity and heterogeneity of these studies, 
with different dose reduction strategies (e.g. interval lengthening vs. dose tapering, gradual vs. 
fixed dose reduction, or using different tapering schemes) and different definitions for relapse 
or flare.10 A recently published paper of Raffeiner et al. is the only other study to show long-
term (median follow-up 3.6 years) data from a prospective semi-randomized tapering trial.24 
However, only etanercept was studied and fixed dose halving was used instead of disease 
activity guided dose reduction versus continuation of etanercept. Reassuringly, the outcomes 
of this study were very similar to ours, with no significant differences in clinical outcomes and 
radiographic progression, albeit with much higher absolute baseline radiographic damage. 
Two points are of interest with regard to adverse events, SAEs being more frequent in the 
dose reduction group and no observed benefits of TNFi tapering on risk for infections. Firstly, 
the higher incidence of SAEs seems an artefact, because it is almost exclusively caused by 
more elective surgery and SAEs that arose from study related PET/CT scanning, that was 
only done in the dose reduction group, resulting in information bias. Secondly, we were not 
able to demonstrate lower infection risks in the dose reduction group, which is in contrast to 
Raffeiner et al, and to what might be pharmacologically expected.3 This difference in outcome 
might be caused by lower patient numbers and follow-up time, and less contrast between the 
treatment arms in the extension phase. Furthermore, duration of TNFi use before study start 
was much longer in our study and as patients susceptible to infections would have been more 
likely to have discontinued their bDMARD before inclusion, this could have led to selection 
bias (healthy survivor bias).
In conclusion, a disease activity guided dose reduction strategy of TNFi in RA patients doing 
well, seems a reasonable long term approach in RA treatment. Further optimization of 
this strategy could consist of identification of predictors for successful dose reduction or 
discontinuation, as this might prevent short-lived flaring.
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APPENDIX 1: Local rheumatoid arthritis treatment protocol (Sint Maartenskliniek Nijmegen and 
Woerden, The Netherlands)
Reumatoid factor and anti-citrullinated peptide antibody (ACPA) negative and no erosions:
Week 0 
Start with Methotrexate 15 mg every week subcutaneously, increase to 25 mg every week when tolerated.
Start with Hydroxychloroquine 400 mg every day.
Intramuscular steroids 120 mg single dose.
Week 6: DAS28-CRP ≥2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Methotrexate 25 mg every week subcutaneously. 
Hydroxychloroquine 400 mg every day. 
Intramuscular or oral steroids. 
Week 14: DAS28-CRP ≥2.9:
Leflunomide 20 mg every day. 
Hydroxychloroquine 400 mg every day. 
Week 26: DAS-28CRP ≥2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Leflunomide 20 mg (or other sDMARD). 
bDMARD (biologic disease modifying antirheumatic drug) no. 1*.
Intramuscular or oral steroids.
Week 39: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Leflunomide 20 mg (or other sDMARD).  
Stop Hydroxychloroquine.
bDMARD no. 2*.
Intramuscular or oral steroids.
After week 39: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
switch bDMARD according to the bDMARD preferential order (see below)*.
Reumatoid factor positive and/or anti-citrullinated peptide antibody (ACPA) positive and/or erosions and/
or high disease activity at disease presentation
Week 0 
Start with Methotrexate 15 mg every week subcutaneously, increase to 25 mg every week when tolerated.
Start with Hydroxychloroquine 400 mg every day.
Intramuscular steroids 120 mg single dose.
Week 6: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Methotrexate 25 mg every week subcutaneously. 
Hydroxychloroquine 400 mg every day. 
Intramuscular steroids 120 mg single dose.
Week 14-16: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Methotrexate 25 mg every week subcutaneously. 
bDMARD no. 1*. 
Intramuscular steroids 120 mg single dose.
Week 26: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Methotrexate 25 mg every week subcutaneously.
bDMARD no. 2*.
Intramuscular steroids 120 mg single dose.
Week 39: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
Methotrexate 25 mg every week subcutaneously. 
Stop Hydroxychloroquine.
Biological 3*.
Intramuscular or oral steroids.
After week 39: DAS-28CRP ≥ 2.4 or ≥ 2.9 if RA diagnosis> 3 years ago:
switch bDMARD according to the bDMARD preferential order (see below)*.
 
*bDMARD preferential order:
If administration of a concomitant DMARD is possible
 1. Etanercept
 2. Adalimumab
 3. Rituximab
 4. Abatacept
 5. Tocilizumab
 6. Golimumab
 7. Certolizumab
 8. Infliximab
If administration of a concomitant DMARD is not possible
 1. Tocilizumab
 2. Etanercept
 3. Adalimumab
 4. Rituximab
 5. Abatacept
 6. Golimumab
 7. Certolizumab
 8. Infliximab
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APPENDIX 2: local bDMARD dose optimization protocol (Sint Maartenskliniek Nijmegen and Woerden, 
The Netherlands)
Baseline: start bDMARD
6 months: evaluate response criteria (DAS28-CRP <2.9 and decrease in DAS28-CRP >1.2). 
 1. Response criteria are met: 
  - Start dose reduction according to predefined dose reduction steps. 
   o Etanercept:
    • From month 0 to month 6: once every 7 days 50 mg 
    • Dose reduction step 1: 3 months once every 10 days 50 mg 
    • Dose reduction step 2: 3 months once every 14 days 50 mg 
    • Then discontinuation 
   o Adalimumab:
    • From month 0 to month 6: once every 14 days 40 mg 
    • Dose reduction step 1: 3 months once per 21 days 40mg 
    • Dose reduction step 2: 3 months once per 28 days 40 mg 
    • Then discontinuation 
  - Evaluation with DAS28-CRP measurement every 3 months with extra visits in case 
   of flare symptoms (temporary bridging with steroids and NSAIDs is allowed).
  - Stepwise further dose reduction until discontinuation if no flare occurs.
  - In case of flare (DAS28-CRP increase >1.2 or DAS28-CRP ≥2.9 with DAS28-CPR 
   increase >0.6) back to previous dose reduction step
 2. Response criteria are not met:
  - Switch to another bDMARD
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SUPPLEMENTARY DATA
Supplementary figure 1. Study conduct
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Supplementary table 1. Disease activity states
Dose reduction
N=115
Usual care
N=57
Baseline N=115 N=57
DAS28-CRP<3.2 107 (93) 51 (89)
DAS28-CRP<2.6 86 (75) 46 (81)
Boolean 30 (26) 21 (36)
18 months follow up
DAS28-CRP<3.2 100 (87) 51 (89)
DAS28-CRP<2.6 83 (72) 45 (79)
Boolean 27 (23) 23 (40)*
24 months follow up
DAS28-CRP<3.2 96 (83) 47 (82)
DAS28-CRP<2.6 80 (70) 39 (68)
Boolean 33 (27) 21 (36)
30 months follow up
DAS28-CRP<3.2 101 (88) 53 (93)
DAS28-CRP<2.6 87 (76) 47 (82)
Boolean 31 (27) 18 (31)
36 months follow up
DAS28-CRP<3.2 92 (80) 48 (84)
DAS28-CRP<2.6 78 (68) 39 (68)
Boolean 30 (26) 15 (26)
* p = 0.005
Boolean based remission criteria: tender joint count, swollen joint count, CRP and patients’ judgement of global disease 
activity using a visual analogue scale all ≤1.
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Supplementary table 2. Safety summary
Cumulative 
incidences
Dose 
reduction
(N=115)
Usual care
(N=57)
Difference 
(95% CI)
Dose 
reduction
(N=115)
Usual care
(N=57)
Difference 
(95% CI)
18 to 36 months 0 to 36 months
Flares, N (%)
Flare 49 (43) 20 (35) 8 (-9 to 23) 96 (83) 25 (44) 40 (25 to 53)
Major flare 12 (10) 7 (12) -2 (-8 to 15) 20 (17) 8 (14) 3 (-10 to 15)
Other adverse events, N (%)
Adverse events 39 (34) 22 (39) -5 (-11 to 21) 104 (90) 54 (95) -4 (-7 to 13)
Serious 
adverse events
22 (19) 9 (16) 3 (-11 to 15) 50 (43) 15 (26) 17 (8 to 31)
Deaths 2 (2) 0 (0) 2 (-5 to 6) 2 (2) 0 (0) 2 (-5 to 6)
Serious adverse events, 
incidence densities 
(95% CI)
Dose reduction
(N=115)
Usual care
(N=57)
Dose reduction
(N=115)
Usual care
(N=57)
18 to 36 months 0 to 36 months
Elective surgery 15.8 (9.8 to 21.8) 6.7 (1.4 to 12.1) 12.3 (8.7 to 15.9) 3.8 (3.5 to 4.1)
PET/CT related † 0.6 (0 to 1.7) 0 0.8 (0 to 1.7) 0
Infectious adverse event 2.5 (1.9 to 3.4) 2.3 (0 to 5.4) 4.2 (2.1 to 6.3) 2.2 (0.05 to 4.3)
Malignancy 4.7 (1.4 to 7.9) 0 3.1 (1.3 to 4.9) 1.1 (0 to 2.6)
Cardiovascular  event 2.3 (0.03 to 4.6) 1.1 (0 to 3.3) 2.0 (0.5 to 3.4) 0.5 (0 to 1.6)
Pulmonary 0.6 (0 to 1.7) 2.2 (0 to 5.8) 0.6 (0 to 1.3) 1.1 (0 to 3.3)
Severe leucopenia 0 2.2 (0 to 5.8) 0 1.6 (0 to 3.5)
Gastrointestinal 1.2 (0 to 2.8) 1.1 (0 to 3.3) 0.6 (0 to 1.3) 0.5 (0 to 1.6)
Neurological 0 1.1 (0 to 3.3) 0.3 (0 to 0.8) 0.5 (0 to 2.6)
PMR 0.6 (0 to 1.7) 0 0.3 (0 to 0.8) 0.3 (0 to 0.8)
Allergic (injection) 
reaction
0 0 0 0
†In the dose reduction group only, patients were asked for participation in a study that involved PET/CT scanning. This 
sometimes yielded unexpected abnormalities.
ID: incidence density per 100 person-years; Dose reduction group= 171 observed person years for 18-36 months and 358 
observed person years for 0-36 months; Usual care= 89 observed person years for 18-36 months and 182 observed person 
years for 0-36 months.
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The DRESS (Dose REduction Strategy of Subcutaneous TNF inhibitors) study previously showed 
clinical non-inferiority and superior cost-effectiveness of disease activity guided tapering of 
tumour necrosis factor inhibitors (TNFi) (dose reduction, DR group) over full dose continuation 
(usual care, UC group) in rheumatoid arthritis (RA) patients with low disease activity.1,2 Long-
term extension data showed that safety and efficacy of this strategy were maintained up to 
three years with a large reduction in TNFi use.3 While the fact that the majority of the UC group 
attempted dose reduction between 18-36 months prevented a valid comparison of disease 
activity guided tapering to full dose continuation over the entire study period, this study 
presented an opportunity to make the following comparisons: 
1. Tapering long-term results (in DR group 18-36 months) vs. short-term results (in DR group 
0-18 months)
2. Tapering at rheumatologist discretion (in UC group 18-36 months) compared to full dose 
continuation (in UC group 0-18 months)
3. Tapering at rheumatologist discretion (in UC group 18-36 months) compared to protocolised 
tapering (in DR group 0-18 months) 
We previously reported the main results of the DRESS study (Dutch trial register, NTR3216), 
an open label non-inferiority randomised controlled trial (RCT) in which RA patients with 
low disease activity on a stable TNFi dose (adalimumab or etanercept) were randomised 2:1 
to disease activity guided tapering or full dose continuation. In the first 18 months in the 
DR group, the TNFi dose was reduced stepwise until flare or TNFi discontinuation. In the 
extension phase, both groups were treated according to a treat-to-target protocol: tapering 
was recommended in case of stable low disease activity, at discretion of the rheumatologist in 
both groups. Visits were planned every 6 months, and assessments included disease activity 
(DAS28-CRP), quality of life (EQ5D-5L) and medication use.1,3 Quality adjusted life years (QALY) 
were determined by trapezoid method. Since medication costs were the main cost drivers in 
the DRESS study, only medication costs were recorded from 18-36 months. 
Results from 1000 bootstrapped replications concerning mean QALYs and total (biological and 
non-biological) medication costs for the 3 comparisons are presented in Figure 1 and Table 
1. As shown, for the tapering strategy, costs are slightly but non-significantly higher after 
18 months (higher in 86.3% of replications) with QALY being equal (lower in 66.2%, higher in 
33.8% of replication, 0.007 (95% CI: -0.039 to 0.026) higher QALY for 0-18 months). Tapering 
at rheumatologist discretion is associated with lower cost (100% of replications) and slightly 
lower QALY (in 98.5%) compared to full dose continuation, but also with higher cost (in 99.7% of 
replications) and non-significantly lower QALYs compared to protocolised tapering (in 80.2%).
In conclusion, cost-effectiveness of protocolised tapering was maintained from 18 to 36 
months, although medication costs rose slightly (ns), possibly because a subset of patients 
returned to a higher dose during follow-up. Tapering at rheumatologist discretion was less 
cost-saving than protocolised tapering and resulted in higher QALY loss than protocolised 
tapering, but is still cost-effective compared to full dose continuation.
2.2
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Comparisons within one treatment group are paired observations, and to take this into account for a more efficientanalysis, 
we bootstrapped QALY (0 to 18) - QALY (18 to 36) rather than QALY (0 to 18) 
-
 QALY (18 to 36) 
and likewise for cost.
 
Table 1. Summary of results for each comparison
Comparison Difference in QALY Difference in 
medication costs
Incremental net 
monetary benefit 
Dose reduction 18-36 
vs dose reduction 0-18 
-0.007
(-0.039 to 0.026)
578€
(-575 to 1732)
-1104€
(-3819 to 1612)
Usual care 18-36 to 
usual care 0-18
-0.047 
(-0.092 to -0.005)
-5940€
(-7764 to -4013)
2151€
(-1507 to 5571)
Usual care 18-36 vs. 
tapering 0-18 
-0.028
(-0.096 to 0.043)
4013€
(1676 to 6199)
-6309€
(-12272 to – 280)
Positive QALY or iNMB and negative cost differences favour the group listed first. All figures are presented as mean (95% 
percentile based confidence interval); QALY: Quality adjusted life years; iNMB: incremental Net Monetary Benefit based on 
a willingness to pay of €80,000 per QALY. 4
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Abstract
Objective
In a randomized controlled trial investigating tapering of TNF inhibitors (TNFi) compared 
with usual care in rheumatoid arthritis patients, minimal radiographic progression was more 
frequent in patients who attempted tapering. Possible explanations include higher incidence 
of flaring, higher mean disease activity, or lower TNFi use. 
Methods
18-months data from the DRESS study were used. Change in Sharp van der Heijde (∆SvdH) 
score (linear regression) and proportion of patients with >0.5 ∆SvdH (logistic regression) were 
used as outcomes. Cumulative incidence and number of short-lived and major flares per 
patient, mean time weighted disease activity (MTW-DAS28-CRP), and TNFi use were used as 
independent variables. Regression models were done stratified per study group and corrected 
for possible confounders.
Results
175 of 180 patients had 18-month data available. Mean ∆SvdH were 0.75 and 0.15 units with 
37/116 (32%) and 9/59 (15%) patients exceeding 0.5 points in the tapering and usual care group 
respectively (both p<0.05). MTW-DAS28-CRP, but not incidence or number of short-lived or 
major flares, or TNFi use, was independently associated with mean progression score, but only 
in the tapering group. Additional analyses on DAS28-CRP subcomponents showed that this 
was mainly caused by MTW swollen joint count. No confounders were identified. 
Conclusions
Radiographic progression was associated with higher MTW-DAS28-CRP (and especially 
swollen joint count), but only in patients that tapered TNFi. This finding stresses the 
importance of maintaining disease activity as low as possible in patients in whom TNFi is 
tapered and to check for radiographic progression regularly.
Keypoints
What is already known about this subject?
• The TNFi tapering strategy used in the DRESS study resulted in an increase in radiographic 
progression for patients that attempted tapering compared to patients that continued 
TNFi dosing.
• Although this increase was minimal over 18 months, it may become significant in 
subsequent years and lead to disability.
What does this study add?
• We investigated possible causes and found that higher disease activity (especially swollen 
joints) in combination with lower TNFi exposition was associated with mean radiographic 
progression.
How might this impact on clinical practice?
• This finding stresses the importance of maintaining a state of low disease activity or 
remission in patients in whom TNFi is tapered and to check for radiographic progression 
regularly.
• However, further progression in subsequent years is not to be expected, as higher disease 
activity is a temporary effect of a trial-and-error tapering strategy.
Introduction
Disease activity guided tapering of TNF inhibitors (TNFi) in rheumatoid arthritis (RA) results in 
a significant reduction in TNFi use and subsequent cost, without compromising on important 
clinical outcomes(1). However, in the DRESS (Dose REduction Strategy of Subcutaneous TNF 
inhibitors) study a minimal increase in radiographic progression was observed for patients 
that attempted tapering compared to patients that continued TNFi dosing. 
We propose three hypotheses that could explain this: firstly, in DRESS, short-lived flares were 
more frequent in patients tapering than in patients not tapering, which is a temporary effect 
of the trial-and-error type of tapering strategy. It could be hypothesized that the tapering 
strategy leads to a higher incidence of flares, thus causing radiographic progression(2). 
Secondly, a significantly higher mean time-weighted (MTW) disease activity was observed 
in the tapering group, again induced by the tapering and possibly resulting in radiographic 
progression. Thirdly, tapering causes lower TNFi exposition. Previous studies have suggested 
that TNFi use itself may prevent radiographic progression. Therefore, lower TNFi exposition 
could lead to progression, independent of increased disease activity(3-5). 
These hypotheses have different clinical implications. In the first two hypotheses the effect 
is temporarily: progression is caused by a (sometimes unsuccessful) tapering attempt, not 
by lower TNFi use itself – so in subsequent years damage would not progress further. Tight 
control should be optimized, and if flares could be predicted, progression would be reduced. 
The third hypothesis would mean an ongoing process of radiographic progression in following 
years (Figure 1) and although the increase in progression that we found is minimal, it may 
become significant in subsequent years with consequent loss of function or pain symptoms. 
It would not be preventable by tight control alone and would require frequent radiographic 
monitoring and adaptation of TNFi use. 
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Therefore, we investigated the effects of the occurrence of short-lived or major flare, MTW 
disease activity and TNFi exposition on radiographic progression in patients tapering TNFi 
compared to patients not tapering. 
Figure 1.
 
Patients and methods
Patients and definitions
Clinical and radiographic data from the DRESS study were used: an 18-month, open 
randomized clinical trial, investigating non-inferiority of a disease activity guided tapering 
strategy of adalimumab or etanercept compared to usual care (UC)1,6.
Radiographs from baseline and 18 months were scored pairwise and in chronologic order 
using the Sharp-van der Heijde (SvdH) score by 2 researchers, blinded for clinical outcome 
and study group7. Absolute SvdH score with subcomponents and change (∆) in SvdH score 
between baseline and 18 months were calculated. The proportion of patients with minimal 
progression, defined as ∆SvdH>0.5 points, was calculated. Additionally, proportions of patients 
exceeding the minimal clinically important change (MCIC) (8 points per 18 months, based on 
previous values of 4 points per year)8,9 and smallest detectable change (SDC) (4.1 points)1 were 
calculated. 
Disease activity was defined using a 28 joint based disease activity score (DAS28) with 
C-reactive protein and MTW-DAS28-CRP was calculated over 18 months. For (short-lived) 
flare, a validated flare criterion was used: DAS28 increase of >1.2 compared with baseline, or 
DAS28 increase of >0.6 and current DAS28 ≥3.210. A major flare was defined as a flare lasting 
>3 months. Cumulative incidence of patients with short-lived or major flare and number of 
short-lived or major flares per patient were calculated. 
TNFi use was calculated in both the dose reduction and usual care group, as the normalized 
proportion of the defined daily dose (DDD) of TNFi, with 1.0 as full dose equivalent. DDD: 
40mg/14 days for adalimumab and 50mg/7days for etanercept.
Statistical analyses
STATA/IC v. 13.1 was used. Descriptive statistics were done, (non) parametrically when 
appropriate. Univariate and multivariate analyses were performed with cumulative incidence 
and number of short-lived and major flares per patient, MTW-DAS28-CRP and TNFi use as 
independent variables. Both radiographic progression yes/no (ΔSvdH >0.5; logistic regression) 
and mean ∆SvdH (linear regression) were used as dependent variables. Possible confounders 
that were checked were: age, sex, body mass index, smoking, baseline SvdH score, DAS28-
CRP, CRP, rheumatoid factor, anticitrullinated protein antibody status, oral glucocorticoid 
use and intramuscular or intra-articular glucocorticoid injections, number of glucocorticoid 
injections per patient and synthetic disease modifying antirheumatic drug use. To check for 
effect modification, all analyses were done stratified by allocation group (tapering or UC).
Results
Radiographic progression
175 (116 taper group/59 UC) of 180 patients had clinical and radiographic data available. 
Baseline characteristics were comparable between patients with missing and non-missing 
data. 
Mean SvdH scores were 38.3 (SD 49.3) and 42.1 (58.7) at baseline (p= 0.65), and 39.0 (49.6) and 
42.2 (58.7) at 18 months (p= 0.71) for the taper and UC group respectively (Table 1). Mean ∆SvdH 
over 18 months were 0.75 (1.5) and 0.15 (1.1) in the taper and UC group respectively (p<0.05). The 
difference in ∆SvdH between groups was mainly caused by joint space narrowing; change in 
erosion score was similar (Table 1). No patients exceeded the MCIC. The SDC was exceeded by 
5 (4%) patients in the taper group and no patients in the UC group. Minimal progression was 
found in 37/116 (32%) and 9/59 (15%) patients in the taper and UC group respectively (p<0.05). 
Table 1. Radiographic outcomes
Taper 
group 
(n=116)
Usual care group
(n=59)
Difference 
(95% CI)
Total 
(n=175)
SvdH baseline* 38.3 (49.3) 42.1 (58.7) -3.79 (-20.4 to 12.8) 39.6 (52.5)
SvdH 18 months* 39.0 (49.6) 42.2 (58.7) -3.19 (-19.9 to 13.5) 40.1 (52.7)
Progression SvdH score* 0.75 (1.5) 0.15 (1.1) 0.60 (0.16 to 1.0) 0.55 (1.4)
Progression erosion score* 0.29 (0.8) 0.12 (0.7) 0.17 (-0.07 to 0.42) 0.23 (0.8)
Progression joint space 
narrowing*
0.46 (1.2) 0.03 (0.9) 0.43 (0.07 to 0.78) 0.32 (1.1)
Progression >MCIC† 0 (0) 0 (0) 0 (0) 0 (0)
Progression >SDC† 5 (4) 0 (0) 5 (4) 5 (3)
Progression >0.5† 37 (32) 9 (15) 28 (17) 46 (26)
SvdH: Sharp-van der Heijde score; Progression SvdH: Sharp-van der Heijde progression between baseline and 18 months; 
MCIC: Minimal Clinical Important Change (8 units); SDC: Smallest Detectable Change (4.1 units); *Mean with standard 
deviation (SD); †Number (%)of patients.
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Disease activity and (major) flare
MTW-DAS28-CRP was 2.3 (0.5) and 2.1 (0.6) in the taper and UC group respectively (p<0.01). For 
patients with minimal progression, median MTW-DAS28-CRP was 2.3 (interquartile range, 
IQR 2.0 to 2.8) in the taper group and 2.0 (1.9 to 2.4) in the usual care group. Additional data 
on mean DAS28-CRP at certain time points is provided in Supplementary Table 1. Short-lived 
flares occurred in 84/116 (72%) in the taper group and 16/59 (27%) in the UC group (p<0.001). 
Cumulative incidence of major flare was 14/116 (12%) and 6/59 (10%) in the taper and UC group 
respectively. 
TNFi exposition
The median proportions of DDD were 0.47 (IQR 0.27-0.68) and 1.00 (IQR 0.95-1.00) in the taper 
and UC group respectively(p<0.0001). The lower bound of the IQR of the median proportion of 
DDD was slightly below 1.00 in the UC arm due to patients: discontinuing because of adverse 
events (n=6) or inefficacy (n=2); tapering because of low disease activity (n=5); being on lower 
than DDD dose at inclusion (n=2). 
Regression modelling
Logistic regression with ΔSvdH >0.5 yes/no as dependent variable did not yield any association 
with short-lived or major flares, MTW-DAS28-CRP or TNFi use. In univariate linear regression 
with mean ΔSvdH as dependent variable, only MTW-DAS28-CRP, not occurrence of short-
lived or major flares or TNFi use, was independently associated with progression (β= 0.51 (p= 
0.005)). In multivariate analyses, only MTW-DAS28-CRP remained significantly associated 
with mean ΔSvdH. Effect modification was present by allocation group (Table 2), with a 
significant association between MTW-DAS28-CRP and progression in the taper group , but not 
in the UC group . Stratified corrected analyses for taper and UC group showed non-significant 
associations, except for MTW-DAS28-CRP. Additional exploratory analyses on subcomponents 
of DAS28-CRP showed that MTW tender and swollen joint count (MTW-TJ and MTW-SJ) were 
significantly associated with mean progression in the taper group. Patient global visual 
analogue scale (PG-VAS) and CRP were not significantly associated with mean progression 
(Table 2). Collinearity between MTW-TJ and MTW-DAS28-CRP was high (>0.7) but lower for 
MTW-SJ and MTW-DAS28-CRP, thus, MTW-SJ was added to the model. Afterwards, only MTW-
SJ remained significantly associated with mean progression in the taper group with β=0.52 
(95% CI 0.05 to 0.99)). No significant confounding was identified.
Table 2. Univariate linear regression models stratified by allocation group
Tapering 
group
Usual care 
group
Beta 95% CI Beta 95% CI
MTW-DAS28-CRP 0.64 0.14 to 1.14 0.17 -0.29 to 0.62
constant -0.73 -0.20
MTW-TJ 0.24 0.07 to 0.10 0.05 -0.13 to 0.24
MTW-SJ 0.65 0.25 to 1.04 0.21 -0.19 to 0.62
MTW-PG-VAS 0.02 -0.0001 to 0.38 0.004 -0.02 to 0.03
MTW-CRP -0.001 -0.05 to 0.05 0.006 -0.03 to 0.05
Occurrence of flare 0.24 -0.38 to 0.87 0.091 -0.57-0.75
constant 0.58 0.13
Number of flare per patient -0.025 -0.34 to 0.29 0.041 -0.36 to 0.44
constant 0.78 0.14
Occurrence of major flare 0.69 -0.16 to 1.53 0.82 -0.86 to 1.08
constant 0.67 0.14
Number of major flare per patient 0.71 -0.06 to 1.47 0.11 -0.86 to 1.08
constant 0.66 0.14
TNFi use (% ddd) 0.43 -0.65 to 1.51 -0.068 -1.38 to 1.25
constant 0.54 0.21
95% CI: 95% confidence interval. MTW-DAS28-CRP: mean time-weighted DAS28-CRP. %ddd: percentage of the defined daily 
dose. TJ: tender joint count. SJ: swollen joint count. CRP: C-reactive protein. PG-VAS: patient global visual analogue scale.
Table 3. Final linear regression model stratified by allocation group
Tapering 
group
Usual care 
group
Beta 95% CI Beta 95% CI
MTW-DAS28-CRP 0.28 -0.30 to 0.87 -0.02 -0.70 to 0.65
MTW-SJ 0.52 0.05 to 0.99 0.23 -0.37 to 0.84
constant -0.24 -1.5 to 1.01 0.07 -1.15 to 1.29 
95% CI: 95% confidence interval. MTW-DAS28-CRP: mean time-weighted DAS28-CRP. SJ: swollen joint count. 
Causes of radiographic progression in RA patients tapering TNFi Causes of radiographic progression in RA patients tapering TNFi
33
5756
Discussion
In this study, we investigated possible causes of the minimal difference in radiographic 
progression in RA patients tapering TNFi compared with usual care that was observed in the 
DRESS study. MTW-DAS28-CRP was the only variable significantly associated with progression, 
in the intervention arm of this study. Additional analyses on subcomponents of the DAS28-CRP 
showed that this was mainly caused by swollen joint count. Thus, it is the small overall increase 
in disease activity over time, and more specifically swollen joints, caused by the tapering 
strategy, and not the intermittent episodes of high disease activity (flares) that appear to 
cause progression. In patients that did not taper TNFi this association was not present. This 
suggests that radiographic progression occurs when both necessary causes (higher disease 
activity and lower TNFi exposition, which coincide in tapering), are present. Therefore, tight 
control - although also important in non-tapering patients - is even more important when 
tapering TNFi, to prevent additional progression. However, further progression in subsequent 
years is not to be expected, as higher disease activity is a temporary effect of a trial-and-error 
tapering strategy. 
Our study has some limitations. Firstly, follow-up time of 18 months was limited. Furthermore, 
the level of radiographic progression that is of clinical relevance, is somewhat debatable. In 
2006, Welsing et al established a level of 5 Sharp-Van der Heijde points per year as the minimal 
clinically important change8. This level may be different for the current RA population 
treated with more strict tight control. Therefore we also analyzed progression with different 
cut-off levels (SDC and minimal progression <0.5 SvdH points). Lastly, the observed SDC is 
relatively high and some misclassification of patients with progression that is actually due 
to measurement error could be present. However, this would cause bias towards a null result, 
whereas we did find differences in radiographic progression and in associations between 
disease activity and progression. 
Our findings are in line with three studies that have shown some effect of discontinuation 
but no effect of tapering of TNFi tapering on radiographic progression in RA11-13. In the STRASS 
study, patients were randomized to disease activity guided TNFi tapering or continuation of 
treatment11. Multiple tapering attempts were allowed. A difference in disease activity and 
relapse rate was observed, but no difference in radiographic progression. Follow-up time 
and SDC were comparable to our study but sample size was smaller, which may explain 
why no progression was observed. In PRESERVE, patients were treated with etanercept and 
methotrexate for 36 weeks after which they were randomized to etanercept fixed dose halving, 
discontinuation, or full-dose continuation12. A significantly greater proportion of patients in 
the discontinuation group exceeded the SDC compared with patients continuing etanercept. 
This was explained by the fact that patients had moderate disease activity and were refractory 
to methotrexate monotherapy at study start. Furthermore, disease activity was not steered 
upon, leading to a significant rise in DAS28 after etanercept discontinuation. Lastly, Raffeiner 
et al. showed that randomization of RA patients in remission under etanercept, to either 
receive fixed halve dose etanercept or continuation of full dose etanercept, did not lead to 
differences in radiographic progression after two years13. 
In conclusion, disease activity guided TNFi tapering may result in a small increase in 
radiographic progression. This is possibly due to the disappearance of the direct inhibitory 
effect of TNFi on radiographic progression (‘disconnect’), so that inflammation resumes 
driving this progression. These findings stress the increased importance of maintaining a state 
of low disease activity or remission – especially low swollen joint count – in patients in whom 
TNFi is tapered and to check for radiographic progression regularly. Long-term studies on TNFi 
tapering need to confirm that radiographic damage does not continue to progress over the 
years. Also, future studies should focus on predictors of successful tapering or discontinuation 
to further prevent the rise in disease activity that is the consequence of tapering. 
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Abstract
Objectives
As data on disease activity guided dose optimization of abatacept and tocilizumab are scarce, 
we explored the feasibility, effectiveness and safety of dose optimization of these bDMARDs in 
rheumatoid arthritis (RA) patients in daily practice.   
Methods
RA patients who were treated with abatacept or tocilizumab ≥ 6 months, with DAS28 <3.2 were 
included. Four groups were identified: abatacept dose reduction (DR) and usual care (UC), and 
tocilizumab DR and UC. Successful DR and discontinuation entailed being on lower dose than 
at baseline or having discontinued abatacept or tocilizumab, whilst maintaining DAS28 <3.2. 
Proportions of patients with successful DR or discontinuation at 12 months were described. 
DR maintenance was investigated using Kaplan-Meier curves. Between-group differences in 
mean DAS28 and HAQ-DI change (Δ) over 6 and 12 months were estimated. 
Results
119 patients were included. DR was attempted in 13/28 (46%, 95% CI 28-66%) abatacept 
and 64/91 (70%, 60-79%) tocilizumab patients. At 12 months, 3/11 (27%, 6-61%) abatacept 
and 20/48 (42%, 28-57%) tocilizumab patients were successfully tapered. 1/11 (9%, 0-41%) 
abatacept and 5/48 (10%, 3-23%) tocilizumab patients were successfully discontinued. Mean 
ΔDAS28 and ΔHAQ-DI at month 6 and 12 were not significantly different between DR and UC. 
For tocilizumab, DAS28 was significantly higher in the DR compared to UC group at 6 months. 
Adverse events were comparable between groups. 
Conclusion
Abatacept and tocilizumab DR appears to be feasible,and safe in clinical practice. No benefits 
in terms of fewer adverse events in the DR group were observed. Furthermore, DR was 
suboptimal, since all patients were eligible for DR but in a substantial number of patients, no 
DR was attempted.
Introduction
The advantageous effects of biologic disease modifying anti-rheumatic drug (bDMARD) 
treatment in rheumatoid arthritis (RA) on clinical, functional and radiographic outcomes have 
been well documented. However, bDMARDs are associated with adverse events (e.g. (serious) 
infections) and high costs 1,2. With this in mind, dose optimization becomes important, which 
entails: 1) starting treatment when it is needed, 2) disease activity guided dose reduction to 
the lowest effective level when a patient is doing well, 3) discontinuing the drug when it is no 
longer required and 4) restarting or re-escalating in case of a flare. Disease activity guided dose 
reduction of tumor necrosis factor inhibitors (TNFi) in RA patients has proven to be feasible 
and safe3-5 and has recently been included in RA management recommendations6, however, 
data on disease activity guided dose optimization of non-TNFi bDMARDs are scarce. 
Abatacept is a human fusion protein that selectively modulates the CD80/CD86:CD28 
costimulatory signal required for full T cell activation. It is an effective treatment (either as 
monotherapy or in combination with a conventional synthetic DMARD (csDMARD)) in patients 
who are either csDMARD naïve or had an inadequate response to csDMARD or bDMARD 7-9. 
Tocilizumab is a humanized monoclonal antibody directed against the Interleukin-6 (IL-6) 
receptor and is an effective treatment option after failure of a csDMARD or bDMARD, either as 
monotherapy or in combination with a csDMARD 10-13. 
Few studies have been performed focusing on dose reduction or discontinuation of  abatacept 
or tocilizumab 14-19. With regard to abatacept, Takeuchi et al. observed abatacept-free remission 
in 22 of 34 (65%) patients after one year of discontinuation 15. Furthermore, in the AGREE study, 
a double-blind randomized controlled trial, the efficacy of reduction of intravenous abatacept 
from 10 to 5 mg/kg in early RA patients was investigated 16, showing that the proportions of 
patients who lost DAS28-defined remission status were similar between groups at month12. 
Also, the AVERT study showed that in early RA patients reaching low disease activity after 
abatacept treatment for 12 months, radiographic benefits were maintained at 6 months after 
withdrawal of abatacept17. 
With regard to tocilizumab, Nishimoto et al. investigated discontinuation of tocilizumab 
in patients with early RA treated with tocilizumab monotherapy in the DREAM study18. Low 
disease activity was maintained in 35% after 6 months and in 13% after one year. Furthermore, 
the effects of dose reduction of tocilizumab were described in a small retrospective study in 
22 patients 19. Dose reduction was successful in 55% of patients after 6 months and all patients 
with worsening of disease activity after dose reduction regained low disease activity after 
dose escalation. 
Thus, data on disease activity guided dose reduction of abatacept or tocilizumab in RA 
is limited. Moreover, most studies have focused on early RA patients enrolled in clinical 
trials, leaving uncertainty to its’ feasibility in daily clinical practice. Therefore we aimed to 
retrospectively investigate the feasibility (including frequency of dose reduction attempts 
and persistence), effectiveness and safety of tapering of abatacept and tocilizumab in RA 
patients in daily practice. 
Abatacept and tocilizumab tapering in RA
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Methods
Study design and participants
SONATA (Study ON Abatacept and Tocilizumab Attenuation) is a retrospective explorative 
mono-center controlled cohort study, investigating disease activity and functioning in 
RA patients that reached low disease activity on abatacept or tocilizumab treatment and 
attempted dose reduction, compared with control groups of patients that reached low disease 
activity on abatacept or tocilizumab treatment but never attempted dose reduction. All 
patients at the rheumatology department of the Sint Maartenskliniek, a specialized hospital 
in Nijmegen, The Netherlands, that had been or were still treated with either abatacept or 
tocilizumab were screened for eligibility. Patients were considered eligible if they were 
diagnosed with RA according to the 1987 and/or 2010 ACR criteria and/or clinical diagnosis by 
the treating rheumatologist and were treated at any time with abatacept and/or tocilizumab, 
reached low disease activity (DAS28-ESR <3.2) after 6 months of treatment and had at least 6 
months of follow-up available.
Four cohorts were defined: abatacept dose reduction (DR) group, abatacept usual care 
(UC) group, tocilizumab DR group and tocilizumab UC group. Patients that attempted dose 
reduction because of low disease activity with or without adverse events were included in 
the DR group. Patients in whom DR was attempted solely because of adverse events were 
excluded. Patients who were eligible for DR but in whom no dose reduction attempt was 
undertaken (because of either patient or physician preference or unspecified reasons), were 
included in the UC group. Patients that were treated with both abatacept and tocilizumab 
were included in analyses only once for the first bDMARD used. 
All patients eligible for inclusion were asked for written informed consent for retrospective 
data collection. According to the Central Committee on Research involving Human Subjects 
(CCMO), this type of study does not require approval from an ethics committee in the 
Netherlands. 
Procedures
Abatacept and tocilizumab were started, according to registration specifications: for 
abatacept either intravenously (i.v.) 500, 750 or 1000 mg/4 weeks depending on body weight, or 
subcutaneously (s.c.) 125 mg/week. Tocilizumab was administered either i.v. 8 mg/kg/4 weeks 
or s.c. 162 mg/week. Both were used as monotherapy or in combination with a csDMARD, 
preferably methotrexate. 
Since 2010, a dose optimization protocol is being used in the Sint Maartenskliniek, which 
includes DAS28 steered dose reduction when DAS28 <3.2 is reached in longstanding RA 
patients for at least 6 months (or DAS28 <2.6 if RA is diagnosed <3 years ago). This is done 
by tapering the dose for i.v. bDMARDs and by increasing the interval for s.c. bDMARDs. For 
abatacept and tocilizumab, the following dose reduction regimens are used: 1) Abatacept i.v.: 
dose reduction of 250 mg every 3 months until discontinuation, or dose reduction of 250 mg 
every 6 months until discontinuation in patients with a baseline dose of 500 mg, 2) Abatacept 
s.c.: increasing the interval every 3 months, from 125 mg/7 days, to once every 10, 14 and 21 
days, then discontinuation, 3) Tocilizumab i.v.: dose reduction every 3 months from 8 to 6 to 
4 mg/kg /4 weeks, then discontinuation, 4) Tocilizumab s.c.: increasing the interval every 3 
months, from 162 mg/7 days, to once every 10, 14 and 21 days, then discontinuation. 
All treatment choices were left to the discretion of the treating rheumatologists. If symptoms of 
loss of disease control occurred, temporary treatment with Non-Steroidal Anti Inflammatory 
Drugs (NSAIDs) or steroids was advised. If a flare persisted, either according to a flare criterion 
(DAS28 increase of >1.2 or >0.6 with current DAS28>3.2)20 or according to the judgement of 
the treating rheumatologist, the bDMARD was restarted or the dose was increased to the last 
efficacious dose. In case of persistently high disease activity, the dose was further reinstalled 
up to the registered dose, after which, if disease activity remained high, the bDMARD was 
switched. 
Outcomes
Patient-, disease- and treatment characteristics were collected, as well as data on disease 
activity (28 joint Disease Activity Score using erythrocyte sedimentation rate (DAS28)) and 
functioning (health assessment questionnaire, HAQ-DI). Data was collected at start of 
abatacept or tocilizumab, at baseline (t=0) and every 3 months thereafter. Baseline was 
defined as being eligible for dose reduction. In the DR group this moment was set at initiation 
of dose reduction. In the UC group this moment was set at reaching low disease activity 
and using abatacept or tocilizumab for at least 6 months (theoretical time of start of dose 
reduction). Successful dose reduction and discontinuation were defined as having a lower 
dose or longer interval than at baseline or complete withdrawal of the bDMARD, respectively, 
with concurrent low disease activity (DAS28 <3.2). Follow-up time was 12 months for all 
outcomes, except for survival analysis using the maximal follow up until censoring or stopping 
of abatacept or tocilizumab.
Statistical analyses
STATA/IC v13.1 was used for all analyses. Descriptive statistics were used for demographic 
data and provided with mean (± standard deviation, SD) or median (interquartile ranges, IQR) 
depending on distribution. Proportions and 95% confidence intervals (CI) of patients in whom 
DR and discontinuation was considered successful at 12 months were described. Median time 
of persistence of successful dose reduction and discontinuation was calculated. A survival 
analysis was done using a Kaplan-Meier curve for time to re-escalation due to high disease 
activity in the DR group. Prevalence of patients switching to other bDMARDs within 12 months 
and reasons for switching were compared between the DR group and the UC group for both 
abatacept and tocilizumab. An unpaired t-test was used to assess differences in mean and mean 
change (Δ) in DAS28 and HAQ-DI at 6 and 12 months after becoming eligible in the DR versus 
UC group for abatacept and tocilizumab separately. Linear regression analyses for differences 
in DAS28 at 6 and 12 months between the DR and UC group were constructed to adjust for 
confounders specific for these outcomes. All baseline factors were checked for possible 
confounding. Because of low patient numbers in subgroups, abatacept and tocilizumab were 
combined in these analyses. Only factors that resulted in a change in beta >10% or (in case of 
too many factors relative to patient numbers) that were considered relevant were included 
in the final model. All factors were added to the model at once. Prevalence of pre-specified 
categories of serious adverse events were compared between the DR group and the UC group 
for both abatacept and tocilizumab. Frequencies of missing data were checked. In case of 
single missing values, single imputation was applied by last observation carried forward or 
calculation of the mean of the previous and next value. For linear regression analyses, missing 
baseline values were imputed using multiple imputation (10 times). 
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Results
Patients
From January 2007 until June 2015, 320 patients were treated with abatacept and/or 
tocilizumab, of whom 119 patients were considered eligible. Twenty-eight patients were using 
abatacept: 13 (46%) in the abatacept DR group and 15 (54%) in the abatacept UC group. Ninety-
one patients were using tocilizumab: 64 (70%) in the tocilizumab DR group, and 27 (30%) in the 
tocilizumab UC group. Details and numbers of patients at follow-up are depicted in Figure 
1. Patient characteristics at start of abatacept or tocilizumab and at baseline are depicted 
in Table 1. No large between group differences were observed. At baseline, mean duration of 
abatacept use was 1.1 years (SD 0.4) in the abatacept DR group and 0.7 years (SD 0.3) in the 
abatacept UC group. For tocilizumab, mean duration of tocilizumab use at baseline was 1.4 
years (SD 0.4) in the tocilizumab DR group and 0.7 years (SD 0.3) in the tocilizumab UC group.
Figure 1. Flow chart with patient disposition (*abatacept/tocilizumab)
Table 1. Patient characteristics at start of abatacept or tocilizumab
Abatacept DR
(n=13) 
Abatacept UC
(n=15)
Tocilizumab DR
(n=64)
Tocilizumab UC
(n=27)
Age, years (SD) 59 (14) 59 (12) 61 (11) 55 (17)
Female, n (%) 12 (92) 14 (93) 47 (73) 19 (70)
Weight, kg (SD) 73 (16) 74 (9) 75 (18) 75 (15)
Disease duration, years 
median [p25-p75]
15 [10-18] 17 [12-21] 12 [5-16] 9 [2-16]
Rheumatoid factor
positive, n (%)
12 (92) 12 (80) 51 (80) 19 (70)
Anti-CCP positive, n (%) 9 (69)* 12 (80)* 47 (73)* 17 (63)*
Erosive disease, n (%) 10 (77)* 9 (60)* 36 (56)* 10 (37)*
DAS28 (SD) 4.6 (0.9) 4.1 (1.4) 4.4 (1.2) 4.2 (1.1)
HAQ-DI (SD)† 1.8 (0.6) 1.5 (0.6) 1.5 (0.6) 1.7 (0.6)
I.v. administration, n (%) 11 (85) 9 (60) 56 (88) 19 (70)
S.c. administration, n (%) 2 (15) 6 (40) 8 (13) 8 (30)
Previous csDMARDs,
median [p25-p75]
4 [3-5] 5 [3-6] 3 [2-4] 2 [2-3]
Previous bDMARDs,
median [p25-p75]
4 [3-4] 4 [3-4] 3 [2-4] 3 [3-4]
Concomitant csDMARD,
n (%)
7 (54) 6 (40) 30 (47) 17 (63)
Concomitant MTX, n (%) 4 (31) 5 (33) 11 (17) 10 (37)
Concomitant 
glucocorticoid, n (%)
5 (38) 9 (60) 45 (70) 17 (63)
Anti-CCP: anti-cyclic citrullinated peptide; DAS28: 28 joints disease activity score- erythrocyte sedimentation rate; HAQ-DI: 
health assessment questionnaire – disability index; I.v.: intravenous; S.c.: subcutaneous; csDMARD: synthetic disease-mod-
ifying anti rheumatic drug; bDMARD: biologic DMARD; MTX: methotrexate. *Anti-CCP positivity: 14/119 (12%) missing data 
(2/13 abatacept DR; 2/15 abatacept UC; 8/64 tocilizumab DR; 2/27 tocilizumab UC). Erosive disease: 5/119 (4%) missing data 
(0/13 abatacept DR; 1/15 abatacept UC; 2/64 tocilizumab DR; 2/27 tocilizumab UC). †HAQ-DI: 33/119 (28%) missing data (4/13 
abatacept DR; 3/15 abatacept UC; 21/64 tocilizumab DR; 5/27 tocilizumab UC). 
Medication use
At 12 months, 3/11 (27%, 95% CI 6% to 61%) patients in the abatacept DR group were successfully 
tapered, with the i.v. dose being lowered by 50% in all 3 patients (from 750 mg to 375 mg i.v. 
every 4 weeks in 2 patients and from 500 mg to 250 mg i.v. every 4 weeks in 1 patient). For the 
tocilizumab DR group, 20/48 (42%, 95% CI 28% to 57%) were successfully tapered at 12 months, 
with the baseline i.v. dose of 8 mg/kg being lowered by to 6 mg/kg in 4 patients, to 5 mg/kg in 1 
patient, to 4 mg/kg in 10 patients and to 2 mg/kg in 1 patient. For tocilizumab s.c., the dose was 
lowered from 162 mg/kg every 7 days to every 10 days in 1 patient, to every 14 days in 2 patients 
and to every 28 days in 1 patient. 1/11 (9%, 95% CI 0% to 41%) patients using abatacept and 
5/48 (10%, 95% CI 3% to 23%) using tocilizumab were successfully discontinued. Of these 
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successfully tapered patients, in all 3 abatacept patients and in 12 tocilizumab patients, 
subsequent discontinuation could have been attempted, since these patients were having 
persistent low disease activity, but this was not done for unknown reasons. In 1/13 (8%, 95% CI 
0% to 36%) patients in the abatacept DR group and 14/64 (22%, 95% CI 13% to 34%) patients 
in the tocilizumab DR group, more than one dose reduction attempt was made in the first 6 
months after baseline. Median time of dose reduction with concurrent low disease activity 
was 6 months [p25-75 6-24) for abatacept and 9 months [6-18] for tocilizumab. Median time of 
discontinuation with concomitant low disease activity was 3 months for abatacept (n=1) and 
3 [3-6] months for tocilizumab. 
Figure 2 shows a Kaplan-Meier curve for time until re-escalation to baseline dose for both 
abatacept and tocilizumab, showing tapering was persistent up to 72 months.
Figure 2. Kaplan-Meier survival estimates until re-escalation to baseline dose for abatacept and 
tocilizumab
Hash marks indicate censored patients (end of follow-up)
 
In patients that attempted DR, 22/77 (29%, 95% CI 19 to 40%) patients that re-escalated 
again were having low disease activity at time of re-escalation. Of these, 1 patient using 
abatacept and 17 patients using tocilizumab re-escalated the dose because of a subjective 
increase in disease activity (more complaints, but no increase in swollen joint counts and 
ESR). Four patients using tocilizumab initially reduced the dose because of adverse events 
(in combination with low disease activity) and re-escalated again once the adverse event 
was resolved. None of the patients re-escalating ended up on a higher dose than at baseline. 
The median time to reach low disease activity again after re-escalation was 4.5 [3-6] months 
in the abatacept DR group and 3 [3-6] months in the tocilizumab DR group. In the DR group, 
5/13 (38%, 95% CI 14 to 68%) patients using abatacept were ultimately switched to another 
bDMARD: 2 were switched due to secondary inefficacy after the dose reduction attempt, 2 
were switched due to secondary inefficacy later on (after being back at baseline dose for a 
substantial amount of time) and 1 was switched due to adverse events. 13/64 (20%, 95% CI 
11 to 32%) patients using tocilizumab were ultimately switched to another bDMARD: 2 were 
switched due to secondary inefficacy after dose reduction, 8 were switched due to secondary 
inefficacy later on and 3 were switched due to adverse events. In the UC group, 2/15 (13%, 
95% CI 2 to 40%) patients using abatacept were switched to another bDMARD, both due 
to adverse events. For tocilizumab, 4/27 (15%, 95% CI 4 to 34%) were switched to another 
bDMARD: 3 due to secondary inefficacy and 1 due to adverse events. 
Disease activity and functioning
Mean ΔDAS28 and ΔHAQ-DI at month 6 and month 12 were univariately not significantly 
different between DR and UC groups in both abatacept and tocilizumab (Figure 3 and 
Supplementary table 1), although confidence intervals were wide especially for abatacept. 
Absolute DAS28 scores were univariately significantly higher for tocilizumab in the DR group 
than in the UC group at 6 months, but not at 12 months. No differences were seen for absolute 
DAS28 scores in the abatacept groups. However, adjusted for confounders no significant or 
relevant differences were seen for DAS28 course at 6 and 12 months: DAS28 difference adjusted 
for confounders (age, bDMARD (abatacept or tocilizumab), erosive disease, disease duration 
and DAS28 at baseline): +0.28 higher in DR group (-0.19 to 0.74) at 6 months and (adjusted for 
age, erosive disease, HAQ at start of the bDMARD, DAS28 at baseline) -0.34 lower in DR group 
(-0.98 to 0.29) at 12 months. 
Figure 3a. Mean DAS28 for abatacept and tocilizumab DR and UC groups from baseline to month 12
Low disease activity defined as DAS28 <3.2
Figure 3b. Mean HAQ-DI for abatacept and tocilizumab DR and UC groups from baseline to month 12
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Safety
In the DR groups, 4/13 (31%, 95% CI 9 to 61%) patients using abatacept and 38/64 (59%, 95% CI 
46 to 71%) using tocilizumab experienced at least one adverse event. In the control groups, 2/15 
(13%, 95% CI 2 to 40%) using abatacept and 14/27 (52%, 95% CI 32 to 71%) using tocilizumab 
experienced at least one adverse event. Incidence densities of different categories are depicted 
in Table 3, and were not significantly different between groups. 
Table 3. Incidence densities of different adverse event categories per 100 patient years
Incidence densities Abatacept DR Abatacept UC Tocilizumab DR Tocilizumab UC
Infections 11 (2.2 to 31) 0 19 (12 to 29) 28 (14 to 51
Malignancies 0 3.8 (0.1 to 21) 1.5 (0.2 to 5.4) 5.1 (0.6 to 5.2)
Cardiovascular 0 3.8 (0.1 to 21) 1.5 (0.2 to 5.4) 0
Allergic reaction 0 3.8 (0.1 to 21) 0.7 (0.0 to 4.2) 2.6 (0.1 to 14)
Leucopenia 0 0 14 (8.5 to 22) 7.7 (1.6 to 23)
ALT increase 3.6 (0.1 to 20) 3.8 (0.1 to 21) 5.2 (2.1 to 11) 5.1 (0.6 to 19)
Surgery 7.1 (0.9 to 26) 7.7 (0.9 to 28) 0.7 (0.0 to 4.2) 2.6 (0.1 to 14.3)
Death 0 0 1.5 (0.2 to 5.4) 0
Other 11 (2.2 to 31) 7.7 (0.9 to 28) 9.7 (5.2 to 17) 10 (2.8 to 26)
Incidence density per 100 patient years. Abatacept DR: 28 observed person-years; abatacept UC: 26 observed person-years; 
tocilizumab DR: 134 observed person-years; tocilizumab UC: 39 observed person-years.
Discussion
To our knowledge, this is the first study to investigate the feasibility, effectiveness and safety 
of the implementation of a dose optimization strategy of abatacept and tocilizumab in RA 
patients in daily clinical practice. We could confirm that disease activity, functioning and 
safety were comparable between patients in whom a dose reduction attempt was undertaken 
and patients that never attempted dose reduction, with the exception of a significantly higher 
DAS28 at 6 months in the tocilizumab DR group as compared to the UC group. Furthermore, in 
the majority of patients that were successfully tapered at 12 months, the dosage was lowered 
at least 50% or the interval between injections was doubled (or longer). Also, dose reduction 
seems to be persistent in up to 30% of patients. However, the number of patients in whom 
dose reduction was attempted was lower than expected and tapering was not always done 
according to prespecified protocolised tapering steps. Also, in both the abatacept DR and UC 
group, mean DAS28 rose above the level of low disease activity during follow-up in contrast 
to tocilizumab where DAS28 remained low. We would like to discuss these findings in more 
detail. 
We found that change in disease activity, functioning and safety were comparable between 
patients who tapered and patients who did not taper. This finding is comparable to other 
studies showing that tapering is feasible and safe in abatacept and tocilizumab 15,16,18,19,21-24 
and to disease activity guided tapering in TNFi 3-5. However, direct comparison of results is 
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hampered by the differences in tapering strategies (gradual tapering versus discontinuation 
without tapering first and dose lowering versus injection interval prolongation), criteria for 
successful tapering or discontinuation (low disease activity versus remission and necessity to 
use steroids or csDMARDs), open label versus blinded tapering, and follow-up time used in the 
studies. 
The number of patients in whom a dose reduction attempt was undertaken was lower than 
expected, considering that all included patients were eligible for dose reduction. Furthermore, 
in the DR groups, duration of abatacept and tocilizumab use before a dose reduction attempt 
was made was much longer than in the UC groups. A reason for these low numbers and 
longer time before tapering could be timing. Dose reduction protocols have only been fully 
implemented in our clinic since 2014. Although dose reduction was done multiple times in trial 
settings in our clinic, it could be postulated that the absence of an outpatient clinic protocol 
and lack of experience with dose reduction outside of trial settings in the early years may have 
led to doctors being hesitant to dose reduction. Furthermore, in contrast to subcutaneous 
TNFi, where tapering consists of injection interval prolongation, dose reduction by lowering 
the dose has less obvious advantages to a patient, as the number of infusions needed remains 
the same. Thus, patients may have been more motivated to attempt dose reduction after 
subcutaneous abatacept and tocilizumab have become available. This argument is supported 
by a recent study showing that tapering of subcutaneous tocilizumab by injection spacing 
was more successful than tapering of intravenous tocilizumab by reduction of the dose 25. 
Another possible explanation for the low percentage of dose reduction attempts is the fact 
that abatacept and tocilizumab were initially reserved for RA patients being refractory to 
other bDMARDs. Selection of a worse patient population may induce hesitation from patients 
and physicians to attempt tapering, when improvement in disease activity has proven to be 
a difficult goal to reach in the first place. This might especially be true for discontinuation 
attempts, which were not done in the majority of DR patients. Finally, patients might have 
negative expectations about dose reduction which may cause hesitation to dose reduce or 
induce negative symptoms during dose reduction, the so-called nocebo response 26,27. All these 
factors are ‘real world’ issues and future studies should investigate these facilitators and 
barriers for dose optimization. 
Remarkably, we observed a rise in disease activity above the level of low disease activity in 
both abatacept groups during follow-up, where DAS28 remained below low disease activity 
in both tocilizumab groups. An explanation could be that in our center, abatacept patients 
are more refractory to treatment than tocilizumab and thus a (small) rise in disease activity 
may be accepted more often than in patients using tocilizumab. It could also be that DAS28 
is underestimated in the tocilizumab groups due to the inhibitory effects of tocilizumab on 
inflammation parameters. However, this would be most noticeable in DAS28-CRP whereas we 
used DAS28-ESR. All in all, the apparent rise in disease activity in abatacept patients might 
constitute a spurious finding , explained by small patient numbers in the abatacept groups as 
compared to the tocilizumab group. 
With regard to adverse events, we expected to find a lower incidence of adverse events in the 
DR groups, especially fewer infections, but cumulative incidences were comparable with the 
UC groups. This may be explained by the retrospective, explorative design of this study (with 
probable underreporting of less severe adverse events) and the small numbers of patients in 
the subgroups. However, leucopenia was observed more often in both tocilizumab groups, 
which is a well-known adverse event of this bDMARD and this may suggest that adverse 
events were reported properly. We did not, however, investigate radiographic progression, 
7372 Abatacept and tocilizumab tapering in RA Abatacept and tocilizumab tapering in RA
44
which would have provided further data on safety of tapering of abatacept and tocilizumab, 
especially in the long term. 
Lastly, successful dose reduction appears to be persistent in this study. A recent study 
reported persistent response up to 2 years in patients prolonging the tocilizumab interval 
from 4 to 5 or 6 weeks 28. Other studies reported outcomes with fixed follow-up time of 6 to 
18 months15,16,18,19,21-24, and our study adds that successful dose reduction or discontinuation 
persists up to 72 months in a subset of patients. Although we did not investigate medication 
cost, one may infer that this is associated with a significant cost reduction. 
Our study has some important limitations. Firstly, due to the relatively small patient numbers, 
confidence intervals are large and results should be interpreted with caution. Of course, 
although superiority tests could not demonstrate differences, this cannot be interpreted 
as proof of equivalence, as the latter needs comparison of the confidence interval with an a 
priori chosen non-inferiority margin. Furthermore, at baseline, the prevalence of concomitant 
csDMARD use was low. However, abatacept and tocilizumab are equally effective as 
monotherapy compared to combination therapy, and indeed are registered in the USA as 
such29,30. Furthermore, at least for tocilizumab it is shown that tapering is equally successful in 
patients with and without concomitant methotrexate 23. Also, concomitant csDMARD use has 
been shown not to be a predictor for successful dose reduction 30. 
In contrast to most other studies, we used low disease activity (DAS28 <3.2) instead of remission 
to define successful dose reduction or discontinuation. This was done since remission is only 
reached in 30-80% of patients 32-35, because remission is not always attainable, and because 
protocol adherence of a physician to adjust medication in case disease activity rises above 
remission level is suboptimal (around 65%) 36, reflecting discordance with this strict goal. 
Furthermore, lower disease activity before tapering has not shown to be a predictor for higher 
chance of successful tapering 31. 
All in all, dose optimization of abatacept and tocilizumab in daily clinical practice appears 
to be feasible and safe in a clinical practice setting. However, no benefits in terms of fewer 
adverse events in the dose reduction groups were yet observed. Future research should 
provide further information on possible predictors of successful dose reduction, long-term 
effects of dose optimization of these drugs, as well as the risk of radiographic joint damage. 
Furthermore, protocol adherence may be improved by research on possible facilitators and 
barriers of dose optimization. 
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Abstract
Objective
To evaluate the predictive value of the baseline multi-biomarker disease activity (MBDA) score 
in long-standing rheumatoid arthritis (RA) patients with low disease activity tapering tumor 
necrosis factor inhibitors (TNFi) for successful tapering or discontinuation, occurrence of flare 
and major flare, and radiographic progression. 
Methods
DRESS (Dose REduction Strategies of Subcutaneous TNF inhibitors; Dutch Trial Register, NTR 
3216) is 18-month non-inferiority RCT comparing tapering of TNFi until discontinuation or 
flaring with usual care (UC) in long-standing RA patients with stable low disease activity. Flare 
was defined as DAS28-CRP increase >1.2 or >0.6 if current DAS ≥3.2; major flare was a flare 
lasting >3 months, despite treatment intervention. MBDA scores were measured at baseline. 
Radiographs were scored at baseline and 18 months using the Sharp-van der Heijde score 
(SvdH). Area Under the Receiver Operating Characteristic curve (AUROC) was used to analyze 
the capability of baseline MBDA score for predicting the above-mentioned outcomes.  
Results
Serum samples and outcomes were available for 171 of 180 patients from DRESS (115 tapering; 
56 UC). AUROC analyses showed that baseline MBDA score was not predictive for the above-
mentioned clinical outcomes in the taper group, but did predict major flare in the UC group 
(AUROC 0.72, 95% CI 0.56-0.88). Radiographic progression was minimal and was not predicted 
by MDBA score. 
Conclusion
In this disease activity-guided strategy study of TNFi tapering in RA patients with low disease 
activity, baseline MBDA score was not predictive for successful tapering, discontinuation, 
flare, major flare or radiographic progression in patients who tapered TNFi.  
Key messages
• Predictors for successful tapering or discontinuation of TNFi in RA patients are needed.
• The multi-biomarker disease activity score showed low to moderate correlations with 
DAS28-CRP in this long-standing RA population.
• The multi-biomarker disease activity score did not predict flare-related outcomes in this 
disease activity-guided TNFi tapering trial.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires frequent 
monitoring of disease activity to achieve tight control by setting a treatment target and 
changing treatment accordingly1. The disease activity score (DAS28), based on erythrocyte 
sedimentation rate (ESR) or C-reactive protein (CRP), is currently the most widely used 
measure of RA disease activity2. In either version, DAS28 is a composite measure that includes 
28 tender and swollen joint counts, patient global assessment by visual analogue scale and a 
laboratory measure of inflammation. 
Although use of the DAS28 for treating-to-target has been extensively validated, there 
are possible drawbacks to DAS28, as for any composite disease activity measure. Clinical 
assessments are subject to interobserver variability, resulting in measurement error and 
suboptimal precision3,4. Also, DAS28 can be influenced by other factors than RA disease activity 
(e.g. osteoarthritis, fibromyalgia or other causes of inflammation, such as infection) resulting 
in clinical misclassification of disease activity state. Additionally, ongoing subclinical disease 
activity can cause long-term damage in RA patients who are classified as having low disease 
activity or remission according to DAS285. Finally, joint examination requires face-to-face 
contact and time with trained personnel, which may hamper feasibility in some settings. 
It would thus be desirable to have tools that are more objective and convenient than those 
currently used for measuring RA disease activity. Biomarkers could be promising candidates.
Biomarkers have the potential for smaller measurement error than clinical measures, and 
measuring serum markers may be less costly and more feasible than face-to-face contact 
with full joint counts. Biomarkers could potentially be better for detecting subclinical disease 
activity and, consequently, predicting risk for radiographic damage. Potential drawbacks of 
serum biomarkers include laboratory measurement error and misclassification, as biomarker 
levels may sometimes be affected by other factors than RA6,7. Lastly, despite the inherent 
desirability of objective measurement, it is currently expected that for a measure of RA 
disease activity to have good face, content and construct validity, it needs to include a patient 
perspective on disease activity. This approach contrasts with the reductionist laboratory 
measurement approach, although both approaches may be complementary.  
The multi-biomarker disease activity (MBDA) blood test combines the serum concentrations 
of 12 protein biomarkers in an algorithm, to provide a score that quantifies RA disease activity 
on a scale of 1−100. The MBDA score was designed to correlate with DAS28-CRP, although 
the two can be discordant8−10. The MBDA score often detects elevated disease activity when 
DAS28-CRP or CRP do not11−13. In a study of RA patients receiving ongoing treatment with 
non-biologic disease modifying anti-rheumatic drugs (DMARDs) (median disease duration 
4.6 years), including those in remission or with low disease activity, the MBDA score was a 
stronger predictor of future radiologic progression than the DAS28-CRP11,12. In patients with 
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early RA initiating methotrexate (MTX) treatment, the MBDA score predicted development of 
radiographic progression13 independently of DAS28. It therefore seems possible that the MBDA 
score may be complementary to conventional clinical disease activity assessments.
Treatment strategies in established RA are shifting toward dose optimization, which includes 
dose tapering of biologic DMARDs (bDMARDs) when remission or low disease activity is 
reached. Hitherto, no predictive factors for treatment reduction have been validated. Thus, 
the MBDA score may potentially be of help in identifying patients who could successfully taper 
or discontinue their bDMARD. 
In the present study we therefore investigated the clinical utility of the MBDA score in 
patients with long-standing RA and low disease activity, who were randomly assigned to 
either taper their tumor necrosis factor inhibitor (TNFi) or continue treatment14, by evaluating 
the capability of the MBDA score for predicting successful tapering and discontinuation, the 
occurrence of flare or major flare and radiographic progression. 
Methods
Study population and design 
Baseline serum samples and clinical and radiographic outcomes were used from the Dose 
REduction Strategy of Subcutaneous TNF inhibitors (DRESS) study (Dutch Trial Register, 
www.trialregister.nl, NTR 3216): an 18-month, open randomized clinical trial that investigated 
non-inferiority of a dose reduction strategy of adalimumab or etanercept compared with 
usual care 14. The study was performed at the Sint Maartenskliniek in Nijmegen and Woerden, 
the Netherlands, from December 2011 through May 2014, and was approved by the local ethics 
committee (CMO region Arnhem-Nijmegen, NL37704.091.11). The ethical approval was for the 
DRESS study as well as the collection of serum samples and radiographs for future studies. No 
separate ethical approval was require for the current study. Consenting patients with RA (2010 
American College of Rheumatology RA criteria and/or 1987 RA criteria and/or clinical diagnosis 
by the treating rheumatologist), treated with adalimumab or etanercept at a stable dose for 
at least 6 months and with stable low disease activity at 2 consecutive visits were included. 
Randomization took place by a research physician who allocated patients to the taper group or 
usual care group in a ratio of 2:1, using a randomization list generated by computer, stratified 
for adalimumab and etanercept. 
All patients were treated according to tight control with visits scheduled every 3 months up to 
month 18. Starting at baseline, etanercept and adalimumab injection intervals were increased 
every 3 months in the dose-tapering group. For adalimumab, which was being administered at 
enrollment as 40 mg every 14 days, the steps were: 40 mg every 21 days starting from baseline, 
40 mg every 28 days starting from month 3, then discontinuation at month 6. For etanercept, 
which was being administered at enrollment as 50 mg every 7 days, steps were: 50 mg every 
10 days, 50 mg every 14 days, then discontinuation. In the control group patients were treated 
according to usual tight control care. If patients experienced worsening of disease activity, an 
extra visit was planned. Non-steroidal anti-inflammatory drugs (NSAIDs) and intramuscular 
and intra-articular steroids were allowed and a follow-up visit after 4 weeks was advised. In the 
case of a flare persisting after 4 weeks, the last effective TNFi dosing interval was reinstated; 
if no improvement of disease activity occurred, TNFi was increased stepwise, if needed, to the 
shortest registered interval 14. If a flare persisted thereafter, treatment was switched. Only one 
attempt at tapering was made per patient.
Clinical measurements
The predictive value of baseline MBDA score was evaluated for five clinical outcome measures in 
three categories relevant to TNFi dose reduction: successful dose tapering or discontinuation; 
occurrence of flare or major flare; and occurrence of radiographic progression. Successful 
tapering was defined at 18 months as using the TNFi at a longer interval or lower dose than 
at enrollment, with concurrent low disease activity and absence of flare. Occurrence of a 
flare was defined according to a previously validated criterion: a DAS28-CRP increase of >1.2 
compared with baseline or a DAS28-CRP increase of >0.6 compared with baseline and current 
DAS28-CRP ≥3.2 15. Major flare was defined as a flare persisting >3 months. Thus, a flare was 
defined prior to administration of any treatment for the flare, whereas a major flare was 
defined after up to 3 months of such treatment. For patients with multiple flares, only the first 
flare was considered for analyses. 
Biomarker measurement and the MBDA test
Serum samples were collected at baseline, processed within 2 hours after blood collection and 
stored in standard separator tubes at −80°C. One or two freeze-thaw cycles were required to 
prepare the samples for shipping. All samples were shipped frozen to Crescendo Bioscience 
(South San Francisco, California, USA) for MBDA testing in the CLIA certified laboratory that is 
used for the Vectra® DA test. The 12 biomarkers that were measured are: VCAM-1, EGF, VEGF-A, 
IL-6, TNF-RI, MMP-1, MMP-3, YKL-40, leptin, resistin, SAA and CRP. The MBDA algorithm 
combines the concentrations of these 12 biomarkers to generate a score on a scale of 1 to 100, 
with validated categories of <30 for low disease activity, 30−44 for moderate, and >44 for high 
disease activity 6,10,16. 
Radiography
Standard radiographs of hands and feet were obtained at baseline and after 18 months. 
Sharp van der Heijde (SvdH) scoring was performed by 2 trained observers, who evaluated 
X-rays in chronological order and were blinded to the occurrence of flares and medication 
use. Radiographic progression was defined as change in SvdH >0.5 point from baseline to 
month 1817. The calculated smallest detectable change in SvdH was 4.1 points. For exploratory 
analyses, radiographic progression was evaluated using definitions of change in SvdH >3 
points and change in SvdH >5 points.
Statistical analyses
Descriptive statistics were done parametrically or non-parametrically, as appropriate, and 
mean DAS28-CRP and mean MBDA scores at baseline were calculated. Correlations between 
baseline MBDA score and DAS28-CRP and its subcomponents were assessed by Spearman’s 
ρ. Disease activity categories (low, moderate and high) according to DAS28-CRP and MBDA 
score were cross-classified. Agreement was calculated using quadratic weighted Cohen’s κ. 
Categories used for DAS28-CRP were <2.7 for low disease activity, 2.7−4.1 for moderate disease 
activity and >4.1 for high disease activity 18.
All analyses were performed for all patients combined and by randomization group, with the 
exception of those analyses of successful tapering and successful discontinuation (which 
apply only to the tapering group) and sensitivity analyses of radiographic progression by 
3 or 5 SvdH points (performed only for all patients combined). Analyses of Area Under the 
Receiver Operating Characteristic curve (AUROCs) were used to evaluate the predictive value 
of baseline MBDA score for successful tapering, successful discontinuation, flare, major flare 
Predictive value of the MBDA score for TNFi tapering in RA Predictive value of the MBDA score for TNFi tapering in RA
5.15.1
8584
and radiographic progression. Kaplan-Meier curves were generated for the time to flare using 
baseline MBDA score categories. Cumulative probability plots were generated to display 
radiographic progression for each baseline MBDA category. Characteristics of patients with 
and without missing data were compared. Afterwards, patients with missing data were 
excluded from further analyses.
 
Results
Patient baseline characteristics
180 patients participated in the DRESS study, with 121 patients randomized to dose tapering 
and 59 patients to usual care. Of these patients, 171 (115 tapering, 56 usual care) had baseline 
and outcome measures available, eight patients had no baseline serum sample and one 
patient had no 18-month clinical outcome data. Baseline characteristics were comparable 
between patients with and without missing data. For the 171 patients in the present analyses, 
mean age was 59.0 years (standard deviation [SD] 9.7), 63% were female and median disease 
duration was 10 years (25−75 percentile, 6−16) (Table 1). Mean baseline DAS28-CRP was 2.16 (SD 
0.68) and mean baseline MBDA score was 33.7 (SD 12.3) (Table 2). 
Outcomes related to tapering and flare
At 18 months, 19% (22/115) of patients in the taper group had successfully discontinued TNFi, 
44% (51/115) had successfully tapered the dose and 37% (42/115) were not able to taper the 
dose. Flares occurred in 99/171 (58%) patients, with 84/115 (73%) in the taper group and 15/56 
(27%) in the usual care group (odds ratio, OR 7.4, 95% CI 3.6-15.2). Major flare occurred in 20 of 
171 patients (12%), with 14/115 (12%) in the taper group and 6/56 (11%) in the usual care group 
(OR 1.2, 95% CI 0.4-3.2).
Rates of radiographic progression
Baseline serum samples and radiographic data at baseline and 18 months were available 
for 167 patients. Median SvdH scores at baseline were 23 and 17.5 in the taper and usual care 
groups, respectively (14). Mean (SD) change in SvdH score was 0.71 (1.5) in the taper group and 
0.22 (1.5) in the usual care group. Radiographic progression (change in SvdH >0.5) occurred in 
43/167 (26%) patients: 34/111 (31%) in the taper group and 9/56 (16%) in the usual care group. 
In the total group, 10/167 (6%) had change in SvdH >3 and 4/167 (2%) had change in SvdH >5. 
Table 1. Baseline characteristics
Total
(N=171)
Tapering
(N=115)
Usual care
(N=56)
P value
Demographics
Age, years, mean (SD)
Female, n (%)
Current smoking, n (%)
59.0 (9.7)
108 (63)
43 (25)
59.5 (9.9)
70 (61)
25 (22)
58.0 (9.3)
38 (68)
18 (32)
0.34
0.38
0.14
Disease characteristics
Disease duration, years, median (IQR)
RF positive, n (%)
ACPA positive, n (%)
DAS28-CRP, mean (SD)
MBDA score, mean (SD)
10 (6-16)
136 (80)
123 (72)
2.16 (0.68)
33.7 (12.3)
10 (5-16)
89 (77)
80 (70)
2.17 (0.65)
33.8 (12.5)
10 (6-15.5)
47 (84)
43 (77)
2.15 (0.76)
33.4 (12.0)
0.83
0.32
0.33
0.82
0.82
Treatment characteristics
Duration of current TNFi, mean (SD)
Etanercept, n (%)
Adalimumab, n (%)
Previous bDMARDs, median (IQR)
Concomitant therapy, n (%)
                   sDMARD
                   Methotrexate
                   Glucocorticoids
                   NSAIDs
3.4 (2.4)
111 (65)
60 (35)
0 (0-1)
114 (67)
93 (54)
8 (5)
96 (56)
3.4 (2.4)
74 (64)
41 (36)
0 (0-1)
70 (61)
55 (48)
5 (4)
64 (56)
3.5 (2.2)
37 (66)
19 (34)
0 (0-1)
44 (79)
38 (68)
3 (5)
32 (57)
0.73
0.83
0.83
0.79
0.02
0.01
0.77
0.85
RF: rheumatoid factor; ACPA: anti-citrullinated peptide antibodies; DAS28: 28 joint based disease activity score with C 
reactive protein; MBDA: multi-biomarker disease activity; bDMARD: biologic disease modifying anti rheumatic drug; 
sDMARD: synthetic DMARD; NSAIDs: Non-steroidal anti-inflammatory drug.
Table 2. Multi-biomarker disease activity scores and DAS28-CRP at baseline
18-Month outcome MBDA DAS28-CRP
Successfully stopped 
(N=22)
33.6 (13.1) 2.05 (0.62)
Successfully tapered 
(N=51)  
34.4 (11.3) 2.08 (0.60)
No tapering possible  
(N=42)
33.3 (13.7) 2.34 (0.70)
Usual care 
(N=56)
33.4 (12.0) 2.15 (0.76)
Total
(N=171)
33.7 (12.3) 2.16 (0.68)
Values given as mean (SD). MBDA: multi-biomarker disease activity.
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Association of MBDA score with DAS28-CRP
Spearman correlation between MBDA score and DAS28-CRP at baseline demonstrated a 
significant but low ρ value (ρ=0.2, P=0.01) (Table 3). Correlations of subcomponents of DAS28-
CRP with MBDA score at baseline were greatest for CRP (ρ=0.60, P<0.01) and lowest for tender 
joint count (ρ=0.05, P=0.49) (Table 3). Cross-classification of baseline MBDA score and baseline 
DAS28-CRP showed that most patients (81%) had low disease activity by DAS28-CRP, yet 
65% had moderate or high MBDA scores (Table 4). Agreement by Cohen’s κ with quadratic 
weighting was 0.02. 
Table 3. Spearman’s correlations of baseline multi-biomarker disease activity score vs. DAS28-CRP and 
its subcomponents
Spearman’s ρ p-value
DAS28-CRP 0.20 0.01
TJC -0.05 0.49
SJC 0.01 0.88
VAS-DA 0.05 0.50
CRP 0.60 <0.01
DAS28-CRP: 28-joint count disease activity score with C-reactive protein; TJC: tender joint count; SJC: swollen joint count; 
VAS-DA: visual analogue scale disease activity; MBDA: multi-biomarker disease activity.
Table 4. Cross-classification of DAS28-CRP and multi-biomarker disease activity score
MBDA
DAS28-CRP Low Moderate High Total
Low 48 66 24 138
Moderate 11 14 5 30
High 0 2 1 3
Total 59 82 30 171
Weighted (quadratic) Cohen’s κ was 0.02. MBDA: multi-biomarker disease activity.
Predictive value of baseline MBDA score
Successful tapering and discontinuation 
AUROC for predicting successful tapering vs. no tapering possible by baseline MBDA score 
was 0.53 (95% CI 0.41-0.66) (Table 5). AUROC for predicting successful discontinuation vs. no 
discontinuation possible by baseline MBDA score was 0.51 (95% CI 0.36-0.66) (Table 5; AUROC 
curves in Supplementary Figure 1a and 1b). 
Table 5. Prediction analyses (Area Under Receiver Operating Characteristics curves) using baseline 
multi-biomarker disease activity score
Tapering 
(N=115)
Usual care
(N=56)
Total
(N=171)
Tapering/discontinuation
Successful tapering
Successful discontinuation
0.53 (0.41-0.66)
0.51 (0.36-0.66)
-
-
-
-
Flaring 
Flare
Major flare
0.44 (0.32-0.57)
0.35 (0.18-0.53)
0.63 (0.46-0.80)
0.72 (0.56-0.88)
0.50 (0.41-0.59)
0.46 (0.32-0.65)
Radiographic progression
>0.5 SvdH points
>3 SvdH points
>5 SvdH points
0.49 (0.37-0.60)
-
-
0.67 (0.46-0.87)
-
-
0.53 (0.43-0.63)
0.46 (0.25-0.68)
0.68 (0.39-0.99)
AUROC (Area Under the Receiver Operating Characteristic Curves) values (95% CI). For radiographic progression analyses, N 
values: 111, 56 and 167. SvdH: Sharp-van der Heijde score.
Flare and major flare 
AUROC for predicting any (i.e., first) flare by baseline MBDA score was 0.50 (95% CI 0.41-0.59) 
for both groups combined; 0.44 (95% CI 0.32-0.57) for the taper group and 0.63 (95% CI 0.46-
0.80) for the usual care group (Table 5; Supplementary Figure 2a and 2b). AUROC for predicting 
major flare by baseline MBDA score was 0.46 (95% CI 0.32-0.65) for both groups combined; 0.35 
(95% CI 0.18-0.53) for the taper group and 0.72 (95% CI 0.56-0.88) for the usual care group (Table 
5; Supplementary Figure 2c and 2d). After removal of patients who were not having in low 
disease activity at baseline (DAS28-CRP>3.2), AUROC for any flare by baseline MBDA score was 
0.52 (95% CI 0.43-0.61) for all patients combined: 0.40 (95% CI 0.27-0.53) for the taper group 
and 0.70 (95% CI 0.53-0.87) for the usual care group. For major flare, AUROC was 0.47 (95% CI 
0.32-0.61) for all patients combined: 0.34 (95% CI 0.17-0.52) in the taper group and 0.79 (95% CI 
0.64-0.95) in the usual care group. The time to flare is represented in Kaplan-Meier curves for 
the low, moderate or high MBDA categories in the taper and usual care groups, respectively 
(Supplementary Figures 3a and 3b). No association between MBDA category and flare was 
present in the taper group. In the usual care group, a trend toward an association of greater 
MBDA score with more frequent flares was observed.
Radiographic progression
AUROC for predicting radiographic progression of >0.5 SvdH point by baseline MBDA score was 
0.53 (95% CI 0.43-0.63) for the taper and usual care groups combined; 0.49 (95% CI 0.37-0.60) 
for the taper group; 0.67 (95% CI 0.46-0.87) for the usual care group (Supplementary Figure 4a 
and 4b). AUROCs for predicting progression by SvdH cut-off values of 3 and 5 points in the total 
group were also non-significant (Table 5). 
Cumulative probability plots of radiographic progression (i.e., change in SvdH from baseline to 
18 months) for the low, moderate and high categories of baseline MBDA score demonstrated 
no association between MBDA category and progression rate in the taper group and a trend 
toward greater progression among patients with high MBDA score in the usual care group 
(Supplementary Figure 5). 
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Discussion
This is one of the first studies to investigate the MBDA score in patients with long-standing 
RA who tapered TNFi treatment. Our primary findings are that the MBDA score before the 
initiation of tapering was not predictive of successful tapering or stopping of TNFi treatment, 
occurrence of flare or major flare, or radiographic progression in the clinical context of DRESS, 
a study of long-standing RA patients tapering TNFi under tight control 14. 
Our findings seem robust and valid, at least in this specific context. The design, determinant 
and outcome measurements, analyses and reporting used for this diagnostic prediction study, 
closely follow STARD recommendations 19. Although this study was not a priori powered for 
these analyses, the sample sizes appear to be reasonable, as witnessed by sufficiently narrow 
confidence intervals. Finally, most of our analyses show similar results.
Some misclassification of successful dose tapering or discontinuation may be present in 
this study. Although we used a previously validated flare criterion in the study protocol 15, 
a proportion of patients could have been falsely classified as being unable to taper or stop 
if, for example, their continuation of TNFi treatment was due to fear of flaring (by patient 
or rheumatologist) rather than actual flare symptoms. This effect could have caused a bias 
towards lower correlation measures, but it seems unlikely that it would have caused the 
null results that were found. It is possible that treatment administered for flares altered the 
relationship between baseline MBDA score and the subsequent declaration of major flares, 
potentially explaining that negative finding. However, the relationship between simple flares 
and MBDA score should not have been comparably affected. 
A borderline positive predictive value of baseline MBDA score for major flare was found in 
the entire usual care group and for flare and major flare in usual care patients who had low 
disease activity at baseline. These results should be interpreted cautiously as they may be false 
positive findings due to multiple testing. In addition, the association with major flare in the 
tapering group was nearly significant in the opposite direction (higher MDBA score associated 
with less flare). Review of medication use (sDMARDs and steroids) during the trial does not 
indicate that patients in the taper group were treated more aggressively in anticipation of 
flare, which if true, may have caused flares to be less prevalent and less severe in that arm 14. 
Also, in this scenario we may have found significant AUROCs for flares, which were untreated, 
whereas we found only a non-significant trend in the usual care group. 
The capability of the MDBA score to predict outcomes after reduction of RA treatment has 
been evaluated in two other studies, RETRO and POET 20,21. Both studies differed from DRESS 
in several ways, and both reported the MBDA score to be a significant predictor of outcomes. 
Rech et al. described the predictive value of the MBDA score for relapse in RETRO, a 3-arm, 
12-month RCT of dose tapering and discontinuation of bDMARDs and sDMARDs for RA patients 
in sustained DAS28 remission 20. MBDA score and ACPA were each predictive for relapse vs. 
remaining in remission, with improved predictive value when they were used together. 
Interpretation of this result needs to consider that all RA medications, including bDMARDs, 
sDMARDs and low dose steroids, were tapered in RETRO, with or without subsequent 
discontinuation. Moreover, only one-third of patients in the treatment reduction arms were 
using a bDMARD, which included TNFi and tocilizumab. Thus, it is unclear which tapered 
medications were responsible for the predictive ability of MBDA score or ACPA in that cohort20. 
Relapse was more frequent in RETRO than major flares were in DRESS, possibly due to the 
different reduction strategies and definitions for loss of response. In DRESS, neither MBDA 
score nor ACPA was predictive of flares following TNFi tapering 14. 
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A subanalysis of POET showed that the MBDA score was a predictor for flare after TNFi 
discontinuation during 12 months follow-up 21. POET enrolled patients with long-standing RA, 
like DRESS, and with a requirement of stable low disease activity by DAS28 while receiving 
adalimumab or etanercept. Only patients who were randomized to discontinuation were 
included in the subanalyses. The sample size in the analysis of MBDA score in POET was large 
(N=439). The primary clinical objective of POET used a DAS28-based flare criterion that was not 
included in the analyses of prediction by MBDA score 21,22. The four flare definitions that were 
used for the prediction analyses were based on physician/patient judgment or decision 21. The 
occurrence of a flare in POET increased from approximately 60% to 80% between patients 
with low vs. high baseline MBDA score, suggesting that, in that context, the MBDA score was 
most applicable for predicting who was at greatest risk of flare, and not who was at low risk. 
Results of RETRO and POET are intriguing but comparing them with DRESS is difficult due to 
differences in design and analyses. 
Our finding that radiographic progression was not associated with baseline MBDA score 
in DRESS disagrees with five studies in four cohorts of patients, with established RA 11,12,23 
or early RA 13,24. The different results might be due to the low frequency and severity of 
radiographic progression in our study, with only a small difference in favor of the usual 
care group. It might reflect the strict tight control that was applied to patients who were 
already in low disease activity or remission. Moreover, several variables that may have 
driven radiographic progression in DRESS − tapering with associated flaring, temporary 
increases in disease activity, and reduced TNFi use − occurred after baseline and may have 
disconnected radiographic progression from the baseline MBDA score. MBDA score was also 
reported to not be associated with radiographic progression among patients treated with 
abatacept or adalimumab in the AMPLE study 25. This conclusion was based on the analysis 
that presented the distribution of radiographic non-progressors across the low, moderate 
and high MBDA categories, rather than the frequency of radiographic non-progressors within 
MBDA categories. A subsequent re-analysis of the same data from AMPLE used, instead, an 
approach similar that of prior MBDA analyses and demonstrated that the MBDA score was 
positively associated with radiographic progression in AMPLE, although numbers of patients 
with progression were low 26. Additional data from AMPLE supported the findings of this re-
analysis 27. This positive relationship between MBDA score and radiographic progression in 
AMPLE is thus consistent with the results of other studies which, unlike DRESS, did not employ 
a tapering strategy 11−13,23,24.
In summary, the baseline MBDA score was not found to be a predictor of flare-related outcomes 
for patients tapering TNFi in the clinical context of DRESS − a study of disease activity-guided 
TNFi tapering in patients with long-standing RA under tight control. It is conceivable that 
in different contexts, for example in early RA patients, patients with higher levels of disease 
activity, or circumstances with less than optimal tight control, the MBDA score may have 
predictive value for relevant clinical outcomes. Confirmatory research of these findings is 
warranted. 
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Supplementary Figure S1. Baseline multi-biomarker disease activity score predicting successful 
tapering (A) or stopping (B)
Prediction analyses using receiver operating curves. Successful tapering: n=51; successful stopping: n=26.
Supplementary Figure S2. Baseline multi-biomarker disease activity score predicting flare and major 
flare in the taper and usual care group
  
  
Prediction of flare in the taper (A) and usual care (B) groups; prediction analyses using receiver operating curves. Flare in the 
taper group: n=84; flare in the usual care group: n=15. Prediction of major flare in the taper (C) and usual care (D) groups; 
prediction analyses using receiver operating curves. Major flare in the taper group: n=14; major flare in the usual care 
group: n=6.
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Supplementary Figure S3. Kaplan-Meier curves for flare by baseline multi-biomarker disease activity 
category
 
 
A) Taper group (n=115): low MBDA score (n=43); moderate MBDA score (n=49); 
high MBDA score (n=23). B) Usual care group (n=56): low MBDA score (n=16); moderate MBDA score (n=33); high MBDA score 
(n=7).
Supplementary Figure S4. Baseline multi-biomarker disease activity score predicting radiographic 
progression 
    
Prediction analyses using receiver operating curves. A) Baseline MBDA score for predicting RP in taper group. B) Baseline 
MBDA score for predicting RP in usual care group. Occurrence of radiographic progression in the taper group: n=34; usual 
care group: n=9.  
 
Supplementary Figure S5. Cumulative probability plots for radiographic progression by multi-
biomarker disease activity category
A) Taper group (n=111): low MBDA score, n=41; moderate MBDA score, n=48; high MBDA score, n=22. B) Usual care group 
(n=56): low MBDA score, n=16; moderate MBDA score, n=33; high MBDA score, n=7. Triangles: low MBDA score; Squares: 
moderate MBDA score; Circles: high MBDA score. SvdH: Sharp-van der Heijde score; MBDA: multi-biomarker disease activity.
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Abstract
Background
To evaluate if TNF inhibitor serum drug levels (DL) or anti-drug antibodies (ADAb) can predict 
successful dose reduction (in patients with high DL) or discontinuation (in patients with no/
low DL or ADAb) in rheumatoid arthritis (RA) patients. 
Research design and methods
RA patients that were using adalimumab (n=42), etanercept (n=76) or infliximab (n=51) and 
were doing well, were tapered until discontinuation or flare (1-1.5 year follow up). Random 
timed DL for adalimumab and etanercept and trough DL for infliximab were measured before 
dose reduction: Receiver-Operator-Curves (ROC) analyses with optimal cut-off DL were 
determined. 
Results
No predictive value of adalimumab and infliximab DL for all outcomes were found, except for 
an inverse association of lower etanercept DL and higher chance for successful dose reduction 
(Area Under the Curve (AUC) 0.36, 95%CI 0.23-0.49; cut-off <2.6 mg/l). In sub analyses, higher 
adalimumab trough DL predicted successful dose reduction (AUC 0.86, 0.58-1.00; cut-off >7.8). 
ADAb were infrequent and not predictive of successful discontinuation.
Conclusion
No predictive value of baseline adalimumab, etanercept and infliximab DL or ADAb for 
successful dose reduction or discontinuation in RA was found in this context, with the possible 
exception of high adalimumab trough levels for successful dose reduction. 
Introduction
Tumour necrosis factor inhibitors (TNFi) have proven to be effective in clinical, functional 
and radiographic outcomes in patients with rheumatoid arthritis (RA)1. However, TNFi are 
costly and are associated with (dose-dependent) side effects, like infections and melanoma2-4. 
Optimal use of these drugs is therefore warranted, by, amongst others, using the lowest 
effective dose in the individual patient, and discontinuing treatment when this is no longer 
necessary. 
A number of studies in patients who achieve persistent low disease activity demonstrated 
that dose reduction and discontinuation is possible in a relevant proportion of patients 
without increase in disease activity5. However, disease activity guided dose reduction in the 
subset of patients already using the optimal dose, will lead to (temporary) flaring of disease 
activity. Although, fortunately, dose escalation or restart of the drug is effective in the majority 
of patients 5, and short lived flares do not seem to compromise quality of life, functioning or 
radiological outcome 6, they can still present a burden for patients.  
Prediction of successful dose reduction or discontinuation in addition to a disease activity 
guided type of dose reduction could have two advantages: 1) in patients in whom TNFi can only 
partially be dose reduced or in whom dose reduction is not possible at all, the flares caused by 
the dose reduction attempt can be prevented and 2) when successful discontinuation can be 
predicted, no dose reduction phase is necessary, thus saving time and medication. So far, no 
evident biomarkers that are able to predict successful dose reduction or discontinuation have 
been identified 7. 
Possible predictors for successful dose reduction or discontinuation could be TNFi serum drug 
levels (DL) and anti-drug antibodies (ADAb). Clinical scenarios have been proposed in which 
measurement of TNFi DL or ADAb is suggested to be valuable in patients doing well (with low 
disease activity) 8-10. These scenarios follow classic pharmacokinetic rules, based on the concept 
of a therapeutic window with an upper and lower boundary, and they share two central 
hypotheses: 1) a patient with low disease activity and no or low DL and/or ADAb has a higher 
chance of successful discontinuation of the TNFi, as the dose is below the lower boundary 
of the therapeutic window and a clinical effect might not be expected and 2) a patient with 
low disease activity and a high DL has a higher chance of successful dose reduction, as the 
same clinical effect is to be expected with a lower dose (that is still within the therapeutic 
window). Although these hypothesis seem rational, studies testing these hypotheses with the 
appropriate design11 are scarce. 
Therefore, the aim of this study was to investigate whether serum TNFi DL and/or presence 
of ADAb can predict successful dose reduction or withdrawal of adalimumab, etanercept or 
infliximab in RA patients with stable low disease activity. Our study has nine separate null 
hypotheses, three for each TNFi. These are, that there is 1) no positive association between 
high drug levels with successful dose reduction, 2) no positive association between low drug 
levels and successful stopping, and 3) no positive association between the presence of anti-
drug antibodies and successful stopping. In addition to testing these hypotheses, validation 
analyses of previously proposed cut-off levels for high or low adalimumab, etanercept and 
infliximab drug levels will be done by calculating sensitivity and specificity. 
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Patients and methods
Study population and design 
RA patients from 2 different studies were included for analyses: 1) patients included in the 
intervention arm of an open randomised clinical trial investigating non-inferiority of a dose 
reduction strategy of adalimumab or etanercept compared to usual care, and 2) patients 
from an observational cohort study on dose reduction and discontinuation of infliximab6,12. 
The study on adalimumab/etanercept has been approved by the local ethics committee 
(Commissie Mensgebonden Onderzoek region Arnhem-Nijmegen, NL37704.091.11). The study 
on infliximab was an observational cohort study and this study did not require approval of 
an ethical committee according to Dutch legislation. Data on prediction of successful dose 
reduction or discontinuation by using baseline adalimumab or etanercept has been described 
shortly in a previously published letter 13. Analyses done in this letter have been extended with 
sensitivity analyses. Furthermore, data on infliximab drug levels and antidrug antibodies have 
not been published as full text article previously.
In both studies RA patients (either 2010 ACR RA and/or 1987 RA criteria and/or clinical diagnosis 
of the treating rheumatologist) using adalimumab, etanercept or infliximab in any stable 
dose and with a low disease activity (judged by the rheumatologist) for at least 6 months 
were included. Patients were treated according to the tight control principle. Visits were 
planned every 3 months and patients were encouraged to contact the outpatient clinic if they 
experienced deterioration of disease activity. Follow-up was 18 months for patients in whom 
dose reduction of adalimumab or etanercept was attempted and 12 months for patients in 
whom infliximab dose reduction was attempted. 
For patients dose reduction adalimumab or etanercept, the dose reduction strategy consisted 
of stepwise increasing the interval between injections every three months. For adalimumab 
these steps were: 1) 40 mg every 21 days, 2) 40 mg every 28 days, 3) discontinuation. For 
etanercept these steps were: 1) 50 mg every 10 days, 2) 50 mg every 14 days, 3) discontinuation. 
For patients dose reduction infliximab, the dose was reduced with 25% of the baseline dose (3 
mg/kg) every 8 to 12 weeks until discontinuation. 
In case of flare, the last effective interval was reinstated. If the flare persisted, TNFi was 
increased until the shortest registered interval or the last effective dose. If the flare persisted 
thereafter, treatment was switched. A flare was defined using a DAS28 based flare criterion 
(14): a DAS28 increase of >1.2 or a DAS28 increase of >0.6 and current DAS28 ≥3.2. In the 
infliximab cohort DAS28 was used, whereas in the DRESS study, DAS28-CRP was used with the 
same cut-off levels for flare. In the DRESS study, re-escalation was deemed necessary if the 
flare criterion was met for ≥4 weeks. In the cohort study of patients using infliximab, the flare 
criterion was met if it lasted ≥2 weeks. 
At study end (month 18 in the DRESS study and month 12 in the infliximab cohort study), 
patients were categorised as 1) successful dose reduction (lower dose or longer interval than 
at baseline with concurrent low disease activity), 2) successful discontinuation (complete 
withdrawal of the bDMARD with concurrent low disease activity), 3) no dose reduction 
possible (back at dose/ interval used at baseline or higher dose/shorter interval than used at 
baseline or switched to another bDMARD). 
Assays
Serum samples were collected at baseline (before initiation of dose reduction). For pragmatic 
reasons, for adalimumab and etanercept, serum samples were collected at a regular 
outpatient clinic visit, thus unrelated to time of injection. The time of the previous and next 
adalimumab or etanercept injection was noted. For infliximab, serum samples were collected 
just before administration of the next infliximab dose, thus timed at trough level. Serum 
adalimumab, etanercept and infliximab levels were measured batch wise, after the study was 
completed and blinded for individual patient outcome, using enzyme-linked immunosorbent 
assay (ELISA) based on their ability to bind TNF 15,16. 
Adalimumab trough levels have been proposed to be therapeutically low when <5 mg/l and 
high when >8 mg/l 17,18*, for etanercept previously published thresholds were low when <1.8 
mg/l and high when >4.6 mg/l 19*, and for infliximab, thresholds were low when <1.0 mg/l and 
high when >5.0 mg/l 20-22, all on a group level. 
Anti-adalimumab and anti-infliximab antibodies were assessed using a validated antigen-
binding test (Radio Immuno Assay (RIA)). Anti-adalimumab antibodies were considered 
positive based on the lower limit of detection if both the value was >12 arbitrary units/ml and 
the adalimumab level was <5mg/l 16. Anti-infliximab antibodies were considered positive if 
both the value was >12 arbitrary units/ml and trough level was <1.0 mg/l 21. Anti-etanercept 
antibodies were assessed using different assays; RIA, bridging ELISA and IgG4-ABT 15. 
Statistical analyses
Associations were analysed using Receiver Operator Curve (ROC) analyses and calculation of 
the point estimates of the area under the curve (AUC) and surrounding confidence interval, to 
test whether the lower limit of the confidence interval was above 0.5. 
Sample size calculation showed that, with a null hypothesis of a ROC AUC of 0.5, an expected 
AUC of 0.75, an event rate of 20% (being able to stop) to 40% (being able to dose reduce), a total 
of 65 to 43 patients per drug (adalimumab, etanercept or infliximab) respectively were needed 
to be able to reject a null hypothesis with a power (1-beta) of 0.8 and alpha of 0.05.
Descriptive statistics were used for demographic or clinical data. Percentages of patients 
were calculated for three different outcomes: successfully stopped, successfully dose reduced 
(lower dose/higher interval than baseline) or no dose reduction possible. Mean drug levels 
and proportions of patients with anti-drug antibodies were calculated and differences in 
mean drug levels between groups were tested using a t-test. For the primary analysis, ROC 
with optimal cut-off levels (using Youden) were created for adalimumab, etanercept and 
infliximab levels, and for the presence of anti-drug antibodies, versus the outcomes successful 
discontinuation and successful dose reduction separately, compared to the ‘no dose reduction 
possible’ group. Additionally, validation analyses were done by calculating sensitivity and 
specificity of previously proposed cut-off levels. Because adalimumab and etanercept 
sampling was done at random time in relation to injection instead of trough level timing, 
exploratory sub analyses were done for three groups of patients with approximately peak 
sampling (adalimumab day 1-4 and etanercept day 1-2 after last injection), trough sampling 
(adalimumab 11-14 days and etanercept 6-7 days after last injection) and intermediate timed 
sampling. No correction for multiple testing was applied.
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Results
Patient characteristics and baseline (anti) drug levels
For details on patients’ disposition of both studies, we refer to Supplement 1. Baseline serum 
samples and outcome were available for 42 patients using adalimumab, 76 using etanercept 
and 51 patients using infliximab (Table 1). 3 patients using etanercept were excluded because 
of missing serum sample (n=2) and being lost to follow-up after 3 months (n=1). The numbers 
and percentages of patients that could successfully reduce the dose or discontinue or were not 
able to reduce the dose are depicted in table 2. Mean drug levels and anti-drug antibodies were 
not significantly different between the three outcome subgroups (Table 2). Anti-adalimumab 
antibodies (low titres, 15 to 46 U/ml) were detected in 4 patients (10%), 2 patients used 
methotrexate co-medication, the other 2 patients used adalimumab monotherapy. No anti-
etanercept antibodies were detected. Anti-infliximab antibodies were detected in 8 patients 
(16%) of whom 7 were treated with concomitant DMARDs (methotrexate, leflunomide and 
azathioprine).
Table 1. Baseline patient characteristics
bDMARD ADM ETA IFX
(n=42) (n=76) (n=51)
Age, years (SD) 61 (8.2) 58 (10.7) 59 (11.2)
Female, n (%) 27 (64) 46 (61) 29 (57)
Current smoking, n (%) 13 (31) 14 (18) 8 (16)
BMI (SD) 27 (5.0) 27 (4.8) 26 (3.4)
Diagnosis according to 2010 and/or 1987 ACR criteria, n (%) 42 (100) 70 (93) 51 (100)
Disease duration, years median [p25-p75] 7.5 [5-15] 13 [10-21] 12 [9-18]
RF positive, n (%) 32 (76) 60 (79) 42 (82)
ACPA positive, n (%) 32 (76) 51 (67) 37 (73)
DAS28-CRP (SD) 2.2 (0.6) 2.2 (0.7) -
DAS28-ESR (SD) 2.6 (0.8) 2.4 (0.7) 2.5 (0.7)
Duration of current TNFi therapy, years (SD) 4.5 (2.2) 2.9 (2.5) 5.6 (2.6)
Previous sDMARDs, median [p25-p75] 2 [1-3] 2 [1-3] 3 [2-3]
Previous TNFi, median [p25-p75] 1 [0-1] 0 [0-1] 5 (10)
Concomitant therapy
   sDMARD, n (%)
   MTX, n (%)
   glucocorticoid, n(%)
   NSAID, n (%)
27 (64)
23 (55)
2 (5)
23 (55)
45 (59)
34 (45)
3 (4)
42 (55)
41 (80)
35 (68)
2 (4)
27 (53)
bDMARD=biologic Disease Modifying AntiRheumatic Drug; ADM= adalimumab; ETA= etanercept; IFX= infliximab; 
BMI= Body Mass Index; RF= rheumatoid factor; ACPA= anti-Citrullinated Peptide Antibodies; DAS28= 28 joints disease 
activity score; CRP= C reactive protein; TNFi= Tumor Necrosis Factor inhibitor; sDMARD=synthetic Disease Modifying 
AntiRheumatic Drug; MTX= Methotrexate; NSAID= Non-Steroidal Anti Inflammatory Drug
Table 2. Mean or median drug levels and antidrug antibodies at baseline
A: adalimumab (n=42)
Outcome at 18 months Mean drug level at 
baseline mg/l (SD)
Anti-drug antibodies (%)
Successfully discontinued, n=11 8.5 (2.8) 0
(26%, 95% CI 14 to 42%)
 
Successfully dose reduced, n=15 8.1 (5.2)                 ns 1 (7)
(36%, 95% CI 22 to 52%)
No dose reduction possible, n=16 6.8 (4.1) 3 (19)
(38%, 95% CI 24 to 54%)
B: etanercept (n=76)
Outcome at 18 months Mean drug level at 
baseline mg/l (SD)
Anti-drug antibodies (%)
Successfully discontinued, n=11 2.7 (1.3) 0
(15%, 95% CI 7 to 24%)
Successfully dose reduced, n=37 2.0 (0.9)               ns 0
(49%, 95% CI 37 to 60%)
No dose reduction possible, n=28 2.4 (1.0) 0
(37%, 95% CI 26 to 49%)
C: Infliximab (n=51)
Outcome at 12 months Median drug level at baseline 
mg/l (IQR)
Anti-drug antibodies (%)
Successfully discontinued (n=8)  1.0 (IQR 0.3-1.1) 1 (12.5)
(16%, 95% CI 7 to 29%)
Successfully dose reduced (n=23) 1.7 (IQR 0.54-5.1)                      ns 1 (4)
(45%, 95% CI 31 to 60%)
No dose reduction possible (n=20) 0.55 (IQR 0.03-2.35) 6 (30)
(39%, 95% CI 26 to 54%)
SD=standard deviation; IQR=interquartile range; ns= not statistically significant
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Primary analysis
ROC analyses showed no significant predictive value of adalimumab, etanercept or infliximab 
serum levels for successful dose reduction or discontinuation (Figure 1), except for a significant 
but small -inverse- association between lower etanercept levels and higher chance for 
successful dose reduction (AUC 0.36, 95% CI 0.23-0.49; optimal cut point <2.6 mg/l; sensitivity 
81%, specificity 44%). Presence of anti-adalimumab or anti-infliximab antibodies was not 
predictive for successful discontinuation.
Figure 1. Receiver Operator Curves (ROC)
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Exploratory sub analyses
Sensitivity and specificity of high, intermediate and low serum drug levels according to the 
previously published cut-off values of low, intermediate and high level for successful dose 
reduction, discontinuation or no dose reduction possible are depicted in table 3. 
Table 3. Sensitivity and specificity for previously proposed high, low and intermediate drug level cut-off 
values for the outcomes successful dose reduction, discontinuation or no dose reduction possible
TNFi Outcomes Sensitivity (95%CI) Specificity (95%CI)
Adalimumab level
High (>8.0 mg/l) Successful dose 
reduction
40% (16-68%) 63% (42-81%)
Low (<5.0 mg/l) Successful 
discontinuation
0% (0-7%) 68% (49-83%)
Intermediate (5.0-8.0 mg/l) No dose reduction 
possible
38% (15-65%) 62% (41-80%)
Etanercept level
High (>4.6 mg/l) Successful dose 
reduction
0% (0-4%) 95% (83-99%)
Low (<1.8 mg/l) Successful 
discontinuation
18% (2-52%) 62% (48-93%)
Intermediate (1.8-4.6 mg/l) No dose reduction 
possible
68% (48-84%) 42% (28-57%)
Infliximab level
High (>5.0 mg/l) Successful dose 
reduction
26% (10-48%) 82% (63-94%)
Low (<1.0 mg/l) Successful 
discontinuation
50% (16-84%) 56% (40-71%)
Intermediate (1.0-5.0 mg/l) No dose reduction 
possible
20% (6-44%) 58% (39-75%)
Mean serum drug levels for the different serum sampling times show a trend to lower levels 
with increasing time after injection, although the differences are small and mostly non-
significant (Table 4). 
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Table 4. Mean serum levels for different sampling times
A: adalimumab n=42
Sampling time Mean drug level at 
baseline mg/l (SD)
Peak (n=11) 8.5 (5.6)
Intermediate (n=22) 7.7 (4.2)                 ns
Trough (n=9) 6.7 (2.0)
B: etanercept n=76
Sampling time Mean drug level at 
baseline mg/l (SD)
Peak (n=25) 2.4 (1.2)
                          ns
Intermediate (n=28) 2.5 (1.0)                         -
                           -
Trough (n=23) 1.7 (0.6)
SD=standard deviation; ns= not statistically significant
*p<0.05
A sensitivity analysis showed that for intermediate timed serum etanercept level, low levels 
were associated with a higher chance of successful dose reduction (AUC 0.28 95% CI 0.08-0.47) 
with an optimal cut point <2.5 mg/l and sensitivity 76% and specificity 67%. For adalimumab, 
high trough timed levels were associated with successful dose reduction (AUC 0.86, 95% CI 
0.58-1.00), with trough levels >7.8 mg/l showing a sensitivity of 100% and a specificity of 86%. 
None of the patients had adalimumab trough levels ≥ 12 mg/l. All other prediction analyses 
(peak and trough for etanercept and intermediate and peak for adalimumab) showed non-
significant results for successful dose reduction or discontinuation. 
Discussion
We could not reject any of our null hypotheses with regard to the predictive value of (anti)drug 
levels of adalimumab, etanercept or infliximab for successful dose reduction or stopping of 
TNFi treatment in RA patients doing well. In contrast to the previously mentioned hypothesis, 
we did find a significant -inverse- association between lower etanercept levels and higher 
chance for successful dose reduction.
Our results are not directly conflicting with the established body of evidence, as other studies 
that test the hypotheses on which previously proposed treatment algorithms rely, using the 
appropriate design, are scarce. The most comparable data are the recently described analyses 
from the STRASS study23, a randomised controlled trial on adalimumab or etanercept dose 
reduction until discontinuation. In this paper the predictive value of baseline adalimumab or 
etanercept level and anti-drug antibodies for successful dose reduction or discontinuation 
in the STRASS study was assessed, and no predictive value could be proven for (anti-) drug 
level. Another study by Chen et al. did show that successful adalimumab dose halving was 
nearly perfectly predicted by baseline adalimumab trough levels. However, the extremely 
high AUROC curves led to the results being disputed 24,25. Of note, for prediction of response 
after treatment start or dose escalation, two studies (prediction of response after golimumab 
dose escalation by means of golimumab trough levels in ankylosing spondylitis patients, and 
prediction of response after start of infliximab by means of infliximab trough levels in RA) 
could also not confirm a strong predictive value 26,27.
Seemingly conflicting results emerged from a number of cross-sectional or non-interventional 
studies, that did find (low to moderate) positive correlations between TNFi serum trough levels 
and response on a group level 8,18,18,19,28,29, although for etanercept, the association between drug 
level and response is unclear 30-32. A possible explanation for this could be that, although dose-
response curves have been found on a group level, concentration-response curves show high 
inter-individual variation in effective serum drug levels 16. This means that the same serum 
drug level can be supra-therapeutical for one patient, but too low for another. Secondly, it has 
been suggested that the inflammation process itself may influence pharmacokinetics of TNFi, 
implying that for patients with higher disease activity, higher target levels are required 33,34. 
Thus, it remains to be debated if weak associations found on a group level, can be translated 
to strong predictive test characteristics in an individual patient.
An important design choice in our study was that serum sampling was performed unrelated to 
timing of the next injection (random timed) for adalimumab and etanercept. This was done as 
trough sampling may be difficult to establish, since trough level sampling may require an extra 
visit when it does not coincide with a regular 3- or 6-monthly outpatient clinic visit. In most 
– though not all - studies, trough level sampling is opted for. This is based on the assumption 
that dose reduction is possible if trough levels are (much) higher than the minimum inhibitory 
concentration (MIC) of a drug, and that discontinuation is possible for trough levels lower 
than MIC. However, the difference between peak and trough categories for all three bDMARDs 
tested in these patients was small, which is consistent with previously described low peak and 
trough levels (peak-to-trough ratios) for subcutaneous TNFi 35. Furthermore, for infliximab 
we did measure trough levels and both these analyses as well as additional sub analyses for 
timing relative to the following injection did not yield different results.
The results of the exploratory sub analyses are most likely false positive findings. An inverse 
association between (intermediate timed) etanercept serum levels and successful dose 
reduction (low intermediate timed serum etanercept level with a higher chance of successful 
dose reduction) was found, as well as a (positive) association between high adalimumab trough 
levels and successful dose reduction. This would suggest a predictive value of adalimumab 
trough levels above 7.8 mg/l, but this finding should be interpreted with caution, as previously 
found cut-offs for supra-therapeutical adalimumab trough levels ranged from 8 mg/l to 
12 mg/l 10,17. However, more importantly, these results are contradictive (and for etanercept 
counterintuitive) and most probably caused by multiple testing.
A notable finding was the low percentage of patients with anti-adalimumab and anti-
infliximab antibodies (10% and 16%) compared to other studies (17-30% RIA measured anti-
adalimumab antibodies and 13-50% RIA measured ant-infliximab antibodies) in RA patients8. 
This difference might be explained by the fact that included patients were having long-
standing RA and had been treated with tight control for an extensive period of time prior to 
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participation in this study. Patients not responding (which could theoretically be caused by 
anti-drug antibodies) would have been switched to another bDMARD already. This patient 
selection does not invalidate our findings, however, as it is compatible with current state of 
art RA care and therefore this represents a relevant study population, although these findings 
may not be generalisable to early RA patients Nevertheless, this means that even if we would 
have found an association between anti-drug antibodies and successful discontinuation in 
our study, the low prevalence of anti-drug antibodies in this population, would lead to a high 
number needed to diagnose (NND). However, in contrast to previously mentioned hypotheses, 
in our study, we observed the numerical lowest prevalence of ADAb in patients that were able 
to discontinue their TNFi instead of the highest. 
All in all, the hypothesis that either random timed or trough serum TNFi levels can be used 
for prediction of successful dose reduction or discontinuation and anti-drug antibodies for 
successful discontinuation in RA patients doing well on adalimumab, etanercept or infliximab 
could not be confirmed in this setting. 
 
Conclusions
This study showed that serum TNFi drug levels or anti-drug antibodies cannot predict 
successful dose reduction or discontinuation of adalimumab, etanercept or infliximab in 
rheumatoid arthritis patients with stable low disease activity. Since measurement of serum 
TNFi drug levels or anti-drug antibodies was not useful in rheumatoid arthritis patients in 
whom adalimumab, etanercept or infliximab were tapered, these tests should not be used in 
this clinical setting. 
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SUPPLEMENT 1
Supplementary figure 1. Flow chart with patients’ disposition for A. adalimumab or etanercept and B. 
infliximab. 
1A.
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Introduction
Rheumatoid arthritis (RA) treatment outcomes have improved in the last decades by the 
introduction of drugs like biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) 
and targeted synthetic Disease Modifying Anti-Rheumatic Drugs (tsDMARDs), as well as 
new treatment strategies including ‘hit hard, hit early’, ‘tight control’ and ‘treat-to-target’. 
These developments have led to more patients achieving low disease activity or remission. 
Rheumatoid arthritis is considered a chronic disease, but due to improved outcomes the 
question has been raised whether patients could lower the dose of their drugs or even 
(temporarily) stop them. Tapering may be motivated by patient preferences, to reduce adverse 
events and to lower costs.1-3 Previous studies have already shown that tapering of bDMARDs in 
RA patients with stable low disease activity or remission is feasible and safe,4,5 at least in the 
short term, and this has lead to the addition of disease activity guided tapering as treatment 
recommendation in the international RA treatment guidelines.6 This thesis further increases 
the existing body of knowledge on dose optimisation of bDMARDs in patients with RA.
Main findings
Dose optimisation of tumor necrosis factor inhibitors (TNFi) has been investigated in a 
number of studies. In a previous review, immediate discontinuation has shown to be inferior 
to full dose continuation.4 It was hypothesized that disease activity guided tapering until 
discontinuation may be non-inferior to full dose continuation. This was investigated in the 
DRESS study: a pragmatic randomised open-label non-inferiority trial comparing dose 
tapering of adalimumab and etanercept with full dose continuation in RA patients with stable 
low disease activity. This study shows that tapering is non-inferior to full dose continuation 
with regard to risk for major flare, although short-lived flare and minimal radiographic 
progression were more frequent in the tapering group.7
Chapter 2.1, investigates the long-term effects of the disease activity guided dose 
optimisation strategy used in the DRESS study by performing a long-term extension study. In 
the intervention phase (months 0-18), patients were randomised to either tapering or usual 
care. In the tapering group, the intervention consisted of stepwise tapering of adalimumab or 
etanercept until discontinuation or until flare. In the usual care group, patients continued with 
full dose adalimumab or etanercept under tight control. In the extension phase (months 18-
36) treatment strategies in both groups converged to the same treatment strategy: treatment 
choices were left to the discretion of the treating rheumatologist with dose optimisation being 
allowed in both groups after low disease activity was reached. Results show that the initial 
efficacy and safety of the tapering strategy were maintained up to three years. No relevant 
difference in the number of major flares was found between the tapering and usual care 
group. Disease activity, functioning and quality of life were also similar between groups and 
no significant difference in radiographic progression was found after three years. However, no 
other benefits (i.e. less adverse events) were observed. 
In chapter 2.2 a cost-effectiveness analysis performed on data of the DRESS long-term 
extension study shows that non-protocolised tapering (usual care group in the extension 
phase) is associated with higher cost and higher quality adjusted life year (QALY) loss, 
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compared to protocolised tapering (tapering group in the intervention phase), but that it 
still is cost saving compared to no tapering at all (usual care group in the intervention phase). 
Furthermore, in the tapering group, costs were slightly higher in the extension phase with 
QALY being roughly equal.
In the DRESS intervention phase, it was observed that minimal radiographic progression 
occurred more frequently in the tapering group. Chapter 3 explores possible causes, including 
short-lived and major flares, disease activity and TNFi exposition. Findings demonstrate that 
radiographic progression is associated with disease activity, especially with swollen joint 
count, but only in the tapering group. This means that when the necessary causes (higher 
disease activity and tapering) are both present, a higher chance to develop radiographic 
progression occurs. Thus the need for tight control – already essential in the treatment of 
RA patients in general – is even more important when a tapering attempt is undertaken. 
Furthermore, radiographic progression should be monitored in patients tapering. With this 
finding, however, further progression is not to be expected in the future, since higher disease 
activity is a temporary side effect of the trial-and-error type of tapering strategy that was used 
in the DRESS study. 
Although tapering of TNFi has been investigated extensively, data on tapering of other 
bDMARDs are scarce. Furthermore, most studies on tapering are clinical trials, leaving 
uncertainty on the effects of tapering in a daily clinical practice setting. Chapter 4 researches 
whether tapering of abatacept and tocilizumab in a daily clinical practice setting is feasible 
and safe in a retrospective, explorative, controlled cohort study. The research compares 
patients with stable low disease activity in whom a tapering attempt was undertaken 
with patients with similarly stable low disease activity in whom no tapering attempt was 
undertaken. Tapering was attempted in 46% of abatacept patients and 70% of tocilizumab 
patients. After 12 months, in the abatacept group, 27% and 9% were successfully tapered and 
discontinued, respectively. In the tocilizumab group, 42% and 10% were successfully tapered 
and discontinued respectively. Tapering was maintained up to 72 months in one patient. DAS28 
was significantly higher in the tocilizumab tapering group compared to the usual care group 
at six months but this difference disappeared at 12 months. For abatacept, disease activity 
was similar in the tapering group and usual care group during follow-up. All in all, it is shown 
that dose tapering of abatacept and tocilizumab in a daily clinical practice setting is feasible 
and seems clinically non-inferior to full dose continuation. However, numbers of patients in 
whom a tapering attempt was undertaken were suboptimal. 
In the trial-and-error type of tapering strategy that was used in the DRESS study, flares are 
inevitable. If we would be able to predict which patient could successfully taper or discontinue 
and which patient could not, flares that are related to tapering could be prevented. Thus far, 
no clear predictors for successful tapering or discontinuation have been identified yet.8 In 
chapter 5, two candidate predictors for successful tapering or discontinuation in the DRESS 
study are considered. The predictive value of the multi-biomarker disease activity (MBDA) 
score (chapter 5.1), measured at baseline (before tapering), for successful dose tapering or 
discontinuation, flare and radiographic progression was investigated. Baseline MBDA score 
was not predictive of successful tapering or discontinuation, occurrence of short-lived or 
major flare or radiographic progression. A borderline positive predictive value of baseline 
MBDA score for major flare was found in the usual care group, but this might well be a false 
positive finding due to multiple testing. 
Baseline serum adalimumab or etanercept drug level or anti-drug antibodies (chapter 5.2) 
were also tested for their predictive value in the DRESS study. No clear predictive value for 
successful dose tapering or discontinuation was found, although subanalyses showed 
that adalimumab trough level was predictive of successful tapering. However, an inverse 
association was found between intermediate timed etanercept levels and successful tapering. 
These results again may reflect false positive findings, since the associations have opposite 
directions and the inverse association found for etanercept is incongruent with previous 
hypotheses. 
 
Reflection
Knowledge on dose optimisation of bDMARDs in RA is expanding, but a few key points of 
discussion remain: 1) What is the best dose optimisation strategy in RA patients? 2) Can 
successful tapering or discontinuation of bDMARDS be predicted? 3) Which outcome measures 
should be used in dose optimisation studies? 4) How to improve implementation of bDMARD 
optimisation in daily clinical practice? 5) How do future developments affect the relevance of 
tapering in RA? 
1. Dose optimisation strategies
Based on available evidence, the international guidelines on the management of rheumatoid 
arthritis have included a recommendation on tapering of bDMARDs, stating that tapering 
of bDMARDs may be considered when persistent remission is reached after glucocorticoids 
have been tapered.6 Tapering can especially be considered in patients using a concomitant 
csDMARD. In the light of this thesis, some remarks can be made on this recommendation.
1.1 Tapering versus discontinuation
The guideline starts with the recommendation to taper bDMARDs, which implies 
tapering instead of immediate discontinuation. Indeed, previous studies have shown that 
discontinuation without prior tapering is inferior to full dose continuation with regard to 
disease activity, functioning and radiographic progression, but that tapering is non-inferior 
to full dose continuation.4 In the DRESS study a gradual tapering strategy was opted for with 
stepwise tapering until discontinuation or until a flare occurred. This strategy can be used to 
both identify patients who are able to discontinue their TNFi as well as patients who are able 
to taper, with the additional advantage of identifying different dosages in different patients. 
The disadvantage of this gradual tapering strategy is that in patients who are actually able 
to discontinue their TNFi, a tapering phase is still required prior to discontinuation. This is 
costly in both time and drug exposition. However, this can be counterbalanced by the fact that 
several studies, including the DRESS and DRESS long-term extension study, show that, on a 
whole, patients who are able to taper are more prevalent than patients who can discontinue 
their drug completely. Thus, savings of cost and medication in patients who are able to taper 
(but not discontinue) will be substantial as well.7, 9, 10 It is not clear however, what tapering steps 
are the most optimal (gradual tapering in multiple steps or dose halving) and if and how they 
would differ for each bDMARD separately. In my opinion, a gradual disease activity guided 
tapering strategy in multiple steps is the most feasible, safe and cost-effective approach.
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1.2 Remission versus low disease activity
The EULAR recommendations also state that patients should have reached persistent 
remission before tapering. However, clear consensus on which definition for remission to 
use is lacking. In previous studies with remission as inclusion criterion, several different 
definitions were used.5 Nevertheless, I think that this statement can be disputed for several 
reasons. First, there is no clear evidence that tapering in patients considered to be in remission 
is superior to tapering in patients with low disease activity with regard to flaring. In fact, in 
this thesis, we have shown that tapering in patients with low disease activity is feasible and 
safe, with the exception of minimal radiographic progression in the tapering group. Second, 
when using persistent remission, implementation of tapering will be limited, without 
good reason, because persistent remission is only reached in a subset of patients (20-60% 
depending on the definition used).11,12 Third, rheumatologists’ adherence to a disease activity 
guided treatment protocol may be less when the target is remission instead of low disease 
activity.13 Similarly, low disease activity is often considered an acceptable level by both patient 
and rheumatologist; at least it is the level at which a patient is considered well enough to 
continue the bDMARD without treatment alterations because of inefficacy. Lastly, in the 
DRESS study, disease activity at start of tapering was not a predictor for successful tapering 
or discontinuation.7
On the other hand, findings show a small but significantly higher radiographic progression 
score in patients who had tapered compared to patients who had not tapered in a low disease 
activity state and it could be hypothesized that this may not have occurred when patients 
in remission were included. However, other studies on TNFi tapering or discontinuation in 
patients with low disease activity did not find any difference in radiographic progression 
between groups.14,15 Furthermore, the DRESS study identifies an association between mean 
time-weighted DAS28-CRP and mean radiographic progression. Baseline DAS28-CRP is not a 
confounder in this association. Thus, I conclude that low disease activity instead of remission 
as a prerequisite for tapering seems a safe and more clinically applicable approach.
1.3 Biologic versus conventional synthetic DMARD tapering or glucocorticoid tapering
Another point of debate is the order of tapering the different classes of drugs used in 
RA treatment. No studies have compared the safety and efficacy of tapering of steroids, 
csDMARDs and bDMARDs. Since glucocorticoids are associated with an increased risk of 
infections, osteoporosis and cardiovascular incidents, and are mostly used as escape drugs, it 
seems reasonable to taper them first.16, 17 
With regard to csDMARDs and bDMARDs, there are several reasons why bDMARDs should 
be tapered first. An important argument is that bDMARDs are much more expensive than 
csDMARDs (400 to 1,500 versus 14,000 euro per patient per year in the Netherlands) and 
tapering of a bDMARD will thus lead to much bigger cost savings.2 Also, bDMARDs therapy 
is associated with more severe infection compared to csDMARD therapy1 and it requires 
injections or infusions, usually leading to more patient burden than oral administration as 
tablets. On the other hand, csDMARDs may be less well tolerated compared to bDMARDs and 
tapering of the csDMARD may therefore be attractive.18 Furthermore, bDMARD therapy is 
started when the csDMARD as monotherapy does not lead to sufficient disease control. Thus, 
the bDMARD may be the more effective drug and it might seem reasonable not to taper it, 
but to taper the csDMARD instead. Unfortunately, data on csDMARD tapering is limited 
with studies describing mostly mixed tapering of bDMARDs and csDMARDs and it is unclear 
whether csDMARDs can be tapered safely as well.19-24 Since bDMARD tapering is much more 
extensively investigating and considering the high cost-savings, reduction of injections/
infusions, and infections, it seems a rational choice to taper the bDMARD first. 
The EULAR recommendation further states that tapering of a bDMARD should especially be 
considered in RA patients that use a concomitant DMARD. In my opinion, this is not a valid 
recommendation. Firstly, for some bDMARDs monotherapy is just as effective as combination 
treatment.25-27 This is also true in other diseases than RA, for instance in psoriatic arthritis and 
spondyloarthritis. Furthermore, in previous studies, concomitant csDMARD use was not a 
predictor for successful tapering or discontinuation.8 
All in all, bDMARD tapering prior to csDMARD tapering seems reasonable, especially with 
regard to cost-savings, but further studies are needed to investigate whether csDMARD 
tapering may be safe as well. In fact, one study is currently being executed, comparing tapering 
of a bDMARD or methotrexate in patients on combination therapy.28 Furthermore, future 
studies should focus on whether it is indeed equally safe and effective to taper a bDMARD in 
patients that do or do not use a concomitant csDMARD.
1.4 Failed tapering attempts
What is not mentioned in the EULAR recommendations is what to do when a tapering attempt 
has failed. One should bear in mind that dose optimisation does not solely mean tapering 
or discontinuation but also reinstallment or re-escalation of the drug when a patient is 
not doing well. Although this has not been investigated separately, stepwise backward re-
escalation until the lowest effective level seems a face valid, effective and safe method and 
would have more advantages than directly restarting the bDMARD at the registered dose and 
then tapering again in an attempt to find the lowest dose, because the latter will require more 
medication. On the other hand, the stepwise backward re-installment could lead to longer 
flaring. However, the results of the DRESS study (non-inferiority of prolonged flaring in the 
tapering group compared to patients not tapering) have shown that this is not the case.
It is also unclear whether multiple tapering attempts should be undertaken. Undertaking a 
second tapering attempt after a first tapering attempt has proven unsuccessful would only 
be useful when the dose-response curve within a patient changes over time. Since a small 
proportion of patients develop secondary inefficacy and flare after long-term use of a bDMARD, 
this obviously occurs in some patients. In the DRESS study, multiple tapering attempts were 
not advised. The study shows that in patients attempting to taper, a temporary rise in disease 
activity caused by the tapering attempt is associated with radiographic progression. Since 
multiple unsuccessful tapering attempts could lead to more frequent rises in disease activity, 
one could hypothesize that this would lead to more radiographic progression, but no data is 
available yet. In the STRASS trial, patients were allowed to attempt to taper more than once 
with no differences between the tapering and full dose continuation groups with regard to 
disease activity and radiographic progression.29 However, in only thirteen percent of patients 
randomised to taper a second tapering attempt was undertaken. 
I therefore conclude that as of yet insufficient data is available on the effects of multiple 
tapering attempts and further research addressing this topic is warranted. 
2. Prediction
The prediction of successful tapering or discontinuation has at least two conceptual advantages 
above treat-to-target tapering: 1) In patients predicted not to be able to taper, no tapering 
attempt will be undertaken at all, thus preventing flare, and 2) In patients predicted to be able 
to successfully discontinue their bDMARD, direct discontinuation is possible without having 
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to taper first, thus saving time and medication. Identification of patients in whom tapering or 
discontinuation will be successful may also optimize implementation of tapering since both 
patients and physicians will be more eager to initiate tapering. In previous studies, clinical 
parameters and other biomarkers have not shown to be predictive for successful tapering or 
discontinuation with the exception of shorter symptom duration at the start of the bDMARD, 
which was associated with successful discontinuation.8 Furthermore, lower baseline Sharp- 
van der Heijde erosion score and higher adalimumab trough level (the latter was described 
in this thesis) were associated with successful tapering.8 Although interesting, these were 
mostly weak associations found in low quality studies. Furthermore, many studies on possible 
predictors did not follow the appropriate guidelines (for instance the Standards for Reporting 
of Diagnostic Accuracy Studies (STARD) guideline) for reporting of prediction research.30 Also, 
as mentioned previously, these studies showed heterogeneity in both design and outcome 
measures. Lastly, underreporting of negative results may be a problem and this may lead to 
overestimation of the found associations. Thus, no clear predictors for successful tapering or 
discontinuation are known yet. 
2.1 Multi-biomarker disease activity score
In this thesis two types of serum biomarkers that could be interesting to predict successful 
tapering or discontinuation were tested. First, we investigated the predictive value of the 
MBDA score for successful tapering or discontinuation in the DRESS study. Biomarkers have 
been suggested to have a smaller measurement error than DAS28 and to be more feasible and 
less costly. However, measurement error of most biomarkers has shown to be comparable to 
the measurement error of the DAS28 (around twenty percent)31 and most biomarkers have to 
be measured in specialized laboratories. This takes time and is expensive. Another important 
disadvantage of biomarkers is that they only measure inflammation without taking the 
patient perspective into account. 
The MBDA score was previously tested as being predictive for radiographic progression in 
early RA patients.32 Furthermore, one study showed that the MBDA score was predictive 
for relapse after tapering of bDMARDs, csDMARDs and steroids in RA patients in sustained 
remission.33 The predictive value improved when the MBDA score was combined with ACPA 
(anti citrullinated peptide antibody) status. Another study showed that the MBDA score was a 
modest predictor for flare after TNFi discontinuation.34 The DRESS study could not demonstrate 
any predictive value of baseline MBDA score for successful tapering or discontinuation. 
Although direct comparison of results is difficult due to the different tapering strategies and 
different definitions for flare, a usable predictor should work in all relevant contexts; just like 
ACPA testing is associated with more severe RA outcomes in all cohorts around the world. 
Furthermore, although the measurement error of the MBDA score has shown to be somewhat 
lower as compared to DAS28 (10 percent versus twenty percent)31, 35, other potential benefits like 
cost- and time-savings are not present for the MBDA score since a single MBDA measurement 
costs around €600 and takes two weeks, whereas a full 28-joint count can be estimated to 
cost around €20 (time and personnel required to measure joints and CRP) and takes only 90 
seconds.36 Based on the results in this thesis and the above-mentioned arguments, I can 
conclude that the MBDA score is not useful as a predictor for successful tapering of TNFi in 
rheumatoid arthritis patients.
2.2 Serum TNFi drug level and antibodies
Other serum biomarkers that were tested in this thesis as possible predictors of successful 
tapering or discontinuation were TNFi drug levels and anti TNFi antibodies. In previous studies, 
TNFi drug levels have been shown to be cross-sectionally associated with response. However, 
a clear predictive value has not been demonstrated yet. In this thesis, we did not find a clear 
association between drug level and successful tapering. This could be explained by the fact 
that although an association between drug level and disease activity may be present, dose-
response curves vary too much on an individual level.37 This means that the same drug level 
can be supratherapeutical for one patient but subtherapeutical for others. It has also been 
suggested that the inflammation process itself as well as some co-medications may influence 
pharmacokinetics of TNFi, meaning that other drug levels are required for different disease 
activity levels and different co-medications.38 Furthermore, in the DRESS study, patients 
who were able to discontinue their drug were also included. In these patients, no association 
between baseline drug level and disease activity may be present at all, since these patients 
would do well without the drug. 
However, an association between successful tapering and adalimumab trough level was 
found. Although this association might reflect reality, it could also be a false positive finding 
caused by multiple testing, especially since we found an inverse association for (intermediate 
timed) etanercept level and successful tapering (lower intermediate timed etanercept level 
was predictive of successful tapering). Other studies are needed to replicate these results, 
since there is lack of other data on this subject.39 This should include a trial that examines 
disease activity guided tapering compared to disease activity guided tapering combined with 
drug level and/or anti-drug antibodies guided tapering. 
With regard to anti-drug antibodies, no association between the presence of antibodies at 
baseline and successful tapering is found in the DRESS study, but prevalence of antidrug 
antibodies was low. Previously, claims have been made on the development of antibodies 
after tapering, although no studies have found this association yet. DRESS only measured the 
presence of anti-drug antibodies before tapering. Other studies should investigate whether 
antibodies actually increase after tapering. It still remains the question, however, what the 
clinical utility of the detection of anti-drug antibodies would be, since there is no treatment 
for anti-drug antibodies and the only option when detecting antibodies is to switch to another 
bDMARD. Furthermore, if clinically relevant development of antibodies after tapering does 
occur, one might expect that it would be more difficult to regain low disease activity after 
re-installment or re-escalation of the bDMARD. However, in the DRESS and DRESS long-term 
extension study, disease activity remained low during study course and in patients that had 
experienced a flare, low disease activity was regained after re-installment or re-escalation of 
the bDMARD. 
2.3 Imaging
Besides serum biomarkers, imaging techniques could also be interesting candidate predictors 
as it can be hypothesized that they can detect subclinical inflammation. In RA patients that 
were classified as being in clinical remission, previous studies found that the presence of 
persistent subclinical synovitis, detected by ultrasound (doppler) or MRI (bone marrow edema), 
is associated with an increased risk of relapse and radiographic progression, respectively.40-44 
Recent studies have also shown some potential for ultrasound to predict which patients are 
able to taper.45-47 Furthermore, previously, PET-CT scanning has shown to be able to detect 
subclinical synovitis in RA patients in clinical remission.48 Currently, a sub study of the DRESS 
study is being performed, investigating the value of 18F-FDG PET-CT scanning as possible 
predictor for successful tapering or discontinuation. 
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In conclusion, at this moment, no clear predictors of successful tapering are known yet. Until 
predictors are identified, tight control remains of the utmost importance. Nevertheless, the 
disease activity guided trial-and-error type of dose optimisation used in this thesis already 
seems a very safe and cost-effective approach. Furthermore, since a previous study has shown 
that for a predictor of successful tapering to be cost-effective, it needs to have a very high 
sensitivity and specificity (96% or higher), it may be impossible to find at all.49 
3. Outcome measures
Previous studies on dose optimisation show great heterogeneity in outcome measures and it 
can be debated what the most optimal outcome measures are.
3.1 Flare criteria
There is little consensus in dose optimisation studies on which definition of flare to use, which 
is reflected in the different definitions mentioned in these studies, including loss of response, 
loss of (deep) remission or low disease activity.50 In the DRESS study the use of an OMERACT 
(Outcome Measures in Rheumatology Clinical Trials) validated DAS28 based flare criterion 
was chosen.51 Although this criterion has shown to have the best construct and criterion 
validity and it is easy to use, it is solely based on DAS28 worsening. The last few years, a new 
and broader flare criterion is being developed by the OMERACT flare group that also includes 
patients’ and rheumatologists’ perspectives and currently, DRESS data is being used to validate 
this flare criterion.52, 53 When validation of this flare criterion is completed, it will hopefully lead 
to uniformity in outcome measures, which is of the utmost importance to be able to compare 
results between studies on dose optimisation of bDMARDs in RA.
The flare criterion that was used in this thesis was originally validated using erythrocyte 
sedimentation rate (ESR). However, in this thesis, both DAS28 based on ESR and C reactive 
protein (CRP) has been used. This was caused by the fact that a more rapid measurement of 
CRP became available, making it more convenient to measure DAS28-CRP than -ESR at our 
outpatient clinic. More importantly, CRP has shown to be more sensitive to change and is less 
affected by other confounding factors.54 However, DAS28-CRP and –ESR are not completely 
interchangeable since DAS28-CRP values are proven to be lower compared to DAS28-ESR when 
measuring disease activity and DAS28-CRP will show more improvement when measuring 
change in disease activity compared to DAS28-ESR.55-58 Therefore, a recently published study 
suggested more stringent cut-off values for low disease activity when using DAS28-CRP.59 
Based on these cut-off values, the flare criterion in the long-term extension study was altered 
accordingly. It could be hypothesized that this influences outcomes in the DRESS long-term 
extension. However, it is unclear how this would have affected outcomes, since tight control 
would have become even tighter, and this would have occurred in both the usual care and 
tapering group. 
3.2 Persistence of successful tapering or discontinuation
Data on long-term effects after tapering, as well as data on persistence of successful tapering 
or discontinuation, are scarce. In the long-term extension study of the DRESS study, 29% of 
patients in the tapering group persisted being successfully tapered and 17% of patients in the 
tapering group persisted being bDMARD free with maintenance of low disease activity during 
the extension phase. These numbers are very comparable to the outcomes of the STRASS 
extension study: successful tapering that persisted up to three years after the original trial 
was possible in 30% and successful discontinuation was possible in 12% of patients. In the 
SONATA study, we found that successful tapering of abatacept and tocilizumab was persistent, 
even up to six years in one patient. This suggests that in a subset of patients, bDMARDS can 
be continued on a lower dose or longer interval for a significant period of time, consequently 
leading to a longer reduction in patient burden as well as costs. However, whether mean 
disease activity over time remains low and subsequently no increase in radiographic 
progression occurs should be investigated, both for abatacept and tocilizumab as well as for 
all other bDMARDs. 
3.3 Radiographic progression
Another important outcome measure in this thesis was radiographic progression. We found 
that the difference in mean radiographic progression between the tapering and usual care 
group over eightteen months was 0.6 Sharp-van der Heijde points. This is well below the 
previously suggested cut-off level of what is minimally clinically important (minimal clinical 
important change, MCIC: five points per year).60, 61 Nevertheless, even minimal radiographic 
progression may become clinically relevant if progression lingers on in subsequent years. 
We found that the additional progression in DRESS was caused by a higher disease activity 
in patients that had attempted to taper and hypothesized that this could be caused by the 
disappearance (‘disconnect’) of the inhibitory effect of TNFi on radiographic progression, so 
that when TNFi is tapered, disease activity resumes to drive the development of radiographic 
progression. Although we investigated radiographic progression in the DRESS long-term 
extension study, no direct comparison of the tapering group and usual care group was 
possible over three years, since tapering was also allowed in the usual care group after the 
first eightteen months. Nevertheless, in the extension phase, radiographic progression was 
not significantly different between groups and tapering outside of a controlled trial setting 
seems safe with regard to radiographic progression. In my opinion, and based on the studies 
included in this thesis, tapering will probably not induce clinically significant radiographic 
progression. Other studies are required to investigate whether radiographic progression will 
stabilize or will progress further in the long term. 
3.4 Adverse events
Important outcomes when tapering also include adverse events. We hypothesized that 
tapering of a bDMARD will lead to less adverse events, like infection or skin malignancy. For 
serious infections, full dose bDMARD use is associated with an increase of 0.6% per patient 
per year and this risk may be lowered when the bDMARD is tapered. On the other hand, TNFi 
use has shown to have a protective effect on the development of cardiovascular disease and 
osteoporosis (probably by inhibiting the systemic inflammatory process)62-65 and inversely, 
a raised CRP in patients with polyarthritis is associated with cardiovascular death.66 Thus 
one can also hypothesize that cardiovascular incidents and osteoporosis might increase in 
patients tapering their TNFi. However, when combining the potential risks and benefits of TNFi 
use, the risk reduction of cardiovascular disease and osteoporosis is probably (at best) equal to 
the risk increase on serious infections.1, 65, 67 Furthermore, a previous study showed that when 
patients are kept at low disease activity, the risk of cardiovascular events remains reduced.68 In 
the DRESS study, this prerequisite was met, since patients were closely monitored to maintain 
a state of low disease activity during tapering. Therefore, the numbers needed to harm for 
cardiovascular incidents and osteoporosis after tapering bDMARDs are probably higher than 
the number needed to treat to lower the risk of infection by bDMARD tapering. 
In this thesis we could not confirm any differences in adverse events between patients 
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tapering and not tapering, both in the DRESS long-term extension study, as well as the 
SONATA study. This could be explained by underreporting of adverse events, and by the low 
incidence of important adverse events. Furthermore, in both the DRESS LTE and SONATA 
study, an inclusion criterion was that patients should have used their bDMARD for more than 
six months at baseline. This could have caused a phenomenon called ‘healthy survivor bias’: 
patients that experience adverse events on a particular bDMARD are more likely to have been 
switched to another bDMARD quickly. Thus these patients would not have been included in our 
studies. Nevertheless, data on adverse events in patients tapering their bDMARD are scarce, 
although one study on tapering of etanercept found a significantly lower number of infections 
in patients that had tapered.69 On the other hand, another study comparing disease activity 
guided optimisation of TNFi with full dose continuation did not find a difference in adverse 
events between groups. Future studies should pay attention to adverse events in patients 
tapering their bDMARD, especially focusing on infections, malignancy and cardiovascular 
incidents. 
3.5 Cost effectiveness 
It seems logical that medication reduction will lead to cost reduction, but disease activity 
guided dose optimisation requires frequent monitoring and causes an increase in short-lived 
flares. This may lead to a lower quality of life and higher cost due to work absenteeism and 
more outpatient visits. However, cost-effectiveness analyses of the original DRESS study 
showed that the majority of costs were driven by medication cost and not so much by extra 
outpatient clinic visits or RA-related absence from work. There was a small QALY loss in the 
tapering group. However, even after adjustment to account for the upper limit of what society 
(in the Netherlands) is willing to pay or accept as costs per QALY, net savings were still high. 
Cost-effectiveness analyses during the extension phase showed that cost effectiveness is 
maintained over three years, although medication cost rose slightly during the extension 
phase, which is explained by a slightly higher use of TNFi during the extension phase. This 
may be a reflection of the fact that in the induction phase, tapering was attempted in all 
patients randomised for tapering and not only successful, but also failed tapering attempts 
will account for less medication use. 
At the moment, prices of several bDMARDs as well as bsDMARDs have decreased, but 
sensitivity analyses showed that cost effectiveness is maintained even with significant price 
reductions.2 All in all, I expect that disease activity guided bDMARD tapering will remain very 
cost-effective in the future with protocolised tapering being slightly more cost-effective than 
non-protocolised tapering. Although these cost savings will not directly benefit RA patients, 
they will benefit the health care system and society in general. 
4. Implementation
To be able to successfully implement dose optimisation into a daily clinical practice setting, 
certain conditions should be met first, including: 1) General terms and conditions, 2) Patient 
associated barriers and facilitators and 3) Rheumatologist associated barriers and facilitators. 
4.1 General terms and conditions
An important prerequisite for RA care is the ability to regularly monitor patients to keep 
disease activity as low as possible and make treatment alterations when necessary (the 
previously mentioned 'tight control' and ' treat-to-target'). Although tight control is clearly 
superior over regular follow-up70, studies have also shown that implementation of tight 
control sometimes is suboptimal. Several reasons have been mentioned, including time-
consuming measurements (although, as mentioned previously, measurement of DAS28 
actually only takes 90 seconds)36, long distance of a patient to the hospital and hesitance of 
rheumatologists to use composite scores to measure RA disease activity.71-73 Although some of 
these circumstances may be difficult to alter, it is important to recognize them and investigate 
what can be improved. 
4.2 Patient associated barriers and facilitators
To successfully implement dose tapering, it is important to investigate patients’ preferences, 
especially since patients’ preferences regarding treatment options often differ from those 
of physicians.74 In the SONATA study, implementation of tapering was clearly suboptimal 
since all patients included were considered eligible to taper, but in 35% of these patients no 
tapering was initiated. It was not possible to investigate whether this was caused by patient- 
or rheumatologist associated barriers or facilitators. This is in line with another study on 
tapering where the authors observed that up to 40% of patients refused to participate.75 It was 
speculated that this was related to fear of losing remission state and the impact this would 
have on work participation and quality of life. However, Verhoef et al investigated that 75% of 
patients actually did have favourable views on tapering with the most important points being 
(amongst others): trusting their treating rheumatologist, fear of flaring and the possibility to 
restart the tapered drug.76 
Other important phenomena to consider in tapering are the ‘nocebo effect’ and ‘incorrect 
causal attribution’, causing patients to think that 1) tapering is inferior to full dose continuation 
and therefore disease deterioration may be perceived more often or earlier and 2) in case of 
flare symptoms they will attribute these symptoms to the tapering attempt, although flares 
naturally also occur every once in a while in the disease course, unrelated to treatment 
alterations.77 This is similar to effects seen after transitioning from an originator bDMARD to a 
biosimilar DMARD (bsDMARD).78,79 
Possible facilitators can be found in investigating what makes tapering appealing to a patient. 
We hypothesized that tapering of subcutaneous abatacept or tocilizumab may be more 
successful than tapering of intravenous abatacept or tocilizumab, since less frequent self-
injection is a more directly noticable advantage compared to lowering the dose. This has been 
underlined by a recent study showing that tapering of subcutaneous tocilizumab by injection 
spacing was more successful than lowering the dose of intravenous tocilizumab.80 However, 
tapering of subcutaneous TNFi could also be more successful because overall the subcutaneous 
formulation contains eight percent more drug than the intravenous formulation. It would be 
interesting whether protocol adherence nowadays is higher in patients using subcutaneous 
abatacept or tocilizumab compared to patients using intravenous abatacept or tocilizumab.
It is known that physicians often underestimate patients’ desire for information74 and 
informing patients has shown to be a very effective intervention in a different patient 
population in whom physicians want to taper drugs as well: in a study on patients using 
benzodiazepines, a single intervention by either an information letter or a GP consultation 
decreased benzodiazepine use.81 Thus, paying extra attention on adequately informing a 
patient can be very effective. To develop confidence in tapering, it may be a good strategy to 
inform patients already at the start of their first bDMARD that tapering may be considered at 
some point in the future.
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4.3 Rheumatologist associated barriers and facilitators
For a large proportion, the same barriers and facilitators for patients are present in 
rheumatologists. They should be convinced that dose optimisation is non-inferior to full dose 
continuation and training may help in this process, since training of rheumatologists has 
shown to improve protocol adherence to treat-to- target as well as dose optimisation.82-84 
In the SONATA study, the suboptimal number of patients in whom a tapering attempt was 
undertaken, may be a matter of timing, since during the last few years, several interventions 
took place to train rheumatologists in disease activity guided tapering and the increasing 
experience will improve protocol adherence. This is underlined by the fact that in the DRESS 
long-term extension study in the former usual care group, in the majority of patients a 
tapering attempt was undertaken, although during the extension phase no specific tapering 
advice was given, with results on efficacy and safety being comparable to results of the original 
tapering group during intervention phase. Thus, experience with a stringent tapering advice 
may increase protocol adherence. 
In a previous study on tapering in a daily clinical practice setting, evident differences between 
rheumatologists were identified on whether, when and in whom tapering should be attempted 
and several different patient characteristics are being weighted in this consideration.85 
In general, despite treatment guidelines and protocols, it seems that opinions on which 
patient to taper vary widely. Future studies should investigate these different rheumatologist 
associated characteristics and this may be helpful in refining treatment guidelines and 
optimising protocol adherence.
5. Future developments
An important development is the introduction of the bsDMARDs. These drugs are highly 
similar to the original bDMARDs. Studies with etanercept, infliximab and rituximab bsDMARDs 
have shown that these drugs are equivalent to their original counterpart, also with regard 
to efficacy and safety.86-88 Although treatment with bDMARDs will become less expensive, it 
is to be expected that even with a significant cost reduction, dose tapering will still be cost-
effective, and tapering will remain a relevant treatment strategy. 
It seems logical that in general, tapering of chronically used drugs is also relevant outside 
of RA and other rheumatic inflammatory diseases. For instance, in inflammatory bowel 
diseases, dose optimisation of bDMARDs and csDMARDs is a topic of interest, although it is not 
specifically covered in international guidelines yet and published data on dose optimisation 
mostly consists of retrospective cohort studies.89 Thus, randomised clinical trials are needed 
to investigate efficacy and safety of tapering of bDMARDs In other inflammatory diseases and 
in fact at the moment three trials are being executed on tapering of TNFi in Crohn’s disease 
and psoriasis.90-92 However, many chronic diseases share similarities with inflammatory 
diseases with regard to chronic medication use and associated costs, adverse events and 
patient burden. Therefore, the knowledge that is gained in this thesis on RA may thus have a 
much wider scope. 
Conclusions and implications
This thesis has a number of implications for the use of disease activity guided dose optimisation 
of bDMARDs in RA patients in daily clinical practice:
- Disease activity guided tapering and discontinuation of adalimumab, etanercept, abatacept 
and tocilizumab appears to be feasible and safe in RA patients.
- Tapering of TNFi in RA patients is highly cost-effective and remains cost-effective outside of 
a study protocol.
- Tapering of TNFi in RA patients requires tight control to keep disease activity as low as 
possible and to prevent radiographic progression.
- The MBDA score as well as serum TNFi levels and anti-TNFi antibodies are no useful 
predictors for successful tapering or discontinuation of TNFi in RA patients.
- Protocol adherence for tapering of bDMARDs in RA patients in daily clinical practice is 
suboptimal.
Research agenda
Although this thesis contributes to the existing body of knowledge on dose optimisation in RA 
patients, some questions remain unanswered. Future research should address the following 
topics:
- Identifying the most optimal dose optimisation strategy for each bDMARD 
- Investigating whether bDMARDs or csDMARDs should be tapered first
- Further validating and reaching consensus on a flare criterion that can be widely used in 
dose optimisation studies
- Comparing disease activity guided dose optimisation with drug level and/or anti-drug 
antibody guided dose optimisation
- Investigating laboratory or imaging markers as possible predictors for successful dose 
optimisation
- Exploring facilitators and barriers of dose optimisation for both patients as well as 
rheumatologists
- Investigating efficacy, safety and cost-effectiveness of dose optimisation of drugs in other 
inflammatory (i.e. spondyloarthritis, psoriatic arthritis or inflammatory bowel diseases) or 
non-inflammatory chronic diseases
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Hoofdstuk 1: Algemene inleiding
Reumatoïde artritis (RA) is een chronische ontstekingsziekte van de gewrichten. De meeste 
patiënten met RA ontwikkelen een symmetrische gewrichtsontsteking, waarbij de kleine 
handgewrichtjes het vaakst zijn aangedaan. De ziekte komt meer voor bij vrouwen dan bij 
mannen. Gewrichtsontstekingen leiden tot verminderd functioneren, verlies van kwaliteit 
van leven en in een deel van de patiënten tot gewrichtsschade. Voor de behandeling van RA 
is een aantal soorten medicijnen beschikbaar. Een belangrijke soort van medicijnen zijn de 
zogenaamde biologische reumaremmers (biologic disease modifying anti-rheumatic drugs, 
bDMARDs). Deze medicijnen konden aan het eind van de vorige eeuw worden ontwikkeld 
door een beter inzicht in het onderliggend ontstekingsproces van RA. Binnen deze bDMARDs 
zijn tumor necrose factor blokkers (tumor necrosis factor inhibitors, TNFi) de meest gebruikte 
middelen. Deze middelen worden per infuus (intraveneus) of (meestal) door de patiënt zelf per 
onderhuidse (subcutane) injectie toegediend.
Hoewel bDMARDs effectief en veilig zijn, gaat het gebruik van deze middelen gepaard met 
een iets hogere kans op bijwerkingen, waaronder ernstige infecties en huidkanker. Daarnaast 
zijn bDMARDs veel duurder dan de vroegere reumaremmers (conventional synthetic disease 
modifying antirheumatic drugs, csDMARDs). Om bijwerkingen en kosten te verminderen, is 
de laatste jaren veel onderzoek gedaan naar het afbouwen van bDMARDs of zelfs stoppen 
ervan in RA patiënten bij wie de ziekte rustig is. Afbouwen kan op twee manieren, namelijk 
door de dosering van de bDMARD te verlagen of door de periodes tussen de toedieningen van 
de bDMARD te verlengen. 
In dit proefschrift worden de korte en lange termijn effecten van het afbouwen van TNFi 
bestudeerd alsmede de haalbaarheid en veiligheid van het afbouwen van andere bDMARDs 
in de dagelijkse praktijk. Verder wordt onderzocht of van te voren voorspeld kan worden wie 
succesvol een bDMARD kan afbouwen of zelfs stoppen. 
Hoofdstuk 2: Lange termijn effecten van afbouwen van TNF blokkers
In dit hoofdstuk wordt beschreven wat de lange termijn uitkomsten zijn van het afbouwen 
van TNFi. Hiervoor is gekeken naar de lange termijnuitkomsten van een eerder gepubliceerde 
studie: de DRESS (Dose REduction Strategies of Subcutaneous TNF inhibitors) studie. In deze 
studie, die tussen 2011 en 2014 plaatsvond, werden 180 patiënten met langdurig (tenminste 6 
maanden) rustige RA geïncludeerd. In 120 patiënten werd op proef geprobeerd de TNFi af te 
bouwen door stapsgewijs de periode tussen de injecties langer te maken. Deze afbouwgroep 
werd vergeleken met 60 RA patiënten met rustige ziekte waarin de TNFi niet werd afgebouwd 
(standaardzorggroep). Het afbouwen gebeurde stapsgewijs door iedere 3 maanden het 
tijdsinterval tussen de injecties langer te maken. Deze stappen werden doorlopen tot een 
patiënt helemaal kon stoppen of totdat er een opvlamming van de reuma (flare) optrad. Bij 
een flare werd het tijdsinterval tussen de injecties weer verkort, of, indien de patiënt gestopt 
was, werd de TNFi hervat. Patiënten werden daarvoor gedurende 18 maanden tenminste 
driemaandelijks gecontroleerd waarbij de ziekteactiviteit werd vastgelegd middels de 
DAS28 (een samengestelde score bestaande uit het aantal pijnlijke en gezwollen gewrichten, 
de ontstekingswaarde in het bloed en een beoordeling van de patiënt van zijn algemene 
gezondheid). 
Uit de DRESS studie is gebleken dat het afbouwen van TNFi in RA patiënten met rustige ziekte 
non inferieur is aan (of te wel niet slechter is dan) niet afbouwen. Wel kwamen kortdurende 
flares vaker voor in patiënten bij wie was afgebouwd vergeleken met patiënten waarbij niet 
was afgebouwd. Daarnaast was er in de afbouwgroep sprake van iets meer gewrichtsschade 
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zichtbaar op röntgenfoto’s. Tot slot was afbouwen duidelijk kosteneffectief. Hoewel deze 
uitkomsten veelbelovend waren, is het de vraag of afbouwen van TNFi ook op de lange termijn 
veilig en effectief is.
Hoofdstuk 2.1
In dit hoofdstuk wordt onderzocht of de korte termijn resultaten van 18 maanden van de 
DRESS studie behouden blijven tot 36 maanden. Van belang daarbij is dat er in de DRESS studie 
alleen patiënten in de afbouwgroep hun TNFi mochten afbouwen. In deze lange termijn studie 
(extensiefase, van 18-36 maanden) mocht de reumatoloog in overleg met de patiënt in zowel 
de afbouwgroep als de standaard zorg groep zelf bepalen of een afbouwpoging ondernomen 
werd. 
De belangrijkste uitkomstmaat was het optreden van een langdurige flare (gedefinieerd als 
een flare die meer dan 3 maanden duurde). In de extensiefase trad er in 10% van de patiënten 
in de afbouwgroep en in 12% van de patiënten in de standaardzorggroep een langdurige flare 
op. Dit is niet significant verschillend. Gedurende de gehele periode van 3 jaar trad er in 17% 
van de patiënten in de afbouwgroep een langdurige flare op en in 14% van de patiënten in 
de standaardzorggroep. Ook dit is niet significant verschillend. Ten aanzien van kortdurende 
flares, kwamen deze in de oorspronkelijke DRESS studie vaker voor in de afbouwgroep. 
In de extensiefase is er geen verschil in kortdurende flares tussen de afbouwgroep en de 
standaardzorggroep. Daarnaast is er in de extensiefase geen verschil in ziekteactiviteit, 
functioneren en kwaliteit van leven tussen de studiegroepen. Van tevoren was verondersteld 
dat er mogelijk minder bijwerkingen zouden optreden in de afbouwgroep. Dit wordt echter 
in dit onderzoek niet bevestigd. Wel kan uit dit onderzoek worden geconcludeerd dat 
afbouwen ook haalbaar en veilig is als er een afbouwpoging wordt ondernomen als dit door 
de behandelend reumatoloog in overleg met de patiënt zelf bepaald mag worden (dus zonder 
een leidend onderzoeksprotocol). 
Hoofdstuk 2.2
Een van de belangrijkste redenen om bDMARDs af te bouwen, is omdat deze medicijnen duur 
zijn. In de DRESS studie was reeds onderzocht dat het afbouwen van TNFi kosteneffectief is. 
In hoofdstuk 2.2 wordt aangetoond dat afbouwen ook op de lange termijn kosteneffectief 
is, zonder duidelijk verschil in kwaliteit van leven ten opzichte van niet afbouwen. In de 
oorspronkelijke afbouwgroep blijft de kosteneffectiviteit behouden in de extensiefase. Wel 
stijgen de kosten in de oorspronkelijke afbouwgroep, waarschijnlijk omdat sommige patiënten 
uiteindelijk toch weer op een hogere dosering TNFi uitkomen, en omdat op proef afbouwen 
geld scheelt, ook als het niet succesvol blijkt. In de standaardzorggroep is de kwaliteit van 
leven tijdens de extensiefase wat slechter en zijn de kosten hoger (gemiddeld 4000 euro meer 
per patiënt per 18 maanden) dan in de afbouwgroep tijdens de interventiefase. Dit kan worden 
verklaard doordat er tijdens de interventiefase volgens een strikt onderzoeksprotocol werd 
afgebouwd. Als een reumatoloog zelf mag bepalen om af te bouwen, dan is dit dus minder 
kosteneffectief dan wanneer er wordt afgebouwd volgens een strikt onderzoeksprotocol. Als 
er door de reumatoloog zelf bepaald mag worden of er wordt afgebouwd, dan is dit echter nog 
steeds beduidend meer kosteneffectief dan helemaal niet afbouwen (gemiddeld bijna 6000 
euro kostenbesparing per patiënt per 18 maanden). 
Hoofdstuk 3: Röntgenschade na afbouwen van TNF blokkers
In de DRESS studie was geconstateerd dat radiologische gewrichtsschade (gewrichtsschade 
zichtbaar op röntgenfoto’s), wat meer voorkwam in patiënten bij wie de TNFi was afgebouwd. 
Hoewel het ging om minimale gewrichtsschade over een periode van 18 maanden, zou deze 
schade wel relevant kunnen worden in de toekomst als het zich voortzet. In hoofdstuk 3 
worden drie potentiële oorzaken voor het ontwikkelen van radiologische gewrichtsschade in 
de DRESS studie onderzocht. Er zou meer gewrichtsschade kunnen zijn ontstaan omdat 1) er 
vaker flares voorkwamen in de afbouwgroep, 2) de ziekteactiviteit gemiddeld genomen hoger 
was in de afbouwgroep of 3) er minder blootstelling was aan het medicijn in de afbouwgroep, 
terwijl we weten dat het medicijn juist beschermt tegen ontstaan van schade. 
Uiteindelijk blijkt alleen de gemiddelde ziekteactiviteit in de afbouwgroep geassocieerd 
te zijn met radiologische gewrichtsschade. Hiervan is met name het aantal gezwollen 
gewrichten geassocieerd met radiologische gewrichtsschade in patiënten bij wie de TNFi is 
afgebouwd. Dit betekent dat deze patiënten nauwgezet gecontroleerd moeten worden om de 
ziekteactiviteit zo laag mogelijk te houden.  
Hoofdstuk 4: Afbouwen van abatacept en tocilizumab 
Hoewel er veel onderzoek is gedaan naar het afbouwen van TNFi, is het afbouwen van andere 
bDMARDs zoals abatacept en tocilizumab minder bestudeerd. Daarnaast is er vooral veel 
bekend over het afbouwen van bDMARDs in onderzoeksverband. In hoofdstuk 4 wordt gekeken 
naar het afbouwen van abatacept en tocilizumab in de dagelijkse praktijk. Uit dit onderzoek 
blijkt dat er maar in 46-70% van de patiënten met rustige ziekteactiviteit (die voldoen aan 
de voorwaarden voor veilig afbouwen) daadwerkelijk een afbouwpoging wordt gedaan. Van 
de patiënten bij wie een afbouwpoging wordt ondernomen, is na een jaar 27-42% succesvol 
afgebouwd en ongeveer 10% succesvol gestopt. Sommige patiënten kunnen langdurig 
afgebouwd blijven, waarbij één patiënt zelfs zes jaar afgebouwd kan blijven. Ziekteactiviteit 
en functioneren zijn vergelijkbaar tussen patiënten die hebben afgebouwd en patiënten die 
niet hebben afgebouwd. Ook in dit onderzoek kan niet worden geconcludeerd dat afbouwen 
leidt tot minder bijwerkingen.  
Hoofdstuk 5: Voorspellers van succesvol afbouwen of stoppen
Tot nu toe werd in RA patiënten met rustige ziekte op proef geprobeerd om af te bouwen. Als 
echter van te voren voorspeld kan worden wie succesvol kan afbouwen of stoppen, heeft dit 
twee belangrijke voordelen:
1. In patiënten met een hoge kans op succesvol kunnen stoppen, hoeven niet eerst alle 
afbouwstappen doorlopen te worden, maar kan direct gestopt worden. Dit scheelt tijd en 
medicatie.
2. In patiënten met een hoge kans dat ze niet succesvol kunnen afbouwen of stoppen, kan 
beter geen afbouwpoging ondernomen te worden. Dit scheelt flares. In hoofdstuk 5 worden 2 
kandidaat voorspellers getest. 
Hoofdstuk 5.1
De multi-biomarker (multibiomarker disease activity, MBDA) score is een bloedtest die is 
ontwikkeld om de ziekteactiviteit van RA te meten. Deze MBDA score zou toegevoegde waarde 
kunnen hebben ten opzichte van de reguliere manier van het meten van ziekteactiviteit in 
RA middels de DAS28. Verondersteld wordt dat de MBDA score ziekteactiviteit zou kunnen 
opsporen die met de DAS28 gemist wordt. Daarnaast zou het meten van de MBDA score 
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simpeler zijn dan het meten van een volledige gewrichtsscore, omdat er geen poliklinisch 
contact met een reumatoloog nodig is. Voorts is de MBDA score in andere onderzoeken 
beschreven als mogelijke voorspeller van radiologische gewrichtsschade in patiënten die 
recent gediagnosticeerd zijn met RA. In dit hoofdstuk  wordt gekeken of de MBDA score in 
de DRESS studie voor start van afbouwen zou kunnen voorspellen bij welke patiënten de 
dosering succesvol afgebouwd of gestopt kan worden. Dit kan echter niet worden aangetoond. 
Daarnaast is er ook geen voorspellende waarde van baseline MBDA score voor het ontwikkelen 
van radiologische gewrichtsschade of flares in patiënten die hun TNFi hebben afgebouwd, met 
uitzondering van flares in de standaardzorggroep. Deze laatste bevinding is mogelijk een fout 
positieve bevinding, doordat meerdere hypothesen worden getest. De kans is dan groter dat 
er bij toeval een positieve bevinding wordt gedaan. Wij concluderen hieruit dat het meten van 
de MBDA score voor de start van afbouwen niet zinvol is om te voorspellen welke RA patiënten 
hun TNFi succesvol kunnen afbouwen of stoppen. 
Hoofdstuk 5.2
Uit eerder onderzoek is gebleken dat de hoogte van medicatiespiegels van TNFi en antistoffen 
gericht tegen TNFi in het bloed van RA patiënten is geassocieerd met het wel of niet reageren 
op TNFi. Daarop is verondersteld dat medicatiespiegels en antistoffen voorspellend zouden 
kunnen zijn voor succesvol afbouwen of stoppen. De achterliggende gedachte hierbij is dat 
patiënten met een hoge medicatiespiegel wellicht ook met een lagere spiegel (dus minder 
medicijn nodig) hetzelfde effect behouden (en dus zouden kunnen afbouwen). Daarnaast 
zou in patiënten bij wie helemaal geen medicatiespiegel wordt gedetecteerd (onder andere 
bijvoorbeeld doordat het medicijn wordt weggevangen door antistoffen) terwijl ze wel lage 
ziekteactiviteit hebben, de rustige ziekte niet het gevolg is van het toegediende medicijn, 
maar het gevolg is van het natuurlijk beloop van de RA (waarbij flares en rustige periodes 
elkaar afwisselen). Mogelijk zijn dit patiënten die hun medicijn zouden kunnen stoppen. 
De hypothesen die worden getest zijn dan ook: 1) Patiënten met een hoge TNFi spiegel kunnen 
afbouwen en 2) Patiënten met geen meetbare TNFi spiegel kunnen stoppen. 
Er wordt in dit onderzoek echter geen voorspellende waarde gevonden van bloedspiegels of 
antistoffen voor succesvol afbouwen of stoppen van TNFi in RA patiënten. Een uitzondering is 
dat een lagere etanerceptspiegel voorspellend is voor succesvol afbouwen. Deze bevinding past 
echter niet bij de hierboven beschreven hypothese waarin juist wordt gesteld dat patiënten 
met een hogere spiegel zouden kunnen afbouwen. In een extra analyse blijkt dat een hogere 
adalimumabspiegel geprikt vlak voor de volgende injectie (dalspiegel) voorspellend is voor 
succesvol afbouwen.  Dit is wel in lijn met bovenstaande hypothese, maar omdat de bevinding 
tegengesteld is aan de bevinding bij etanercept, zou het een toevalsbevinding kunnen zijn. 
Daarom concluderen we dat we niet hebben kunnen aantonen dat medicatiespiegels en 
antistoffen voorspellend zijn voor succesvol afbouwen of stoppen. 
Hoofdstuk 6: Algemene discussie
In het laatste hoofdstuk wordt een overzicht gegeven van de bevindingen van de verschillende 
onderzoeken in dit proefschrift en worden deze bevindingen bediscussieerd in de context 
van andere vergelijkbare onderzoeken. Verder wordt beschreven wat het belang van deze 
bevindingen is voor de dagelijkse praktijk en worden suggesties gedaan voor toekomstig 
onderzoek om de kennis uit dit proefschrift verder aan te vullen. 
De belangrijkste conclusies uit dit proefschrift zijn:
• Ziekteactiviteit gestuurd afbouwen en stoppen van adalimumab, etanercept, abatacept en 
tocilizumab lijkt ook op de lange termijn haalbaar en veilig in RA patiënten (hoofdstuk 2.1, 
hoofdstuk 4).
• Afbouwen van TNFi in RA patiënten is kosteneffectief; ook als wordt afgebouwd buiten een 
studie protocol (hoofdstuk 2.2). 
• Afbouwen van TNFi in RA patiënten vereist nauwgezette controle en follow-up om 
ziekteactiviteit zo laag mogelijk te houden en radiologische gewrichtsschade te voorkomen 
(hoofdstuk 3).
• Protocoladherentie bij reumatologen voor het afbouwen van bDMARDs in RA patiënten in 
de dagelijkse praktijk is suboptimaal (hoofdstuk 4). 
• De multi-biomarker score en TNFi bloedspiegels en anti-TNFi antilichamen zijn niet 
voorspellend voor succesvol afbouwen of stoppen van TNFi in RA patiënten (hoofdstuk 5.1, 
hoofdstuk 5.2).
Nederlandse samenvattingNederlandse samenvatting
145144
List of publications
147146
Chapters in this thesis
1. Bouman CAM, van der Maas A, van Herwaarden N, Sasso EH, van den Hoogen FHJ, 
den Broeder AA. A multi-biomarker score measuring disease activity in rheumatoid 
arthritis patients tapering adalimumab or etanercept: predictive value for clinical and 
radiographic outcomes. Rheumatology (Oxford). 2017;56(6):973-980. 
2. Bouman CAM, van Herwaarden N, van den Hoogen FHJ, Fransen J, van Vollenhoven RF, 
Bijlsma JW, van der Maas A, den Broeder AA. Long-term outcomes after disease-activity-
guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS 
study – a randomised controlled pragmatic non-inferiority strategy trial. Annals of 
Rheumatic Diseases. 2017;76(10):1716-1722 
3. Bouman CAM, den Broeder AA, van der Maas A, van den Hoogen FHJ, Landewé RB, van 
Herwaarden N. What causes a small increase in radiographic progression in rheumatoid 
arthritis patients tapering TNF inhibitors? Rheumatic and Musculoskeletal Diseases Open. 
2017;3(1):e000327.
4. Bouman CAM, van Herwaarden N, van den Hoogen FHJ, van der Maas A, van den Bemt 
BJF, den Broeder AA. Prediction of successful dose reduction or discontinuation of 
adalimumab, etanercept or infliximab in rheumatoid arthritis patients using serum drug 
levels and antidrug antibody measurement. Expert Opinion on Drug Metabolism and 
Toxicology. 2017;13(6):597-604.
Conference abstracts
1. Prediction of successful dose reduction or discontinuation of adalimumab or 
etanercept using serum drug levels and anti-drug antibody measurement. Conferences: 
NVR Najaarsdagen Arnhem 2014 (poster); ACR Boston 2014 (poster); NVZA/NVPF 
ziekenhuisfarmaciedagen 2014 (best abstract, poster). 
2. Predictive Value of a Multi-Biomarker Disease Activity Score for Successful Tapering of 
TNF Inhibitors in Rheumatoid Arthritis: Results of the DRESS Study. Conferences: EULAR 
Rome 2015 (abstract publication); NVR Najaarsdagen Arnhem 2015 (poster).
3. Associations of a Multi-Biomarker Disease Activity Score with Clinical and Radiographic 
Parameters in Rheumatoid Arthritis. Conferences: EULAR Rome 2015 (abstract 
publication); NVR Najaarsdagen Arnhem 2015 (poster).
4. The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in 
Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and 
Radiographic Progression. Conference: ACR San Francisco 2015 (poster).
5. Radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors is 
primarily driven by mean disease activity over time, not so much by flaring or lower TNF 
inhibitor exposition. Conferences: ACR San Francisco 2015 (oral presentation); EULAR 
London 2016 (oral presentation).
6. Study ON Abatacept and Tocilizumab Attenuation (SONATA) in Rheumatoid Arthritis 
Patients: a Retrospective, Explorative Cohort Study. Conferences: EULAR Rome 2016 
(abstract publication); NVR Najaarsdagen Arnhem 2016 (oral presentation).
7. Long-term effects of disease activity guided tapering of  TNF inhibition in rheumatoid 
arthritis: 3 year extension study of a randomised controlled pragmatic non inferiority 
strategy study. Conferences: NVR Najaarsdagen Arnhem 2016 (oral presentation); ACR 
Washington 2016 (oral presentation).
List of publications
149148
Publications outside of this thesis
1. Clinical audit in gynecological cancer surgery: Development of a risk scoring system 
to predict adverse events. Kondalsamy-Chennakesavan S, Bouman C, De Jong S, 
Sanday K, Nicklin J, Land R, Obermair A. International Journal of Gynecologic Oncology. 
2009;115(3):329-33.
2. Hospital costs associated with adverse events in gynecologic oncology. Kondalsamy-
Chennakesavan S, Gordon L, Sanday K, Bouman C, De Jong S, Nicklin J, Land R, Obermair A. 
International Journal of Gynecologic Oncology. 2011;121(1):70-5
3. Adalimumab and etanercept serum (anti) drug levels are not predictive for successful dose 
reduction or discontinuation in rheumatoid arthritis. Van Herwaarden N, Bouman CAM, 
Van der Maas A, Van Vollenhoven RF, Bijlsma JW, Van den Hoogen FHJ, Den Broeder AA, Van 
den Bemt BJ. Annals of rheumatic diseases 2015;74(12):2260-1.
4. Een bijzondere reumatologische aandoening met dermatologische verschijnselen: 
multicentrische reticulohistiocytose - een case report. Bouman C, Romijn D, Jeurissen M, 
Pasch MC, Blokx WAM. Dubbelpublicatie in: Nederlands Tijdschrift voor Reumatologie, 
2015-03 en Nederlands Tijdschrift voor Dermatologie, 2016-03.
5. Letter in response to the article of Chen et al: 'Drug trough levels predict therapeutic 
responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 
weeks of follow-up'. Bouman CAM, Den Broeder A. E-letter in: Rheumatology, February 15, 
2016;(http://rheumatology.oxfordjournals.org/content/55/1/143/reply#rheumatology_
el_218) 
List of publicationsList of publications
151150
Curriculum vitae
153152
Curriculum vitae
Chantal Bouman werd op 5 oktober 1987 geboren 
te Velp. In 2005 behaalde ze haar gymnasium 
diploma aan het Sint Ludgercollege in Doetinchem. 
In hetzelfde jaar startte ze met de opleiding 
geneeskunde aan de Radboud Universiteit in 
Nijmegen. Tijdens haar studie liep ze stage op de 
afdeling chirurgie in het Radboudumc. Aansluitend 
deed ze een wetenschappelijke stage op het gebied 
van gynaecologische oncologie in het Royal Brisbane 
and Women’s Hospital in Brisbane, Australië. 
Aan het eind van haar studie volbracht ze haar 
seniorcoschap chirurgie in het Dr. Horacio E. Oduber 
Hospitaal te Aruba. In november 2011 behaalde ze 
haar artsendiploma en begon ze haar eerste arts-
assistentschap op de afdeling reumatologie in de 
Sint Maartenskliniek, onder leiding van Dr. Maurice 
Jeurissen, Dr. Henk Martens en Dr. Marcel Franssen. Daar ontstond de mogelijkheid van het 
doen van wetenschappelijk onderzoek, hetgeen uitmondde in een promotietraject. Ze werd 
hierin begeleid door Dr. Alfons den Broeder, Dr. Aatke van der Maas en Prof. dr. Frank van den 
Hoogen. Het huidige proefschrift is daarvan het resultaat. 
Per oktober 2016 is ze begonnen met haar vooropleiding interne geneeskunde in het 
Rijnstate Ziekenhuis te Arnhem (opleider Dr. Louis Reichert), in het kader van de opleiding tot 
reumatoloog (opleider Dr. Annelies van Ede). Naast haar opleiding is ze sinds 2011 algemeen 
bestuurslid en secretaris bij KNMG District Groot Gelre. In haar vrije tijd loopt ze graag hard en 
speelt ze dwarsfluit. Chantal woont samen met Itgen Hansen.
155154
Dankwoord
157156
Dankwoord
En dan is het tijd voor het leukste staaltje schrijfwerk van dit promotietraject: het dankwoord. 
Als de woorden van dit laatste hoofdstuk op papier staan, kan het boek dicht. Alhoewel het heel 
fijn is dat de combinatie eindsprint-promotietraject en startsprint-vooropleiding-interne-
geneeskunde van beperkte duur is, kan ik me eigenlijk nog niet goed voorstellen dat het er 
bijna op zit. Want promoveren is een soort achtbaan waar je vol goede moed instapt, je na een 
serie onverwachte wendingen toch een beetje (veel) begint te twijfelen of het allemaal nou 
zo’n goed idee was en als de vaart er dan lekker in zit,  blijkt het tochtje ineens voorbij te zijn. 
Maar stiekem had ik veel van die verschillende hoogte-, en dieptepunten niet willen missen. 
Dat een promotie zoveel verschillende kanten heeft, komt uiteraard doordat er heel veel 
verschillende mensen bij betrokken zijn. Het schilderij op de kaft van mijn proefschrift sluit 
daarop aan. Ik ontdekte dit schilderij bij toeval in een obscure tweedehandswinkel in Berlijn 
en hoe vaker ik ernaar keek, hoe meer verbindingen ik zag met mijn promotietraject. Zoals 
de personen in het schilderij op de kaft van dit proefschrift laten zien, is er soms veel variatie 
in hoe verschillende personen iets ervaren, zoals het beleven van een mooi klassiek concert. 
En dit kan niet alleen tussen personen variëren (inter-observer variabiliteit), maar ook 
binnen het individu (intra-observer variabiliteit). Het had daarmee een directe connectie 
met dit proefschrift: inter- en intra-observer variabiliteit keren meerdere keren terug in de 
methodologie en resultaten van een aantal onderzoeken. Uiteraard is er ook een directe 
verbinding met het overkoepelende thema van mijn proefschrift: het afbouwen van medicijnen 
waarbij voor verschillende patiënten verschillende doses nodig blijken zijn. Tot slot heb ik zelf 
de afgelopen jaren veel intra-observer variabiliteit ervaren doordat ik heel veel verschillende 
kanten van het promoveren heb gezien met verschillende soorten onderzoek, verschillende 
begeleiders en diverse collega’s. Mijn dank gaat uit naar iedereen die heeft bijgedragen aan 
de totstandkoming van dit proefschrift. Een aantal mensen wil ik in het bijzonder noemen.
Allereerst alle patiënten die hebben deelgenomen aan de verschillende onderzoeken. 
Zonder jullie vertrouwen was dit alles niet gelukt. Ik vind het heel fijn dat we met de meeste 
uitkomsten van de onderzoeken uit dit proefschrift en vorige onderzoeken een directe 
vertaalslag maakten naar de praktijk. 
Natuurlijk staat of valt een promotie met de begeleiding. In mijn geval een begeleider met 
regelmatig ‘een leuk nieuw idee’ en een bovenmatig optimistische insteek met betrekking tot 
planning en praktische mogelijkheden. Daarmee mag ik van geluk spreken, aangezien mijn 
promotietraject totaal anders liep dan verwacht. Dr. A.A. den Broeder, Alfons, je enthou-
siasme enorm aanstekelijk en je weet de meest technische wetenschappelijke terminologie 
met humoristische voorbeelden begrijpelijk te maken. Ook probeer je daadwerkelijk een 
promotietraject te smeden rondom iemands kwaliteiten. Dat kan alleen doordat je de 
personen die je begeleid echt probeert te leren kennen, zowel op werkvlak als daarbuiten. Zo 
hadden wij hier en daar een (bepruikte) muzikale samenwerking. En beter nog: wie kan er nou 
zeggen dat zijn sollicitatiegesprek werd beklonken met een viool/dwarsfluit duet!
Hoewel een leuk idee prima is om mee te beginnen, werd al snel een tweede copromotor 
ingeschakeld. Dr. A. van der Maas,  Aatke, gelukkig durfde je het na die ene kennismakingsborrel 
wel aan. Ik heb veel geleerd van je strakke wekelijkse begeleiding, realistische planning 
en opbouwende kritiek.  Daarnaast heb je me de basics van Stata geleerd en kan ik er nog 
steeds van genieten om met woeste programmeertaal en lange syntaxen prachtige output 
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tevoorschijn te toveren. Maar bovenal heb ik altijd het idee gehad dat ik bij je binnen kon 
wandelen voor zowel promotie-, als privé  aangelegenheden en dat waardeer ik zeer.
Tot slot werd daar een geweldige promotor aan toegevoegd. Prof. F.H.J. van den Hoogen, 
Frank, je bent een ontzettend prettige en toegankelijke mentor, met name door je 
relativerende opmerkingen, bijvoorbeeld toen de spanning voorafgaand aan presentaties in 
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aan de begeleiders tijdens mijn eerste baan op de reuma afdeling in de SMK: Henk Martens, 
Marcel Franssen en Maurice Jeurissen. Daar heb ik kennis gemaakt met: 1. veel markante 
patiënten, 2. gedegen dieetgewoontes zoals strakke lunch routines en warme melk bij grote 
visites en 3. het belang van heel veel humor tijdens het werk. Ook al vond ik zo’n eerste baan 
best spannend, ik heb het ervaren als een warm bad. Daarbij zijn jullie alle drie op eigen wijze 
enorm inspirerend, wat wordt onderstreept door de inmiddels lange serie ANIOS (waaronder 
ondergetekende) die binnen de kortste keren voor de opleiding reumatologie kozen. 
Alle reumatologen en PA’s in SMK Nijmegen dank ik voor de ontzettend fijne en leerzame tijd: 
Alfons, Karen, Henk, Hans, Regina, Susan, Aatke, Marcel Flendrie, Joost van Zadelhoff, 
Agnes, Hatice, Annemiek, Maartje, Frank, Elien, Vincent, Esther, Marcel Franssen, 
Maurice, Joost Huijs: jullie zijn een prachtig team. Ik heb van ieder van jullie net weer andere 
dingen geleerd. Ik bewonder de vaardigheid om uiterst efficiënt te werken en de drive om 
altijd te willen blijven verbeteren, maar nooit zonder heel veel humor en oog voor de patiënt 
en elkaar. Ik had me geen betere start van mijn loopbaan kunnen voorstellen.  
Alle AIOS reumatologie van het Radboudumc: wat zijn jullie een gezellige club! Dank 
voor de fijne samenwerking in de SMK en de gezelligheid op congressen, etentjes en 
speeltuinmiddagen. 
Dr. A.E. van Ede, Annelies, dank dat je voor ons de drempel om binnen te lopen altijd weet te 
reduceren tot nul. We hebben maar geluk met zo’n opleider. 
Dank ook aan de reumatologen en verpleegkundig specialisten in SMK Woerden voor 
deelname aan de DRESS studie en de MBDA studie. 
De andere reuma onderzoekers dank ik voor de gezelligheid tijdens de JOO’s en schrijfdagen. 
Michiel, dank voor je geduld bij al mijn Stata vragen en natuurlijk je briljante DRESS database, 
waardoor het maken van de database van de DRESS follow-up een eitje werd.  Els en Joke, 
dank voor jullie begeleiding en ook voor de steun en humor tijdens congresbezoeken. Els, heel 
leuk dat we alsnog een mooi artikel gaan schrijven over de PET scans. 
Leo, dank voor je eindeloze geduld tijdens mijn wekenlange naar 1500 samples in diverse 
vriezers en Ester dank voor je hulp bij de logistiek omtrent de gigantische pipetteerklus die 
daarna kwam. 
Isabelle, Margot en alle reumaverpleegkundigen, jullie hebben het flink te stellen gehad met 
al die nieuwe onderzoeksvoorstellen. Dank jullie wel dat jullie je daardoor niet hebben laten 
afschrikken. Zonder jullie was het niet gelukt!
Dank aan de secretaresses op de afdeling en het secretariaat. Majella, jij hebt alle stroom 
aan correspondentie voor mij gecoördineerd en menig onmogelijk vergaderverzoek weten te 
tackelen. 
Verder kwam er een aantal kamergenoten voorbij. Nienke, we hebben heel wat kilometers 
samen afgelegd, van het veelvuldig aantal keren op en neer door de gang voor het halen van 
kopjes thee ter pre-, per- en posthydratie, tot pauzewandelingen door het bos rondom de 
SMK en later zelfs meerdere Nijmeegse vierdaagses. En ook al hebben we het mysterie van ‘de 
vissende man’ niet kunnen oplossen, die meters waren essentiële klets-tijd. 
Lieke, jij kwam halverwege mijn promotie p1.03 versterken en dat leidde niet alleen tot een 
aantal mooie gedeelde publicaties, gezellige gezamenlijke congresbezoekjes en gedeelde 
pre- presentatiestress, maar uiteindelijk zelfs tot een gedeelde promotiedag en –feest! Wel zo 
gezellig dat we samen op lokatiejacht konden gaan en de organisatieklussen als een geoliede 
machine hebben weten te verdelen. We maken er wat moois van!
Noortje, dankjewel dat ik het DRESS-stokje van je heb mogen overnemen en dat je me mede 
de beginselen van het promoveren hebt bijgebracht. We hebben er vierkante ogen aan 
overgehouden en kunnen geen röntgenfoto meer zien, maar met die ‘agreement’ kwam het 
prima in orde. Samen met Nienke hebben we veel thee-meters gemaakt. Hartstikke gezellig 
dat we elkaar als collega’s in opleiding nog regelmatig tegenkomen.
Lieke Nieboer, jij schoof in p1.03 als laatste aan. Dank voor je gezelligheid en nuchtere, 
relativerende opmerkingen als bij ons de stoom uit de oren kwam. Super dat je nu ook de PA 
opleiding gaat doen. Misschien komen we elkaar in de toekomst weer tegen.
Dieneke, dank dat je bij ons je wetenschappelijke stage hebt durven lopen. Ik bewonder je 
inzet en je kritische blik bij de SONATA. Ik vind het heel leuk dat we nu ook in het Rijnstate 
collega’s zijn. 
Inmiddels werk ik alweer meer dan een jaar in het Rijnstate. Ik dank Louis Reichert en 
Arianne van Bon voor hun steun en soms flexibele roostering zodat er soms wat extra dagen 
in onderzoek gestoken konden worden. Alle internisten en collega arts-assistenten dank 
ik voor hun steun bij soms wel erg drukke weken, maar vooral voor het team-gevoel en de 
gezelligheid. 
Mede bestuursleden van KNMG Groot Gelre: ik heb veel geleerd van mijn bestuurstijd. 
Daarbovenop is het gelukkig ook nog eens heel erg gezellig en eigenlijk nooit saai. Anne, 
gelukkig vond je het nodig om jonge aanwas mee te nemen en mocht ik aanschuiven. 
Naast alle mentale uitdaging, was er gelukkig ook ruimte voor ontspanning en fysieke 
activiteit. Carla, hartstikke leuk dat we elkaar in die beginnerscursus bij de Funrunners 
tegenkwamen. Die zondagochtenden waren ook essentiële klets-uurtjes. Marianne, Rob en 
Vincent, wat zijn jullie inspirerende trainers! Ik dacht een korte cursus te doen om eens een 
vlotte tien kilometer te kunnen rennen, maar inmiddels zijn we alweer vier jaar verder en kan 
ik me niets fijners bedenken dan op zondagochtend met de Funrunners een modderig bos in 
te duiken. Misschien goed om hier nog op te biechten dat de training bij tijd en wijlen niet om, 
maar dwars door de SMK ging (sorry, bewaking). 
Annemarie, we hebben heel wat uurtjes samen bij Lux doorgebracht. Maar bij tijd en wijlen 
met een mini-tentje op een Waddeneiland bivakkeren is, zelfs in de stromende regen, ook aan 
ons besteed. 
Mieke, ik weet nog goed dat er na mijn eerste avonddienst als coassistent een support- 
toetje voor mijn deur stond. Dankjewel je ervoor zorgde dat we studentenhuis-buurvrouwen 
werden. Lief en leed en vooral veel humor hebben we gedeeld. Ik kijk uit naar onze volgende 
kook- dan wel freubelmiddag! 
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Melanie, samen hebben we ons door die coschappen heen gebikkeld en dat heeft ons veel 
levenswijsheden opgeleverd. Zo ervaar ik elke week nog wel een ‘pipo de clown’ moment en 
kan ik af en toe nog steeds een kapel-bibliotheek goed gebruiken. Ik ben blij dat je het met 
Amanda zo goed voor elkaar hebt en je droom om microbioloog te worden uit aan het komen 
is. 
Fabian, regenachtige zondagmiddagen en dromerige zomeravonden blijken uitstekend om 
obscure Argentijnse films te kijken en goede wijn te drinken. Ik bewonder je avontuurlijke 
levensvisie. Waren er maar meer mensen zo on-hokjes-achtig. Op naar nog meer roze-toetjes-
avonden! 
Janneke, wat had ik geluk dat ik bij jou een plek vond in de leukste woongroep van Nijmegen. 
En wat hebben we in de jaren erna een hoop lief en leed gedeeld! ik hoop dat we ook op ons 
tachtigste tandeloos en gerimpeld nog synchroon SATC quotes roepen en er dan zelf het 
hardst om lachen. Ik ben blij dat je het in Amsterdam met Gerben zo goed voor elkaar hebt. Ik 
vond het geweldig om als paranimf naast je te mogen staan bij jouw promotie en ben nog veel 
blijer dat je ook naast mij zal staan!
Tom en Jenna, dank voor de vele etentjes en filmavondjes en heerlijk cynische humor. Pino, 
dank voor je ongebreidelde enthousiasme als we er zijn en ongebreidelde chagrijn als we weer 
weggaan. Jenna, wat leuk dat we ook loopmaatjes zijn geworden. Met onze liefde voor reizen 
en rennen gaan die buitenlandse hardloopavonturen er zeker komen!
En met Itgen kreeg ik er kennelijk gratis en voor niets nog meer gezellige vrienden bij! 
Dank Yvonne en Robin, Marcel en Laura, FJ en Laura met Vera, Marije en Simon, Sonny 
(of Sakar of Bamiltijger of hoe heet je ook weer), Jeroen (dank dat je uit interesse voor mijn 
promotieonderzoek zelfs bij mijn co-promotor in onderricht ging), Jan-‘wat zal ik er eens van 
zeggen’-Joost, René en Erik (in het bijzonder ook voor het bewaken van mijn winterbanden 
en velgen die nota bene het verkeerde Zweedse logo bevatten).
Thea en Aad, vanaf het begin heb ik me ontzettend welkom gevoeld bij jullie. De vaste etentjes 
op vrijdagavond waren essentieel om ons na een vermoeiende werkweek weer van inspiratie 
(Thea), bijzondere uitspraken (Aad) en broodnodige vitamines voorzien. Het afgelopen jaar 
was wellicht wat al te avontuurlijk, maar daar zijn jullie je heldhaftig doorheen gekomen. Nu 
weer vol goede moed samen naar concerten, op kookcursus en die verbouwing nou echt eens 
afmaken. Het gaat allemaal lukken.  
Mam en pap, zonder jullie was ik niet gekomen waar ik nu ben. Jullie hebben me meegegeven 
om overal voor open te staan en door te zetten en (samen met wat Achterhoekse koppigheid) 
kom je daarmee een heel eind. Daarnaast hebben jullie ons altijd de vrijheid gegeven om te 
doen wat we wilden en daardoor zijn we nu van uitermate diverse en gelukkige pluimage. Pap, 
het ging inderdaad voetje voor voetje, net als een vierdaagse eigenlijk. Mam, gelukkig komt 
er nu ook meer tijd aan om vaker naar Duitsland te komen en vaker samen op pad te gaan. 
Kimberly, Ashley en Mathijs, sistertjes en brothertje! Ashley, jij blijft mijn allerschattigste, 
liefste kleine zusje. Als jongste had je wel wat om tegenop te boksen en dat lukt eigenkijk nog 
steeds prima. Kimberly, vroeger konden we nog weleens kibbelen met jouw gezellige-rommel 
en mijn totale-orde insteek, maar dat heeft zich inmiddels aardig uitgemiddeld. Je hebt het 
met Chris goed voor elkaar en als grote zus ben ik heel trots. Mathijs, ik ben blij dat je straks als 
grote broer naast mij staat! Op naar nog meer Arnhem-Nijmegen avonturen. Daniela, thank 
you for taking such good care of Mathias and for namecalling Itgen ‘the outlaw’. 
Itgen, het is dan eindelijk af!! Ik weet inmiddels dat je een dankwoord overbodig vindt, 
maar dit is ook echt jouw prestatie. Er bleef het afgelopen jaar te weinig tijd over voor ons 
samen, maar dat jij onvoorwaardelijk achter mij staat (en zo nu en dan voet bij stuk houdt 
als het echt te gortig wordt) heeft ervoor gezorgd dat ik dit uiteindelijk met een glimlach heb 
kunnen afronden. Samen kunnen we de hele wereld aan en ik kijk al reikhalzend uit naar onze 
geplande avonturen en naar de talrijke nog ongeplande avonturen die altijd in jouw hoofd 
rondzingen. Ik heb je heel veel lief.
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